Scientific Studies DATABASE PAGE 8

CLICK AICI pentru  limba ROmana(DACA nu e deja tradusa)

The following is a list of about 1600 scientific papers quoted in the book of Dr. Nacci (see my book for more details) in the
name of the “Evidence Based Medicine”, which provides this medical method:
1. Formulating a clinical question;
2. Searching for best available scientific evidence;
3. Analysing scientific evidence critically;
4. Acting on the basis of gathered scientific evidence;
5. Evaluating the results;

Dr Nacci won the award BEST SCIENTIFICALLY ARGUMENTED  BOOK .You will also get a link to download Dr. Nacci’s FREE EBOOK as well as the books of Dr. Phillip E. BInzel, Dr. William D. Kelley,  Dr. Matias Rath and of Johanna Brandt , free E books about cancer , when you read my book .

Click here to see more details of my book contents
1) Aapro MS: Retinoids in oncology, Eur J Cancer.; 31A(5): 834-835, 1995.
2) Abel U.: Chemio-Terapia di carcinomi in stadio avanzato: un inventario critico, in: Biomed and Pharmacother, vol.
46, 1992, aggiorn. 1995, pp. 439-452
3) Adamson PC: Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer,
Leukemia.; 8, pp: 1813-1816, 1994 .
4) Ahmad N.: Green Tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in
Human Carcinoma Cells, Journal of the National Cancer Institute Vol 89 No.24, 1997.
5) Ahmad N: Green Tea polyphenols and cancer: biological mechanism and pratical implications, Nutrition Review.
pp: 78-83, 1999
6) Albanes D: Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol,
beta-carotene cancer prevention study: effects of base-line characteristics and study compliance, J Natl Cancer Inst.;
88, pp: 1560-1570, 1996.
7) Alexander H.L. : Cancro, principi e pratica dell’oncologia, Lippincott and Co., Philadelphia, 1993, 4.a ediz.
8) Anscher M.S., Short comunication: Normal tissue injury after cancer therapy is a local response exacerbated by an
endocrine effect of TGF, “British Journal of Radiology”, 68, 331-333, 1995.
9) Arca MJ.: Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-
BL6 melanoma transduced with cytokine genes, Cancer Immunology, Immunotherapy, 42, pp.: 237-245, 1996
10) Arnold A: Phase II trial of 13-cis-retinoic acid plus interferon alpha in non-small-cell lung cancer, J. Natl. Cancer
Inst.; 86, pp: 306-309, 1994
11) Aruga E.: Immune responsiveness to a murine mammary carcinoma modified to express B7-1, Interleukin-12, or
GM-CSF, Cancer Gene Therapy, 4, pp.: 157-166, 1997
12) Ashley F.: The use of Aloe vera in the treatment of thermal and irradiation burns in laboratory animals and
humans, Plastic Reconstr. Surg., 20, 383-396
13) Atiba JO: Correction malignant glioma, J Clin Oncol.; 15: pp.1286-1287, 1997
14) Ault A: Retinoids promising in Kaposi’s sarcoma trials, Lancet; 351, pp. 1185. 1998
15) Baccarani M.: D-Verapamil down-modulates P170-associated resistance to doxorubicin, daunorubicin and
idarubicin, “Anti-Cancer Drugs”, 4, pp 173-180, 1993.
16) Bakowski M.T.: Chemio-Terapia del cancro del polmone non a piccole cellule: una rassegna e uno sguardo al
futuro, Cancer Treatments Reviews, vol.10, pp. 159-172, 1983
17) Band PR: Retinoids and breast cancer, Prog. Clin. Biol. Res. 354A, pp: 361-377, 1990
18) Barthet M: Vitamins A and E in digestive cancers, C R Acad Sci III.; 309, pp: 101-104, 1989, French.
19) Barton DL: Prospective evaluation of vitamin E for hot flashes in breast cancer survivors, J Clin Oncol.; 16, pp:
495-500. 1998.
20) Barth TJ: Redifferentiation of oral dysplastic mucosa by the application of the antioxidants beta-carotene, alphatocopherol
and vitamin C, Int J Vitam Nutr Res.; 67, pp: 368-376, 1997.
21) Belfi C.A.: Comparison of the effects of Hydralazine on tumor and normal tissue blood perfusion by MRI, “Int. J.
Radiat. Oncol. Biol. Phys.” Vol. 29, pp. 473-479, 1994.
22) Bella M.: „Regime di cisplatino convenzionale confrontato con cisplatino a intenso dosaggio nei casi di carcinoma
ovarico avanzato”, Abstract No. 706, in: Proc. Amer. Soc. Clin. Oncol., vol.11, pp.223, 1992
23) Benner SE: Retinoid chemoprevention of second primary tumors, Semin Hematol.; 31(4 Suppl 5), pp: 26-30, 1994.
24) Benner SE: Current status of retinoid chemoprevention of lung cancer, Oncology (Huntingt); 9, pp. 205-210,
25) Bertram JS: Rationale and strategies for chemoprevention of cancer in humans.
Cancer Res ; 47, pp:3012-31, 1987
26) Bisi G., Rest Technetium-99m Sestamibi Tomography in Combination With Short-Term Administration of Nitrates:
Feasibility and Reliability for Prediction of Postrevascularization Outcome of Asynergic Territories, “J. Am. Coll.
Cardiol.”, 24, pp. 1282-1289, 1994.
27) Bissett D., Phase I and pharmacokinetic study of D-verapamil and doxorubicin, “Br. J. Cancer “, pp.1168-
28) Blazsek I: Combined differentiation therapy in myelodysplastic syndrome with retinoid acid, 1 alpha,25
dihydroxyvitamin D3, and prednisone, Cancer Detect Prev.; 16, pp: 259-264, 1992.
29) Bloom H.J.: „Storia naturale del carcinoma della mammella non trattato”, in: Brit. Med. J., Vol. 28, pp. 213-221,
30) Blot WJ: Vitamin/mineral supplementation and cancer risk: international chemoprevention trials, Proc Soc Exp
Biol Med. Nov; 216, pp: 291-296. 1997.
31) Bonomi P.: Studi randomizzati con 3 diverse dosi di cisplatino nei carcinomi a cellule squamose del collo
dell’utero, in: J. Clin. Oncol., vol.3, pp. 1079-1085, 1985
32) Boon T.: Tumor antigens recognized by T lymphocytes, Ann. Rev. Immunol., 12, pp.: 337-365, 1994;
33) Bowen PE: Evidence from cancer intervention and biomarker studies and the development of biochemical markers,
Am J Clin Nutr; 62(6 Suppl), pp:1403S-1409S, 1995
34) Bower M: Phase II trial of 13-cis-retinoic acid for poor risk HIV-associated Kaposi’s sarcoma. Int J STD AIDS; 8,
pp: 518-521, 1997
35) Brawley OW: Cancer chemoprevention trials, Oncology (Huntingt); 10, pp. 324-327, 1996.
36) Brodkin CA: Lobe of origin and histologic type of lung cancer associated with asbestos exposure in the Carotene
and Retinol Efficacy Trial (CARET), Am J Ind Med.; 32, pp: 582-591, 1997
37) Breccia A., in: Bistolfi F., “Campi magnetici in Medicina”, pp 146, 1986.
38) Brennan M.F.: „Cancro del pancreas”, in: De Vita: „Cancro, principi e pratica dell’oncologia”, Lippincott and Co,
Philadelphia, 4 a. edizione, pp. 849-882, 1993
39) Browen M.: „Cancro dei polmoni”, in: Rosenthal S.: „Supporto medico del paziente con cancro”, W.B. Saunders
Co, Philadelphia, pp. 200-215, 1987
40) Brown J.M.: Tumor Hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation, “Int. J.
Radiat.Oncol.Biol.Phys.”, 20, pp. 457-461, 1991.
41) Brown J.M., Therapeutic Advantage of Hypoxic Cells in Tumors: A Theoretical Study, “J.Natl. Cancer Inst.”, 83,
pp. 178-185, 1991.
42) Brown J.M., Keynote Address: Hypoxic cell radiosensitizers: where next ?, Session 2, “Int. J. Radiat. Oncol. Biol.
Phys.” Vol. 16, pp. 987-993, 1988.
43) Brown J.M., Hypoxic cell radiosensitizers: the end of an era ?, “Int. J. Radiat. Oncol. Biol. Phys.” Vol. 32, No.3,
pp. 883-885, 1995.
44) Bruserud O., Effect of Verapamil on T-Lymphocyte Activation in vitro, “Scand. J. Immunol.” 21, pp. 73-79, 1985.
45) Buring JE: The alpha-tocopherol, beta-carotene lung cancer prevention trial of vitamin E and beta-carotene: the
beginning of the answers, Ann Epidemiol.; 4, pp: 75, 1994.
46) Busetto M.: Variazione dei subset linfocitari dopo radioterapia, “La Radiologia Medica”, 80, pp. 909-911, 1990.
47) Bussey HJ: A randomized trial of ascorbic acid in polyposis coli, Cancer, 50, pp:1434-9, 1982.
48) Bussing A., Therapeutic study on the immunological parameters in cancer patiens after vhigh -dose intravenous
administration of Viscum album l. extracts, Zeitschrift fur onkologie, n. 28, pp. 54-59, 1996.
49) Bussing A., Therapeutic study on the immunological parameters in cancer patiens after vhigh -dose intravenous
administration of Viscum album l. extracts, Anticancer Drugs suppl., n. 8, pp-1-2, 1997.
50) Butturi M.: Effetti dell’immunomodulazione nella radioterapia antineoplastica. Studio cinico controllato, “La
Radiologia Medica”, 86, pp. 327-335, 1993.
51) Buyse M.: „Terapia di sostegno del cancro colon-.rettale. Perché non c’è ancora niente di definitivo”, in: J. Amer.
Med. Assoc., vol. 259, pp. 3571-3578, 1988
52) Cairnie: Adverse effects of radioprotector WR2721, “Radiat. Research”, 94, pp. 221-226, 1983.
53) Cameron R.B.: Synergistic Antitumor activity of Tumor-infiltrating Lymphocytes, interleukin 2, and local Tumor
irradiation, “The Journal of Eperimental Medicine”, Volume 171, pp. 249-263, 1990.
54) Cameron E: Vitamin C and cancer: an overview, Int J Vitam Nutr Res Suppl 23:115-27, 1982;
55) Carmeliet P.: angiogenesis in Cancer and other Diseases, in Nature, 407, pp. 249-257, 2000
56) Carter CA: Effects of retinoic acid on cell differentiation and reversion toward normal in human endometrial
adenocarcinoma (RL95-2) cells, Anticancer Res., 16, pp: 17-24, 1996
57) Casalini: Tumor pretargeting: Role of avidin/streptavidin on monoclonal antibody internalization, “J. Nuclear
Med.”, 38/9, pp. 1378-1381, 1997.
58) Cera LM.: The therapeutic efficacy of Aloe Vera cream in thermal injuries: two case reports, J. Am. Anim. Hosp.
Assoc., 16, 768-772.
59) Challem JJ: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol
Efficacy trial, J Natl Cancer Inst., 19; 89: pp.325-326., 1997
60) Chalmers T.”Meta-analisi di studi randomizzati con controllo applicati alla terapia del cancro”, in: De Vita:
„Cancro, principi e pratica dell’oncologia”, Lippincott and Co, Philadelphia , 4.a edizione, pp 235-241, 1993.
61) Chang AE: Current status of Immunotherapy of cancer, Crit. Rev. Oncol.-Hematol, 22, pp.: 213-228, 1996;
62) Chang H.M: “ Pharmacology and Applications of Chinese Materia Medica”, Vol 1 Singapore World Scientific
63) Chang R: Effective Dose of Ganoderma in Humans, Proceedings of Contributed Symposium 59A, B 5th
International Mycological Congress, Vancouver: pp. 117-121 1994.
64) Chang R: Limitations and Potential applications of Ganoderma and related fungal polyglycans in clinical
oncology, First International Conference on Mushroom Biology and Mushroom products: 96, 1993
65) Chang, R.: Potential application of ganoderma polysaccharides in the immunosurveillance and chemoprevention of
cancer, In: Mushroom Biology and Mushroom Products, Proceedings of the 2nd International Conference, Royse DJ
(ed), Penn State U. Press, University Park, pp. 153-9, 1996.
66) Chandler J.: Coley’s toxins and chemotherapy in treatment of breast carcinosarcoma: case report, Am. Surg., vol.
35, pp. 377-383, 1969.
67) Cheever MA: Specific adoptive therapy of murine leukemia with cells secondarily in vitro and expanded in IL-2,
Progress Cancer Research and Therapeutics, 22, pp: 127-133, 1982
68) Chen K.: Advances in anti-aging herbal medicines in China, Abstracts of Chinese Medicine 1, pp.:309-330, 1987
69) Chen YH.: Modulation of interleukin-6/interleukin-6 receptor cytokine loop in the treatment of multiple myeloma,
Leuk Lymphoma.; 27, pp.: 11-23, 1997.
70) Chilton J.S.: The first international Conference on mushroom biology and mushroom products, Herbalgram, 31:57.
71) Chlebowski R.T.: A decade of breast cancer clinical investigation: results as reported in the program/proceedings
of the American Society of Clinical Oncology, Journal of Clinical Oncology, Vol. 12, No.9, 1994, pp.: 1789-1795. (Un
decennio di indagini cliniche sul cancro della mammella: risultati presentati nei verbali della American Society of
Clinical Oncology).
72) Choski A.J.: Chemio-Terapia di supporto per cancro della testa e del collo. Passato, presente e futuro, in: Seminars
in Oncology, vol. 15, Suppl. 3, pp. 45-49, 1998
73) Chuwers P: The protective effect of beta-carotene and retinol on ventilatory function in an asbestos-exposed cohort,
Am J Respir Crit Care Med.; 155, pp: 1066-1071, 1997
74) Clark J.R.: Strategie chemioterapiche nel trattamento multidisciplinare del cancro del collo e della testa, in:
Seminars in Oncology, vol. 15, Suppl. 3, pp. 35-44, 1988
75) Cliffe S., Combining bioreductive drugs (SR-4233 or SN-23862 ) with the vasoactive agents flavone acetic acid or
5,6-Dimethylxanthenone acetic acid, “Int. J. Radiat. Oncol. Biol. Phys.”, Vol. 29, pp 373-377, 1994.
76) Cobleigh MA: Breast cancer and fenretinide, an analogue of vitamin A, Leukemia; 8 Suppl 3: S59-S63, 1994.
77) Collins C.: Roentgen dermatitis treated with fresh whole leaf of Aloe Vera, Am. J. Roentgenal 33, 396-397.
78) Colombo N.: Uno studio randomizzato di Chemio-Terapia a dosi convenzionali confrontato con intensi dosaggi di
cisplatino per il cancro ovarico in stadio avanzato, Abstract No. 614, in: Proc. Amer. Soc. Clin. Oncology, vol. 12, pp
255, 1993.
79) Combs GF Jr: Reduction of cancer risk with an oral supplement of selenium, Biomed Environ Sci., 10(2-3): pp.227-
234, 1997.
80) Comline, “ Biotechnology Medical”, pag.1, 26 apr. 1989.
81) Conte P.F.: Elevate dosi confrontate con dosi standard di cisplatino in combinazione con epidoxorubicina e
ciclofosfamide nei pazienti con cancro ovarico in fase avanzata: uno studio randomizzato, Abstract No. 880, in: Proc.
Amer. Soc. Clin. Oncol. 12, pp 273, 1993.
82) Coveney E.: Active immunization using dendritic cells mixed with tumor cells inhibits the growth of primary breast
cancer, Surgery, 122, pp.: 228-234, 1997
83) Creagan ET: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A
controlled trial. N Engl J Med;301, pp:687-90, 1979
84) D’Arrigo C.:Nuove prospettive di chemioterapia anti-neoplastica cobn spostanze estratte da piante
farmacologicamente sconosciute in campo oncologico, Minerva Med., Vol. 84, 1993, pp 275-289
85) Davis RH, Biological activity of Aloe Vera. Se. fen. Oele, Fette, Wachse, 119, 646, pp 648-649, 1993
86) Davis RH: Anti-inflammatory and wound healing activity of growth substance in Aloe Vera, J. Am. Podiatric Med.
Assoc. 84 (2), pp77-81, 1994
87) Davis RH: processed Aloe Vera administered topically inhibits inflammation, J. Am. Podiatric Med. Assoc., Vol.
79, ISS 8, pp. 395-397, 1989
88) Davis RH: Aloe Vera, Hydrocortisone, and steral influence on wound tensile strenght and anti-inflammation, J.
Am. Podiatr. Med. Assoc. 84 (12) pp. 614-621, 1994
89) Davis RH.: Anti-Inflammtory activity of Aloe Vera against a spectrum of irritans, J. Am. Podriatr. Med. Assoc.,
Vol. 79, ISS 6, pp 263-276, 1989
90) Deacon J.M.: Experimental pharmacokinetics of RSU-1069 and its analogues: high tumor/plasma ratios. Session 1,
“Int. J. Radiat. Oncol. Biol. Phys.”, Vol. 12, pp. 1087-1090, 1986.
91) DeCosse JJ: Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous
polyposis, J. Natl. Cancer Inst.; 81, pp: 1290-1297, 1989.
92) Degos L: Differentiation therapy in acute promyelocytic leukemia: European experience, J Cell Physiol.; 173, pp
285-287, 1997
93) De Palo G: Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia, J
Cell Biochem Suppl.; 22, pp: 11-17, 1995.
94) de Vos S: Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cells, Prostate; 32, pp:
115-121, 1997
95) Dimery IW: Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity, Ann Oncol.; 8, pp: 85-89,
96) Dishe S.: Concentrations achieved in human tumors after administration of misonidazole, SR-2508 and RO 03-
8799, Session 1, “ Int.J. Radiat.Oncol. Biol.Phys.” Vol. 12, pp 1109-1111, 1986.
97) Dische S., Keynote Address: Hypoxic cell sensitizers : clinical developments, Session 3,”Int. J. Radiat. Oncol. Biol.
Phys.”, Vol. 16, pp 1.057-1.060, 1988.
98) Dodion P.: Cancro della testa e del collo, in: Slevin and Staquet, Studi randomizzati del cancro: un inventario
critico per locazioni, Raven Press, New York, pp. 525-547, 1986
99) Doherty N.: Muscle Cramping in phase I clinical trials of Tirapazamine (SR-4233) with and without radiation, “Int.
J. Radiat. Oncol. Biol. Phys.”, Vol. 29, pp. 379-382, 1994.
100) Dolivet G: Current knowledge on the action of retinoids in carcinoma of the head and neck, Rev Laryngol Otol
Rhinol (Bord).; 117, pp. 19-26, 1996 .
101) Dorie M.J.: Comparison of the enhancement of tumor responses to fractionated by SR-4233 (Tirapazamine) and
by nicotinamide with carbogen, “Int. J. Radiat. Oncol. Biol. Phys.” Vol. 29, pp. 145-150, 1994.
102) Dreosti I.E.: Inhibition of carcinogenesis by Tea the evidence from experimental studies, Crit. Rev. Food. Sci.
Nutr.; 37 pp.:761-70 1997.
103) Durrant K.R.: Confronto delle scelte di trattamento in carcinoma bronchiale inoperabile, in: The Lancet, vol. I,
PP. 715-719, 1971
104) Echizen H.: The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans, “Am.
Heart J.”, 109, pp. 210, 1985.
105) EI, Hanna N., Role of Natural killer cells in the destruction of cirulating tumor emboli, Journal National Cancer
Institute, VOL. 65, 1980, PP 801-809
106. Eisenhauer EA: Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors,
Leukemia; 8, pp: 1622-1625, 1994.
107) Eisenhauer E: A phase II study of spirogermanium as second line therapy in patients with poor prognosis
lymphoma. An NCI Canada Clinical Trials Group Study, Invest New Drugs, 3:3, pp: 307-310, 1985.
108) el-Bayoumy K: Evaluation of chemopreventive agents against breast cancer and
proposed strategies for future clinical intervention trials, Carcinogenesis; pp: 2395-2420, 1994.
109) Ellenberg S.: Surrogate endpoints in clinical trials, in : Cancer Statist. In Med., vol. 8, pp. 405-413, 1989
110) Ettinger DS: Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the
treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study, Med Pediatr
Oncol, 17:3, pp: 197-201, 1989.
111) Evans AG: A trial of 13-cis-retinoic acid for treatment of squamous cell carcinoma and preneoplastic lesions of
the head in cats, Am J Vet Res.; 46, pp: 2553-2557, 1985
112) Fair WR: Cancer of the prostate: a nutritional disease?, Urology.; 50, pp: 840-848. 1997.
113) Folkman J.: Angiogenesis, in „Harrison’s Principles of Internal Medicine”, XV Ed. , Braunwald E., Mc Graw-Hill,
114) Forbes J.F.: Oforectomia confrontata con Chemio-Terapia citotossica: unostudio randomizzato in donne in
premenopausa con cancro della mammella in fase avanzata, Abstract No. 146, in: Proc. Amer. Soc. Clin. Oncol., vol.
11, p 80, 1992
115) Fox S.: Angiogenesis: Pathological, Prognostic and Growth-Factor Pathways and Their Link to trial Design and
anticancer Drugs, Lancet, 2001
116) Franz H.: Misletoe Lectins and their A and B chain, Oncology, 43, Suppl. 1, pp.: 1-70, 1986
117) French Epirubicin Study Group: A prospective randomized trial comparing Epirubicin monochemotherapy to two
Fluorouracil, Cyclophosphamide, and Epirubicin regimens differing in Epirubicin dose in advanced breast cancer
patients, Journal of Clinical Oncology, vol.9, No.2, 1991, pp.: 305-312 (Uno studio randomizzato che confronta la
semplice Chemio-Terapia con epirubicina alla poliChemio-Terapia con fluorouracile, ciclofosfamide ed epirubuicina
per pazienti con avanzato cancro della mammella).
118) Frey C.: Studio randomizzato di 5-FU e CCNU per il cancro pancreatico, in: Cancer, vol. 47, pp. 27-31, 1981
119) Fukazawa H: Multidisciplinary treatment of head and neck cancer using BCG, OK-432, and Ge-32 as biologic
response modifiers, Head Neck, 16:1, pp.: 30-8, 1994
120) Fukushima T.: Current situation and perspective for treatment of acute myelogenous leukemia in adults, Gan To
Kagaku Ryoho.; 25, pp: 295-302, 1998, Japanese.
121) Fukutani H: Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute
promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid, Leukemia, 9: pp. 8-1482, 1995.
122) Gallmeier WM: Vitamin C and cancer, MMW Munch Med Wochenschr;124, pp: 31-2, 1982
123) Gao YT: Reduced risk of esophageal cancer associated with green thea consumption, Journal of the National
Cancer Institute Vol. 86, 855-858.
124) Garetto G., La Nuova Medicina d’Urgenza: Riconoscimento-Gestione-Trattamento delle Urgenze Extra ed Intraospedaliere,
C.G. Edizioni Medico-Scientifiche s.r.l., Torino.
125) Garewal HS: Emerging role of beta-carotene and antioxidant nutrients in prevention of oral cancer, Arch
Otolaryngol Head Neck Surg.; 121, pp: 141-144. 1995.
126) Geiger J.D.: Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the
treatment of spontaneous metastases, J. Immunotherapy, 13, pp.: 153-165, 1993.
127) George TK: Sopravvivenza a lungo termine per il carcinoma polmonare a piccole cellule, in : Cancer, vol. 568,
pp. 1193-1198, 1986
128) Gescher A: Suppression of tumour development by substances derived from the diet mechanisms and clinical
implications, Br J Clin Pharmacol.; 45, pp. 1-12. . 1998
129) Gerweck E.L., PO2 in irradiated versus non-irradiated tumors of mice breathing oxygen at normal and elevated
pressure, “Int. J. Radiat. Oncol. Biol. Phys.” 32, pp. 695-701, 1995.
130) Gey KF: Vitamins E plus C and interacting conutrients required for optimal health. A critical and constructive
review of epidemiology and supplementation data regarding cardiovascular disease and cancer, Biofactors. 7, pp: 113-
174, 1998.
131) Giannini F: All-trans, 13-cis and 9-cis retinoic acids induce a fully reversiblegrowth inhibition in HNSCC cell
lines: implications for in vivo retinoic acid use, Int J Cancer, 17; 70: pp.194-200, 1997
132) Gilboa E.: Immunotherapy of cancer with genetically modified tumor vaccines, Sem. Oncol., 23, pp.: 101-107,
133) Giovannucci E: Selenium and risk of prostate cancer (selenio e rischio di cancro alla prostata), Lancet. 5;
352(9130): pp.755-756, 1998.
134) Goldstein A.L., Thymosins, “Clin. Immunnol. Allerg.” 3, pp. 119, 1983.
135) Gomes A.: Anti-hyperglyemic effect of black tea (Camellia sinensis) in rat, J. Ethnopharmacol., 45, pp.: 223-226.
136) Gonzalez PM: Clinical studies in head and neck cancer chemoprevention, Cancer Metastasis Rev., 15: pp. 113-
118, 1996 .
137) Goodman GE: The clinical evaluation of cancer prevention agents, Proc Soc Exp Biol Med.; 216, pp: 253-259,
138) Goodman GE: Pharmacokinetics of 13-cis-retinoic acid in patients with advanced cancer, Cancer Res.; 42, pp:
2087-2091, 1982
139) Goodman S: Therapeutic effects of organic germanium, Med Hypotheses, 1988 Jul, 26:3, 207-15
140) Gottshall RY: Substances in seed plants actaive against Tubercule bacilli, American Review of tubercolosis
1950, Vol. 62
141) Govallo V.: Trenta cinque casi, una compliazione di casi clinici, Lewin B., Genes V., Oxford University Press,
New York 1994
142) Greenberg ER: A clinical trial of antioxidant vitamins to prevent colorectal adenoma, Polyp Prevention Study
Group, N Engl J Med.; 331(3): 141-147, 1994.
143) Greenwald P: Preventive clinical trials. An overview, Ann. N.Y. Acad Sci.; 768, pp: 129-140, 1995.
144) Greiner J.W., Recombinant Interferon Enhances Monoclonal Antibody-Targeting of Carcinoma Lesions in Vivo,
“Science”, Vol. 235, 20 febr. 1987.
145) Greiner, Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumorassociated
glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells, “J. Clin. Oncol.”, 10, 5, pp. 735-
746, 1992.
146) Gribrel N.V.: Antimetastatic properties of Aloe Jiuce, Onkol, 32, pp 38-40, 1986
147) Gurchot C: La teoria dei trofoblasti del cancro, Revisited Oncology, Vo. 31, pp. 310-333, 1975
148) Guskova A.K., Acute radiation effects in victims of the Chernobyl nuclear power plant accident, In: “Sources,
Effects and Risks of ionizing Radiation: United Nations Scientific Committee of the Effects of Atomic Radiation”.
UNSCEAR 1988 Report.
149) Hagi A.: Antibradykinin active material in Aloe Saponaria, J. Pharm. Sci. 71 (10) 1172-4, 1982
150) Hahn S.M., Potential Use of Nitroxides in Radiation Oncology, “Cancer Res. Suppl.”, 54, pp. 2006s-2010s, 1994.
151) Haimovici N., in Bistolfi F., “Campi magnetici in medicina”, Minerva, pp.465, 1986.
152) Hajito T.: NK and ADCC and LGL frequencies in Viscum album. Treated Breast Patients, in: Oncology, 43,
Suppl. 1, pp.: 51- 65; pp. 93-97, 1986.
153) Hajito T.: Increased secretion of tumor necrosis Factor alpha Interleukin 1 and Interleukin 6 by Human
Mononuclear Cells exposed to beta-Galactoside-Specific Lectin from Clinically Applied Mistletoe extract, Cancer
Research, vol. 50, pp. 3322-3326, 1990.
154) Hallissey M.T.: Secondo studio britannico sul cancro dello stomaco con radioterapia o Chemio-Terapia in cancro
gastrico operabile, in : The Lancet, vol. 343, pp. 1309-1312, 1994.
155) Han C.: Screening of anticarcinogenics ingredients in Tea polyphenols, Cancer Lett; 114, pp.: 153-8 1997.
156) Han J: Highlights of the cancer chemoprevention studies in China, Prev Med.; 22, pp: 712-722, 1993.
157) Hansen CM.: EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects
on target cells, Biochem Pharmacol.; 54, pp: 1173-1179. Review. 1997.
158) Hansen: Cancro polmonare non a piccole cellule in fase avanzata: trattare o non trattare?, in: J.Clin. Oncol., vol.
5, pp. 1711-1712, 1987.
159) Harris J.R.: Cancro della mammella, in: De Vita: Cancro, principi e pratica dell’oncologia, Lippincott and Co,
Philadelphia , 4.a edizione, pp. 264-1332, 1993.
160) Hassan HT: Recombinant human interleukin-3 opposes the effects of vitamins A and D on HL-60 human myeloid
leukaemia cells, Anticancer Res.; 12, pp: 821-825, 1992
161) Hayes M.P.: Regulation of Interleukin-12 expression in human Monocytes: selective priming by interferon of
Lipopolysach rideinducible p35 p40 genes, Blood, 86, pp. 646-650, 1995
162) Hart LA: Two functionally and chemically distinct immunomodulatory compounds in the gel of Aloe, J.
Ethnopharmacol., , 23 (1), pp. 61-71, 1988
163) Hart LA, : Effects of low molecular constituents from Aloe Vera gel on oxidative metsabolism and Cytotoxic and
bactericidal activities of human neutrophils, Int. J. Immunopharmacol., Vol. 12, ISS 4, pp. 727-434, 1990
164) Heggers J.P.: Beneficial effects of Aloe in wound healing, Phytotherapy Research Vol.7, No. Special issue, pp.
S48-S52, 10 pl, (5 col. pl.), 1993
165) Heinonen OP: Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and
mortality in a controlled trial, J. Natl. Cancer Inst.; 90, pp: 440-446, 1998
166) Henk J.M., Radiotherapy and hyperbaric oxigen in Head and Neck cancer, “The Lancet”, 16, 1977.
167) Hennekens CH: Antioxidant vitamins and cancer, Am. J. Med.; 97(3A): 2S-4S. 1994
168) Herman T.S.: A phase I-II trial of cisplatin, hyperthermia and radiation in patients with locally advanced
malignancies, “Int. J. Radiat. Oncol. Biol. Phys.” 17, pp. 1273-1279, 1989.
169) Herman T.S.: Interaction of hyperthermia and radiation: hypoxia and acidosis in vitro, tumor subpopulations in
vivo, “Cancer Research”, 49, pp. 3338-3343, 1989.
170) Herman T.S.: Interaction of SR-4233 with Hyperthermia and Radiation in the FSaIIC Murine Fibrosarcoma
Tumor System in Vitro and inVivo, “Cancer Research”, 50, pp. 5.055-5059, 1990.
171) Hermans J.: Terapia di supporto per cancro gastrico dopo intervento chirurgico: meta-analisi di trial
randomizzati, in: J. Clin. Oncol. Vol. 11, pp. 1441-1447, 1993
172) Herscher L.L., Protection against SR4233 (Tirapazamine) aerobic cytotoxicity by the metal chelators
Desferrioxamine and Tiron, “Int.J.Radiat.Oncol.Biol.Phys.” Vol.30, pp.879-885, 1994.
173) Hibasami H: Induction of apoptosis in human stomach cancer cell by Green Tea catechins, Oncol Rep; 5, pp: 527-
9 1998.
174) Hill BT: Identification of synergistic combinations of spirogermanium with 5-fluorouracil or cisplatin using a
range of human tumour cell lines in vitro, Invest New Drugs, 2:1, pp: 29-33, 1984
175) Hine K.R.: Hine K.R.: Prospective randomised trial of early cytotoxic therapy for recurrent colorectal carcinoma
detected by serum CEA, Gut 25, pp.: 682-688, 1984 (Studi randomizzati di terapia citotossica anticipata per cancro
colon-rettale secondario rilevato attraverso CEA).
176) Hiranmoy D.: Vgamma2 V delta 2 T-cell receptor-mediated recognition of aminobisphosphonates, Blood, 98:
1616-1618, 2001.
177) Hirst D.G.: Oxygen delivery to tumors, Session 4, „Int.J. Radiat. Oncol. Biol. Phys.” Vol. 12, pp. 1271-1277, 1986
178) Hockey M.S.: Cancro gastrico, in: Slevin and Staquet, Studi randomizzati del cancro: un inventario critico per
locazioni, Raven Press, New York, pp. 221-240, 1986
179) Hoeji: Anticancer effects of Aloe on Sarcoma 180 in ICR Mouse and on Human Cancer Cell Lines, 38, pp.: 311-
321, 1994
180) Holladay FP.: Cytotoxic T Lymphocytes, but not Lymphokine activated killer Cells, exhibit anti-tumor activity
against established intracerebral Gliomas, J. Neurosurgery 77, pp 757-762, 1992.
181) Holloway C: A randomized trial of vitamins C and E in the prevention of recurrence of colorectal polyps, Cancer
Res,48, :4701-5, 1988.
182) Honma H: Clinical efficacy of schizophyllan (SPG) in treatment of lung cancers. A Randomized controlled study,
Haigan 22, pp: 499-512, 1992
183) Hoogstraten B.: Combination chemotherapy and adriamycin in patients with advanced breast cancer, a Southwest
Oncology Group Study, Cancer, 38, pp.. 13-20, 1976 (Chemio-Terapia multipla con Adriamicina in pazienti con cancro
della mammella in fase avanzata).
184) Horrisman M.R.: Relationship between the Hydralazine-induced Changes in murine Tumor Blood supply and
mouse blood Pressure, “Int. J. Radiat. Oncol. Biol. Phys.”, Vol. 22, pp 455-458.
185) Hoskin P.J.: Administration of Nicotinamide during chart: Pharmacokinetics, dose escalation, and clinical
toxicity, “Int. J. Radiat. Oncol. Biol. Phys.”, Vol. 32, pp 1111-1119, 1995.
186) Hoskins WJ.: Tumori ginecologici, in De Vita: , Cancro, principi e pratica dell’oncologia, Lippincott and Co,
Philadelphia , 4.a edizione, pp. 1125-1152, 1993
187) Hsu MC: Systemic treatment of neoplastic conditions with retinoids, J. Am. Acad. Dermatol. 39, pp. S108-S113,
188) Hu O.Y: Determination of anticancer drug vitamin D3 in plasma by high-performance liquid chromatography, J
Chromatogr B Biomed Appl.; 666, pp: 299-305, 1995.
189) Hutter J.A.: anti-inflammatory C-Glucosyl Chromone from Aloe Barbadensis, J. Nat. Prod., Vol. 59, ISS 5, PP
541-543, 1996
190) Huttunen JK: Why did antioxidants not protect against lung cancer in the Alpha-Tocopherol, Beta-Carotene
Cancer Prevention Study? , I.A.R.C. Sci. Publ. 136, pp: 63-65, 1996;
191) Ikekawa, T: Antitumor action of some basidiomycetes, especially Phellinus linteus, Gann. 59, pp: 155-157, 1968.
192) Inoue, M: Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofilan
immunotherapy: a prospective randomized controlled study, Biotherapy, 6, pp:13-8, 1993.
193) Ishiwata Y: Effects of proxigermanium on interferon production and 2′,5′-oligoadenylate synthetase activity in the
lung of influenza virus-infected mice and in virus-infected human peripheral blood mononuclear cell cultures,
Arzneimittelforschung, , 40:8, pp: 896-899, 1990
194) Ito H.: Protection of acute and late radiation damage of the gastrointestinal tract by WR-2721,“Int. J. Radiat.
Oncol. Biol. Phys.”, Vol. 12, pp. 211-219, 1986.
195) Jacobs C.: Efficacia della Chemio-Terapia di supporto per pazienti con tumore operabile della testa e del collo,
in: J. Clin. Oncol., vol. 8 pp. 838-847, 1990
196) Jaeckle K.A. : Evaluation of Serratia marcesenses extract for malignant astrocytomes, J. Clin. Oncol., vol. 8, pp.
1408-1418, 1990
197) Jaffey M: Vitamin C and cancer: examination of the Vale of Leven trial results using broad inductive reasoning,
Med Hypotheses , 8, pp:49-84, 1982.
198) Jakubowski A: Phase I Study of Continuous-Infusion Recombinant Macrophase Colony-stimulating Factor in
Patients with Metastatic Melanoma, Vol 2, pp. 295-302, 1996.
199) Jirtle R.: Chemical modification of tumor blood flow, “Int. J. Hiperthermia”, Vol.4, pp. 355-371, 1988.
200) Jozan S.: Cytotoxic effect of interferon-alpha2a in combination with all-trans retinoic acid or cisplatin in human
ovarian carcinoma cell lines, Anticancer Drugs; 9, pp.229-238. 1998
201) Kaanders: A convenient and reliable method for carbogen breathing in man, “Radiotherapy and Oncology”, 29,
pp. 341-343, 1993.
202) Kaegi E: Unconventional therapies for cancer: 5. Vitamins A, C and E. The Task Force on Alternative Therapies
of the Canadian Breast Cancer Research Initiative. CMAJ.; 158, pp: 1483-1488. Review, 1998
203) Kalemkerian GP: Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines, J
Natl Cancer Inst.; 87, pp: 1674-1680, 1995.
204) Kane M.J.: Trattamento di supporto per il carcinoma del colon e del retto, in: Seminars in Oncology, vol. 18, pp.
421-442, 1991.
205) Kaufmann M.: Interview in Cancer Care, volume 1, edizioni MMV, p.8, 1994
206) Kearsley J.H.: Cytotoxic chemotherapy for common adult malignancies: “the emperor’s new clothes” revisited,
British Medical Journal, Vol. 293, 1986, pp.: 871-876 (Chemio-Terapia citotossica per carcinomi comuni negli adulti).
207) Kelleher D.K.: Nicotinamide exerts different acute effects on microcirculatory function and tissue oxygenation in
rat tumors, Int. J. Radiat. Oncol. Biol. Phys., Vol. 26, pp. 95-102, 1993.
208) Kelloff GJ: Clinical development plan: vitamin D3 and analogs, J. Cell. Biochem. Suppl.; 20: 268-281, 1994.
209) Kelloff GJ.: New agents for cancer chemoprevention, J. Cell. Biochem Suppl.; 26: 1-28, 1996
210) Kelsen D.: Terapia di supporto per cancri del tratto superiore gastro-intestinale, in: Seminars in Oncol., vol. 18,
pp. 543-559, 1991
211) Ken’ichi I.: Aloctin A, an active substance of Aloe arborescens Miller as an immunomodulator, Phytotherapy
Research, Vol. 7, S20-22, 1993
212) Kessler JF: Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides), Arch Dermatol.; 123, pp:
201-204, 1987.
213) Khuri FR: Molecular epidemiology and retinoid chemoprevention of head and neck cancer, J. Natl. Cancer Inst.
5; 89: pp 199-211, 1997.
214) Khuri FR: Chemoprevention of respiratory tract cancer, Hematol Oncol Clin North Am. Jun; 11, pp: 387-408,
215) Kiang D.T.: Uno studio randomizzato su Chemio-Terapia e ormono-terapia per il cancro avanzato della
mammella, in: The New Engl. J. Med., vol. 313, pp. 1241-1246, 1985
216) Kim JW: Effect of 13-cis-retinoic acid with neoadjuvant chemotherapy in patients with squamous cervical
carcinoma, Am. J. Clin. Oncol.; 19, pp.442-444, 1996.
217) Kim YH: Chemopreventive effect of green tea (Camellia sinensis) among cigarette smokers, Cancer Epidemiol.
Biomarkers Prev., 4 pp.: 387-389, 1995
218) Kimura K: What remaining questions regarding Helicobacter pylori and associated diseases should be
addressed by future research? View from the Far East.Gastroenterology;113(6 Suppl), pp:S155-7, 1997
219) Kimura Y.: Clinical evaluation of sizofilan as assistant immunotherapy in treatment of head and neck cancer, Acta
Oto-Laryngologica – Suppl. 511, pp:92-5, 1994.
220) Kupin, V.: A new biological response modifier – ganoderma lucidum – and its application in oncology, In
Proceedings from the 6th international symposium on ganoderma lucidum. Seoul, II Yang, pp.36-37, 1994.
221) Kingston R.D.: Il trial del West Middlands per la Chemio-Terapia del carcinoma gastrico: impostazioni e
risultati, in: Clinical Oncology, vol. 4, pp. 55-69, 1978
222) Kitamura K: All-trans retinoic acid therapy in acute promyelocytic leukemia current status and prospect, Rinsho
Ketsueki.; 37, pp:760-765,1996, Japanese.
223) Klastersky J.: Cancro dei polmoni a piccole cellule: possono i risultati della Chemio-Terapia essere migliorati
ulteriormente ? , in Seminars in Oncology, vol. 22, Suppl. 2, pp. 11-12, 1995.
224) Klaunig JE: Chemopreventive Effects of Green Tea Components on Hepatic Carcinogenesis, Prev Med, 21 pp:
510-9 1992 .
225) Klein AD. Aloe Vera, J.Am. Acad. Dermatol. , 18 (4 Pt 1), pp.:714-720, 1988
226) Klingerman, “Int. J. Radiat. Oncol. Biol. Phys.”, Vol. 14, pp 1119-1122, 1988.
227) Klingerman, “Cancer Clin. Trial.”, 3, pp. 217-221,1980.
228) Knekt P: Vitamin E and cancer prevention, Am J Clin Nutr.; 53(1 Suppl): 283S-286S, 1991.
229) Knekt P: Role of vitamin E in the prophylaxis of cancer, Ann Med.; 23, pp: 3-12. 1991
230) Kohda, H.: The biologically active constituents of Ganoderma Lucidum. Histamine release-inhibitory triterpenes,
Chem. Pharm. Bull. 33, pp.:1367-1374; 1985.
231) Koike M.: 19-nor-hexafluoride analogue of vitamin D3: a novel class of potent inhibitors of proliferation of
human breast cell lines, Cancer Res.; pp: 4545-4550, 1997
232) Kokron O.: Ifosfamide confrontata con Ifofosfamide + CCNU nel trattamento del cancro inoperabile dei
polmoni a piccole cellule, in : Onkologie , vol. 5, pp. 56-59, 1982.
233) Kozin S.V., Hydralazine at thermoradiotherapy : tumor size and blood flow effects, “Int. J. Radiat. Oncol. Biol.
Phys.”, Vol. 29, pp. 505-510, 1994 .
234) Kristjansen P.E.G., Dexamethasone Reduces the Interstitial Fluid Pressure in a Human Colon Adenocarcinoma
Xenograft, “Cancer Research”, 53, pp. 4764-4766, 1993.
235) Kudelka AP: Metastatic adenocarcinoma of the endometrium treated with 13-cis-retinoic acid plus interferonalpha,
Anticancer Drugs; 4, pp: 335-337, 1993.
236) Kuhn J.A.: Interferon Enhancement of Radioimmunotherapy for Colon Carcinoma, “Cancer Research” 51, pp.
2335-2339, 1991.
237) Kumano N: Effect of Carboxyethylgermanium Sesquiossid on the methylcholonthrene induced tumorigenesis in
mice, Sci Rep Res Inst Tohoku Univ [Med], 25: 3-4, pp.: 89-95, 1978
238) Kunzmann F.: Stimulation of gamma-delta T cells by aminobisphosphonates and induction of antiplasma cell
actiivity in multiple -myeloma, Blood, 96: 384-392, 2000;
239) Kupchan SM: Tumor inhibitors Aloe Emodin: antileukemic Principle isolated from Rhamnus Frangula L., 39, pp
223-224, 1976.
240) Kyle RA: Effect of sodium fluoride, calcium carbonate, and vitamin D on the skeleton in multiple myeloma,
Cancer.; 45, pp: 1669-1674, 1980.
241) Lad T.E.: Immediate versus postponed combination chemotherapy (CAMP) for unresectable Non-Small Cell Lung
Cancer: a randomized trial, Cancer Treatment Reports, Vol. 65, No.11-12, 1981 (Chemio-Terapia immediata
confrontata con Chemio-Terapia ritardata per il cancro inoperabile dei polmoni non a piccole cellule).
242) Laing A.H.: Trattamento di carcinoma bronchiale a piccole cellule, in: The Lancet, vol. II, pp.. 1161-1165, 1975B
243) Lamberts: The role of somatostatin and its analogs in the diagnosis and treatment of tumours, “Endocr. Rev.”, 12,
pp. 450-482, 1991.
244) Lamm DL: Megadose vitamins in bladder cancer: a double-blind clinical trial, J. Urol;151, pp:21-6, 1994.
245) Langmuir V.K.: The combined Use of 131-I-Labeled Antibody and the Hypoxic Cytotoxin SR-4233 in Vitro and in
Vivo, “Radiation Research”, 132, pp. 351-358, 1992.
246) Launoy G: Diet and squamous-cell cancer of the oesophagus: a French multicentre case-control study, Int J
Cancer;76, pp:7-12 , 1998.
247) Lee H.Z.: Effects and mechanisms of emodin on cell death in human lung squamous cell carcinoma, Br. J.
Pharmacol., 134, pp.11-20, 2001.[ 07042050a.pdf]
248) Lee I., Changes in tumor bood flow, oxygenation and interstitial fluid pressure induced by pentoxifylline, “Br. J.
Cancer”, 69, pp. 492-496, 1994.
249) Lee CH: Effects of Germanium oxide and other chemical compounds on phenylmercury acetate-induced
genotoxicity in cultured human lymphocytes, Environ Mol Mutagen, 31:2, pp:157-162, 1998,
250) Lee, SS.: In vivo anti-tumor effects of crude extracts from the myeelium of ganoderma lucidum, J. of Chinese
Oncology Society 5: 22-28, 1984.
251) Lee JM.: Inhibition of lipid peroxidation and oxidative DNA damage by Ganoderma lucidum, Phytother Res., 15,
pp. 245-249, 2001
252) Lenartz D., Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive
therapy in glioma patients, Anticancer Research, pp.: 3799-3802, 1996
253) Lin J.M.: Evaluation of the anti-inflammatory and Liver-protective effects of Anoectochilus formosanus,
Ganoderma Lucidum and Gynostemma pentaphylum in rats, Amer.J. Chin. Med. 21, pp:59-69, 1993.
254) Lipkin M.: Calcium and the prevention of colon cancer, J. Cell. Biochem. Suppl.; 22, pp: 65-73. Review, 1995
255) Lippman SM: The effect of 13-cis-retinoic acid chemoprevention on human serum retinol levels, Cancer Detect
Prev.; 22, pp. 51-56, 1998
256) Lippman SM: Retinoid-interferon therapy of solid tumors, Int J Cancer. 7; 70: pp.481-483. 1997.
257) Lippman SM: Treatment of advanced squamous cell carcinoma of the skin with isotretinoin, Ann Intern Med.;
107, pp.499-502, 1987
258) Lissoni P., Immunonoendocrine Therapy with Low-Dose Subcutaneous Interleukin-2 plus Melatonin of Locally
Advanced or Metastatic Endocrine Tumors, Oncology, 52, pp. 163-166, 1995.
259) Liu R.J.: Risultati della Chemio-Terapia nei carcinomi dei polmoni non apiccole cellule, in : Seminars in Oncol.,
vol. 20, pp. 296-301, 1993
260) Liu T.: Use of radiation with or without WR-2721 in advanced rectal cancer, “Cancer”, 69, pp. 2820-2825, 1992.
261) London RS: The effect of vitamin E on mammary dysplasia: a double-blind study. Obstet Gynecol.; 65, pp: 104-
106, 1985
262) Lorenzetti: Bateriostatic Property of Aloe Vera, Journal of Pharmaceutical Sciences, 1964, Vol. 53, pp. 1287
263) Lotan R: Retinoids as modulators of tumor cells invasion and metastasis, Semin.Cancer Biol.; 2, pp: 197-208,
264) Lovas JG.: Beta-carotene and lung cancer?, Oral Surg Oral Med Oral Pathol Oral Radiol Endod.; 82, pp. 236-237,
265) Lovat PE: Concentration-dependent effects of 9-cis retinoic acid on neuroblastoma differentiation and
proliferation in vitro, Neurosci Lett.; 182, pp: 29-32, 1994.
266) Lovat PE: Apoptosis of N-type neuroblastoma cells after differentiation with 9-cis-retinoic acid and subsequent
washout, J Natl Cancer Inst., 19; 89, pp: pp.446-452, 1997
267) Lushbaugh C.C.: Experimental acute radiodermatitis following beta irradiation of nuclear fallout, USS. Atomic
Energy Commission , pp 698, 1953.
268) Macaulay V.: Cancro della Mammella in fase avanzata, in: Slevin and Staquet, Studi randomizzati del cancro: un
inventario critico per locazioni, Raven Press, New York, pp. 273-357, 1986
269) Mainwaring MG: Complete remission of pulmonary spindle cell carcinoma after treatment with oral germanium
sesquioxide, Chest, 117, pp. 591-593, 2000; Chest, 117, pp. 307-308, 2000
270) Malone WF: Chemoprevention of bladder cancer, Cancer; 60 (3 Suppl), pp: 650-7, 1987.
271) Mannel D.: Induction of tumor necrosis factor expression by a lectin from Viscum album, Cancer Immunology
Immutherapy, vol. 33, pp. 177-182, , 1991.
272) Marschner N: valutazione della rilevanza dell’intensità del dosaggio nella Chemio-Terapia con epirubicina e
ciclofosfamide per il cancro metastatico della mammella,in: Semin in Oncol., vol. 21, Suppl. 1, pp. 10-16, 1994
273) Masafumi O.: Mechanism of anti-inflammatory and antithermal burn action of CPase from Aloe arborescens
Miller var. Natalensis Berger in rats and Mice, Phytotherapy Research, Vol. 7, S30-S33, 1993.
274) Matsumoto H.: Inhibition of lipid peroxidation as a biomarker of carcinogenesis by Green Tea Polyphenols
(Meeting abstracts): Proc. Annu. Meet. Am. Assoc. Cancer Res.; 38: A 2448 1997
275) Matsushita S., Radioprotection by WR-151327 against the late normal tissue damage in mouse hind legs from
gamma ray radiation, “Int.J.Radiat.Oncol.Biol.Phys.”, Vol. 30, pp. 867-872, 1994.
276) McCarty MF: An antithrombotic role for nutritional antioxidants: implications for tumor metastasis and other
pathologies, Med Hypotheses; 19: 345-357, 1986. .
277) Mc Donald: Chemio-Terapia del cancro gastrico in fase avanzata: stato presente e prospettive future, in :
Seminars in Oncology, vol. 15, Suppl. 3, pp. 42-49, 1988
278) Mc Donald S.: Combined Betaseron R (Recombinant Human Interferon Beta) and Radiation for inoperable nonsmall
cell lung cancer, “Int.J. Radiat. Oncol. Bio. Phys.” Vol. 27, pp. 613-619, 1993.
279) Mc Dougall C.J.: Reduced expression of HLA class I and II antigens in colon cancer, “Cancer Research”, 50, pp.
8023, 1990.
280) Mc Keown-Eyssen G: A randomized trial of vitamins C and E in the prevention of recurrence of colorectal
polyps, Cancer Res.; 48, pp: 4701-4705, 1988
281) Mc Millan TJ.: Può la Chemio-Terapia aumentare il comportamento maligno dei tumori ?, in Cancer and
Metastatic Review, vol. 6, pp. 503-520, 1987
282) Meister B.: Antiproliferative activity and apoptosis induced by retinoic acid receptor-gamma selectively binding
retinoids in neuroblastoma, Anticancer Res., 18, pp: 1777-1786. 1998
283) Mende S.: Wandel der Therapieziele beim metastasierten Mammakarzinoma, in: Schmid and Wilmanns, in:
Praktische Onkologie, vol. II, Zuckschwerdt Verlag Munchen, pp 115-122, 1992
284) Meroni P.L., In vivo Immunopotentiating Activity of Thymopentin in Aging Humans: Increase of IL-2 Production,
“Clinical Immunology and immunopathology”, 42, pp. 151-159, 1987.
285) Meyer J.: Therapieergebnisse beim Papillem und Pankreaskarzinom, in : Tumor Diagnostic and Therapie, vol. 8,
pp. 54-58, 1987
286) Meyskens FL: Role of topical tretinoin in melanoma and dysplastic nevi, J Am Acad Dermatol.; 15, pp: 822-825,
287) Mezzetti M: Population attributable risk for breast cancer: diet, nutrition, and physical exercise, J Natl Cancer
Inst.; 90, pp.389-394, 1998
288) Mielke V: Systemic treatment for cutaneous lymphomas, Recent Results Cancer Res.; 139, pp: 403-408, 1995.
289) Milas L., Effect of tumor type, size, and endpoint on tumor radioprotection by WR-2721, “Int. J. Radiat. Oncol.
Biol. Phys.” Vol. 10, pp 41-48, 1984
290) Milas L., Need for studies on factors that influence radioprotection of solid tumors by WR-2721, “ Int. J. Radiat.
Oncol. Biol. Phys.” Vol. 10, pp. 163-165, 1984.
291) Miller T.P., P-Glycoprotein Expression in Malignant Lymphoma and Reversal of Clinical Drug Resistance with
Chemotherapy Plus High-Dose Verapamil, Journal of Clinical Oncology, Vol. 9, No.1, pp 17-24, 1991.
292) Minchinton A.I., A comparison of tuor and normal tissue levels of acidic, basic and neutral 2-nitroimidazole
radiosensitizers in mice, Session 1, “Int.J. Radiat. Oncol. Biol. Phys.” Vol. 12, pp. 1117-1120, 1986.
293) Mitomi T.: Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected
colorectal cancer, Diseases of the Colon & Rectum. 35, pp:123-30, 1992.
294) Mizuno, T.: Antitumor Active Substances of Mushroom Fungi, Based Science and Latest Technology on
Mushroom, Nohson Bunka Sha, Tokyo, pp. 121-135, 1991.
295) Mizuno T.: Oriental Medicinal tradition of Ganoderma lucidum (Reishi) in China.T. Mizuno & B. -K. Kim (Eds.),
„Ganoderma lucidum” (pp.101-106). Seoul, Korea: II-Yang Pharm. Co. Ltd. 1996
296) Mitrou P.S.: Chemotherapy der nicht-Kleinzellingen Bronchialkarzinome, in : Atemw.-Lungenkrhk., vol. 12, pp.
544-549, 1986
297) Mitsuhashi N., Clinical study of radioprotective effects of amifostine (YM-08310, WR-2721) on long-term
outcome for patients with cervical cancer, “Int. J. Radiat. Oncol. Biol. Phys.” Vol. 26, pp 407-411, 1993.
298) Modiano MR: Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and
melanoma, Invest New Drugs.; 8, pp: 317-319, 1990
299) Moertel CG: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have
had no prior chemotherapy. A randomized double- blind comparison, N. Engl. J. Med.;312, pp:137-41, 1985.
300) Moertel CG.: Gestione clinica di cancro gastro-intestinale avanzato, in: Cancer, vol. 36, pp. 675-682, 1975
301) Moertel CG.: Chemio-Terapia del cancro colon-rettale, in : The New Engl. J. Med., vol. 330, pp. 1136-1142, 1994
302) Momparler RL: Interaction of 5-aza-2′-deoxycytidine with amsacrine or 1,25-dihydroxyvitamin D3 on HL-60
myeloid leukemic cells and inhibitors of cytidine deaminase, Leukemia, 7, Suppl. 1: 17-20, 1993
303) Moon RC: Vitamin A, retinoids and breast cancer, Adv Exp Med Biol.; 364, pp: 101-107, 1994.
304) Moon TE : Retinoids in prevention of skin cancer, Cancer Lett., 19; 114, pp: pp. 203-205, 1997
305) Moore DM:Retinoic acid and interferon in human cancer: mechanistic and clinical studies, Semin Hematol.; 31(4
Suppl 5), pp: 31-37, 1994.
306) Morassuti S.: Aspetti radiologici del torace durante terapia con interleukina 2, “La Radiologia Medica”, 84, pp.
368-371, 1992.
307) Moriwaki H: Prevention and treatment of solid tumors with retinoids, Gan To Kagaku Ryoho; 23, pp: 1625-1628,
1996, Japanese.
308) Moro M., Tumor cell targeting with antibody-avididin complexes and biotinylated tumor necrosis factor alfa.,
“Cancer Res.”, 57, pp. 1922-1928, 1997
309) Mukhtar H: Green Tea Polyphenols induce apoptosis and alter the progresion of cell cycle in humana epidermoid
carcinoma cells. A 431 (Meeting abstracts)
Proc. Annu. Meet. Am. Assoc. Cancer Res.; 38: A 3892, 1997
310) Munshi N.C., Effect of Tumor Irradiation on the Uptake of Lymphokine -activated Killer Cells in a Murine Tumor
Model, “ Cancer Research”, 54, pp. 1657-1659, 1994.
311) Murata A: Prolongation of survival times of terminal cancer patients by administration of large doses of
ascorbate, Int J Vitam Nutr Res Suppl;23:103-13, 1982.
312) Murayama C., Radiosensitization by a new potent nucleoside analog: 1-(1′,3′,4′-Trihydroxy-2′-butoxy)methyl-2-
nitroimidazole (RP-343), “Int. J. Radiat. Oncol. Biol. Phys.” 26, pp. 433-443,1993.
313) Muto Y: Preventive use of retinoids for occurrence of liver neoplasm, Nippon Naika Gakkai Zasshi; 84, pp:
2032-2037, 1995. Japanese.
314) Nakasugi: antimutagen of Aloe plants, Kinki Daigaku Nogakubu Kiyo, 27, pp 47-54, 1994.
315) Nelson PS: Chemoprevention for prostatic intraepithelial neoplasia, Eur Urol. 30, pp. 269-278, 1996.
316) Newman H. F., A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508
:toxicity and pharmacokinetics. Session 1., “Int. J. Radiat. Oncol. Biol. Phys.” Vol. 12, pp. 1113-1116, 1986.
317) Nicholls J.: Cancro dell’intestino crasso, in : Slevin and Staquet, Studi randomizzati del cancro: un inventario
critico per locazioni, Raven Press, New York, pp. 241-271, 1986
318) Niibe H., An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent: a double-blind
placebo-controlled study. 1. Head and Neck tumor, “J. Japanese Soc. Cancer Ther.”, 20, pp. 984-993, 1985.
319) North R.J.: The murine anti-tumor immune response and its therapeutic manipulation, Adv Immunol. 35, pp.: 89-
122, 1984.
320) Nunn A., Nitroimidazoles and Imaging hypoxia, Eur. J. Nucl. Med., Vol. 22, No. 3, 1995.
321) O’ Connel M.J.: Stato attuale della Chemio-Terapia per il cancro del collo uterino, in: Seminars in Oncol., vol. 3,
pp. 1032-1039, 1985
322) Ohno R: Progress in the treatment of adult acute myeloid leukemia, Gan To Kagaku Ryoho; 24, pp: 1053-1058,
1997, Japanese.
323) Olson RE: Vitamins and carcinogenesis: an overview, J. Nutr. Sci. Vitaminol. (Tokyo), pp: 313-316, 1992.
324) Omenn GS: Chemoprevention of lung cancer: the rise and demise of beta-carotene, Annu Rev Public Health.;
19: pp.73-99, 1998
325) Omenn GS: Interpretations of the Linxian vitamin supplement chemoprevention trials, Epidemiology; 9, pp: 1-4,
326) Omenn GS: Chemoprevention of lung cancer: the beta-Carotene and Retinol Efficacy Trial (CARET) in high-risk
smokers and asbestos-exposed workers, IARC Sci Publ.; 136: pp.67-85, 1996.
327) Omura G.A.: Chemio-Terapia per il cancro del collo uterino, in : Seminars in Oncol. Vol. 21,pp. 54-62, 1994
328) Osti E.: Ustioni cutanee di vario grado. Nostra esperienza con Burnshield, Pronto Soccorso Nuovo, No. 6, pp:
24-27, 2000.
329) Ozols R.F, Verapamil and Adriamycin in the Treatment of Drug-Resistant Ovarian Cancer Patients, “Journal of
Clinical Oncology”, Vol. 5, pp 641-647, 1987.
330) Ozols R.F.: Trattamento del cancro ovarico, in : Seminars in Oncol., vol. 21, Suppl. 2, pp. 1-9, 1994
331) Pagano F., BCG Immunotherapy in superficial bladder cancer, Cleup, Padova, 1993
332) Palan PR: Plasma concentrations of micronutrients during a nine-month clinical trial of beta-carotene in women
with precursor cervical cancer lesions, Nutr Cancer; 30, pp: 46-52, 1998
333) Palù G.: Aloe-Emodin is a new type of anticancer agent with selective activity against neuroectodermal tumors,
Cancer Research, 60, pp.2800-2804, 2000. [
334) Papadimitrakopoulou VA: Retinoids in head and neck chemoprevention, Proc Soc Exp Biol Med.; 216, pp. 283-
290, 1997.
335) Park CH: Growth modulation of human leukemic, preleukemic, and myeloma progenitor cells by L-ascorbic acid,
Am J Clin Nutr; 54 (6 Suppl), pp:1241S-1246S, 1991.
336) Parris M.: Germanium-32: homeostatic normalizer and immunostimulant a of its preventive and therapeutic
efficacy, International Clinic Nutrition , Vol 7, No 1, January 1987.
337) Patel J.K.: Migliora la sopravvivenza media nei pazienti con cancro della mammella usando un trattamento
palliativo ancora più intenso ?, in : Cancer, vol. 57, pp. :567-570, 1986
338) Patterson BH: Naturally occurring selenium compounds in cancer chemoprevention trials: a workshop summary,
Cancer Epidemiol Biomarkers Prev. 6(1): pp. 63-69, 1997
339) Patterson RE: Vitamin supplements and cancer risk: the epidemiologic evidence, Cancer Causes Control.; 8, pp.
786-802, 1997.
340) Pedersen H: Combined modality therapy for oesophageal squamous cell carcinoma, Acta Oncol.; 26, pp.175-178,
341) Pellegrini R: Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by
N-(4-hydroxyphenyl) retinamide, Cell Growth Differ., 6: pp. 863-869, 1995.
342) Peters C.E.: Blood fow modification in the SCCVII tumor : effects of 5-hydroxytryptamine, hydralazine and
propranolol, “Int. J. Radiat. Oncol. Biol. Phys.”, Vol. 22, pp 463-465.
343) Peters C.E., Mechanisms of action of the radiosensitizer nicotinamide: a physiological study, “The British Journal
of Radiology”, pp. 554, 1995.
344) Petru E.: No relevant influence on overall survival time in patients with metastatic breast cancer undergoing
combination chemotherapy, J.Cancer Res.Clin.Oncol., 1988, No: 114, pp.: 183-185 (Nessun effetto sulla sopravvivenza
totale nei pazienti con cancro metastatico della mammella sottoposti a Chemio-Terapia multipla).
345) Petterson A.V., The role of DT-Diaphorase in determining the sensitivity of human tumor cells to Tirapazamine
(SR4233),“Int. J. Radiat .Oncol. Biol. Phys.”, Vol.29, pp. 369-372, 1994
346) Phillips N.C.: Immunoliposome Tareting to CD4+ Cells in Human Blood, “Cancer Det. and Prev.”, 1990.
347) Pienta KJ: Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the
prostate, Am J Clin Oncol.; 20: pp.36-39, 1997
348) Pierce JP: Feasibility of a randomized trial of a high-vegetable diet to prevent breast cancer recurrence, Nutr.
Cancer; 28, pp. 282-288, 1997
349) Pigott K.: Short communication: The addition of carbogen and nicotinamide to a palliative fractionation schedule
for locally advanced breast cancer, ”The British Journal of Radiology”, 68, pp. 215-218, 1995.
350) Pizza Giancarlo: Immunotherapy of metastatic kidney cancer, Int. J. Cancer, 94, pp.109-120, 2001.
351) Plautz GE.: Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor draining lymph node
cells. Cellular Immunology, 178, pp: 101-107, 1997.
352) Ponzoni M: Differential effects of N-(4-hydroxyphenyl) retinamide and retinoic acid on neuroblastoma cells:
apoptosis versus differentiation, Cancer Res.; 55, pp: 853-861, 1995.
353) Possinger K., Theraiefolgsbewertung nach WHO-kriterien und Brunner Score, in : Nagel and Sauer, Aktuelle
Onkologie, W. Zuckschwerdt Verlag, Munchen, pp. 580-582, 1993
354) Potter JD: beta-Carotene and the role of intervention studies, Cancer Lett. 19; 114, pp: 329-331, 1997
355) Prasanna P.G., Modification of WR-2721 Radiation Protection from Gastrointestinal Injury and Death in Mice by
2-Mercapto-propionyl-glycine, “Radiation Research”, 133, pp. 111-115, 1993.
356) Price G.S., Effect of whole-body hyperthermia on the pharmacokinetics and toxicity of lonidamine in dogs, “Int.
Journal Hyperthermia”, Vol. 11. pp. 531-544, 1995.
357) Pronai L.: Protective effect of carboxyethyl-germanium sesquioxide (Ge 32) on superoxide generation by 60Coirradiated
leukocytes, Biotherapy; 3(3):273-9 1991
358) Queiber W.: Chemio-Terapia del carcinoma gastrico in fase avanzata, in: Onkologie, vol. 9, pp. 319-331, 1986
359) Qun Xu, Leukocyte Chemotactic Activity of Cyclophilin, “The Journal of Biological Chemistry”, pp. 11968-11971,
360) Randazzo A., L’urgenza in medicina interna. Clinica e terapia, Piccin editore.
361) Rankin E.M.: Cancro dei polmoni non a piccole cellule, in : Slevin and Staquet, Studi randomizzati del cancro: un
inventario critico per locazioni, Raven Press, New York, pp. 447-492, 1986
362) Rautalahti M: Antioxidants and carcinogenesis, Ann Med.; 26, pp.:435-441. 1994.
363) Ravi RK.: Induction of gastrin releasing peptide by all-trans retinoic acid in small cell lung cancer cells, Oncol
Rep.; 5, pp. 497-501. 1998
364) Reddy BS: Micronutrients as chemopreventive agents, IARC Sci Publ.,139: pp.221-235, 1996.
365) Redlich CA: Vitamin A chemoprevention of lung cancer. A short-term biomarker study, Adv Exp Med Biol.; 375,
pp: 17-29, 1995.
366) Regnard F.B.: La terapia dei sintomi nel cancro in fase avanzata. Manuale di medicina palliativa, CIS Editore
367) Riboli E: Identifiability of food components for cancer chemoprevention, IARC Sci Publ; pp:23-31, 1996.
368) Rice CD.: Ex vivo expansion of tumor-draining lymph node cells using compounds whith activate intracellular
signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes, J. Neuro-Oncology,
32, pp. 29-38, 1997
369) Robbins R.J., Somatostatin and Cancer, “Metabolism” 45 (8) suppl. 1, pp. 98-100, 1996.
370) Robinson S.P., Non-invasive monitoring of Carbogen-induced changes in tumor blood flow and oxygenation by
functional magnetic resonance imaging, “Int. J. Radiat. Oncol. Biol. Phys.”, Vol. 33, pp. 855-859, 1995.
371) Roffler S., Potentiation of Radioimmunotherapy by Inhibition of Topoisomerase I, “Cancer Research”, 54, pp.
1276-1285, 1994.
372) Rolamboranto L.: Immunomodulating properties of an extract isolated and partially purified from Aloe Vahombe
study of antitumoral properties and contribution to the chemical nature and active principle, Arch. Inst. Pasteur
Madagascar, 50 (1), pp. 227-256, 1982.
373) Romero P.: Cytotoxic T lymphocyte responses of cancer patiens to tumor-associated antigens, Springer Semin.
Immunopath. 18, pp.: 185-198, 1996.
374) Romieum R.: Passive but not active CD8+ T cell-basd immunotherapy interferes with liver tumor progression in a
transgenic mouse model, J. Immunology, 161, pp.: 5133-5137, 1998
375) Rosenberg S.A., Antitumor Efficacy of Lymphokine-activated Killer Cells and Recombinant Interleukin-2 In Vivo,
“Cancer Research”, 46, pp. 676–683, 1986.
376) Rosenberg S.A, Lysis of autologous melanoma cells by tumor-infiltrting lymphocytes: association with clinical
response., “J.N.C.I.”, 83, 932, 1991.
377) Rosenberg S.A., Interferon-gamma and tumor necrosis factor have a role in tumor regressions mediated by
murine CD8+ tumor-infiltrating lymphocytes, “ J. Exp. Med.”, 173, 647, 1991.
378) Rosenberg S.A., Common expression of melanoma tumor-associated antigens recognized by human tumor
infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. “J. Immunother.”, 10, 153, 1991.
379) Rosenberg S.A., Specific release of cytokines by lymphocytes infitrating human melanomas in response to shared
melanoma antigens, “J. Immunotherapy”, 1992
380) Rosenberg S.A., Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor alfa,
and IFN Gamma by human tumor infiltrating lymphocytes after autologous tumor stimulation, “Immunol.”, 146.
381) Rosenberg S.A., Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas:
analysis by cytokine secretion, “Cancer Immunology Immunotherapy”, “Springer Verlag”, 1993.
382) Roth AD: 13-cis-retinoic acid plus interferon-alpha: a phase II clinical study in squamous cell carcinoma of the
lung and the head and neck, Oncology; 51, pp: 84-86, 1994
383) Ruidi C.: Chemoprevention of cancer of uterine cervix: a study on chemoprevention of retinamide II from cervical
precancerous lesions. J Cell Biochem Suppl. 1997; 28-29: 140-143.
384) Ruoslahti E.: an address System in the Vasculature of Normal Tissues and Tumors, in: Annual Review of
Immunology, 18, pp. 813-827, 2000
385) Sacchi S: All-trans retinoic acid in hematological malignancies, an update, GER (Gruppo Ematologico Retinoidi),
Haematologica.; 82: pp.106-121, 1997.
386) Saito MT: Germanium research of surgical patients, International medical convention of surgeons, 1976
387) Saito, Purification of active substances of Aloe arborescens Miller and their biological and Pharmaceutical
activity, Phytotherapy Research, 7, S14-S19, 1993,
388) Saito H.: Effects of Aloe extracts, Aloctin A, on gastric secretion and on experimental gastric lesions in rats,
Yakugaku Zasshi, 109 (5), pp. 335-339, 1989.
389) Plant. Med., 55, pp. 509-512, 1989
390) Sankaranarayanan R:Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment, Oral
Oncol.; 33, pp: 231-236, 1997
391) Sasaki A., Low Deformability of Lymphokine-activated Killer Cells as a Possible Determinant of in Vivo
Distribution, “Cancer Research”, 49, pp. 3742-3746, 1989.
392) Sato Y.: Studies on chemical protectors Radiation XXXI. Protection effects of Aloe arborescens on Skin Injury
induced by X-irradiation, Yakagaka Zasshi , 110 (1), pp. 876-884, 1994
393) Sato Y.: Studies on chemical protectors Radiation XXXI. Protection effects of various extracts on crude drugs on
skin injury induced by X-irradiation Yakagaka Zasshi , 109, iss2, pp. 113-118, 1989
394) Saxton ML.: Adoptive transfer of anti-CD3- activated CD4+ T cells plus cyclophosphamide and liposomeencapsulated
interleukin-2 cure murine MC-38 and 3 LL tumors and establish tumor-specific immunity, Blood 89, pp:
2529-2536, 1997
395) Schafer E., Imaging pattern of radiolabelled lymphokine-activated killer cells in patients with metastatic
malignant melanoma, “European Journal of Nuclear Medicine”, 18, pp. 106-110, 1991.
396) Schalhorn A.: Chemotherapie von Kopf-Hals-Tumoren , in : Schmid and Wilmanns, in : Praktische Onkologie,
vol.: III, W. Zuckschwerdt Verlag Munchen, 1993, pp. : 52-63
397) Schantz S.P. : Cancro della testa e del collo, in : De Vita V. „Cancro, principi e pratica dell’oncologia”,
Lippincott and Co, Philadelphia, 4 a. edizione, pp. 574-630, 1993
398) Sheikh MS: N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptorindependent
pathways in human breast carcinoma, Carcinogenesis, 16, pp: 2477-2486, 1995.
399) Schein PS: Phase I clinical trial of spirogermanium, Cancer Treat Rep, 64:10-11, pp: 1051-1056, 1980
400) Scheithauer W., Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent Dverapamil,
“Br. J. Cancer”, 68, pp. 8-9, 1993.
401) Scheithauer W.: Chemotherapie des metastasierenden PankreasKarzinoms, in : Tumor Diagnostik and Therapie,
vol. 5, pp. 44-48, 1984
402) Scher RL.: Fenretinide-induced apoptosis of human head and neck squamous carcinoma cell lines, Otolaryngol
Head Neck Surg.; 118, pp: 464-471, 1998
403) Schniztler G.: Prospektiv randomisierte Prufung von 5-fluorouracil, Adriamicin, BCNU, versus Beobachtung beim
metastasierten Pankreatiskarzinom, in: Dt. Med. Wschr., vol. 114, pp. 935-938, 1986
404) Schwartz LH: Antioxidant minerals and vitamins. Role in cancer prevention. Vitamines et mineraux anti-oxydants.
Role dans la prevention du cancer, Presse Med;23, pp:1826-30, 1994.
405) Schwartz JL: The dual roles of nutrients as antioxidants and prooxidants: their effects on tumor cell growth, J.
Nutr.; 126 (4 Suppl) pp.1221S-1227S, 1996.
406) Searle PF.: Immunotherapy II: Antigens, receptors and costimulation, Cancer Met Rev., 15, pp:329-349, 1996;
407) Seigel DG: Selenium, retinol, retinol-binding protein, and uric acid: from epidemiology to clinical prevention
trials, Ann Epidemiol.; 2, pp: 343-344, 1992.
408) Senan S., Vasoactivity, a potentially important variable in the sequencing of tirapazamine (SR-4233) and
radiation, “Int. J. Radiat. Oncol. Biol. Phys.”, Vol. 29, pp. 209, 1994 .
409) Serri F: Combination of retinoids and PUVA (Re-PUVA) in the treatment of cutaneous T cell lymphomas, Curr
Probl Dermatol., 19, pp: 252-257, 1990.
410) Shalinsky DR: A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against
human oral squamous carcinoma xenografts in nude mice, Cancer Res.; 57, pp: 162-168, 1997
411) Shih L.B., The processing and Fate of Antibodies and Their Radiolabels Bound to the Surface of Tumor Cells in
Vitro: A Comparison of Nine Radiolabels, “J. Nuclear Medicine”, 35, pp. 899-908, 1994.
412) Shimizu Y., Effects of cytokines on in vitro growth of tumor -infiltrating lymphocytes obtained from human
primary and metastatic liver tumors, “Cancer Immunol. Immunother.” 32, 280, 1991.
413) Shin-Hwa Yeh, Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in
nasopharyngeal carcinoma, “European Journal of Nuclear Medicine”, Vol. 23, No. 10, pp. 1378-1383, 1996.
414) Schneider A: The role of vitamins in the etiology of cervical neoplasia: an epidemiological, Arch Gynecol
Obstet; 246, pp:1-13, 1989
415) Schorah CJ: Ascorbic acid metabolism and cancer in the human stomach., Acta Gastroenterol Belg; 60, pp:217-
9, 1997
416) Schorah CJ: Micronutrients, antioxidants and risk of cancer, Bibl Nutr Dieta, pp.: 92-107, 1995
417) Shorr R.G.L., D.I.C. Enzon Inc. 40 Kingsbridge Road, Piscataway, NJ 08854.
418) Shu S.. Tumor Immunology, JAMA, 278: 1972-1981, 1997;
419) Shu S.: Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy
against a murine tumor that lacks apparent immunogenicity, J. Immunology 143, pp.: 740-748, 1989
420) Siegfried JM: Biology and chemoprevention of lung cancer, Chest.; 113(1 Suppl) pp: 40S-45S, 1998
421) Silvestrini B., “Oncology”, 41, Supplement 1, pp 1-124, 1984.
422) Skargard L.D., The effect of low pH and hypoxia on the cytotoxic effects of SR-4233 and Mitomycin C in vitro,
“Int. J. Radiat. Oncol. Biol. Phys.”, Vol. 29, pp. 363-367, 1994.
423) Skargard L.D., Radiosensitization of Hypoxic cells at low doses. Session 1, “Int. J. Radiat. Oncol. Biol. Phys.”,
Vol. 12, pp 1075-1078, 1986.
424) Sledge G.W.: Sviluppi della Chemio-Terapia per il cancro della mammella metastatizzato, in: Seminars in Oncol.,
vol. 19, pp. 317-332, 1992
425) Smith MA: Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer, J
Clin Oncol.; 10, pp: 1666-1673, 1992.
426) Smith MA: Retinoids in cancer therapy, J Clin Oncol.; 10, pp: 839-864, 1992.
427) Soloway MS: Systemic therapy for superficial bladder cancer, Urology, 23(4 Suppl) pp: 88-93. 1984.
428) Song C.W., Cytotoxic and radiosensitivity of biological systems, IAEA Ed., pag. 39, 1976.
429) Soybel D.L.: Carcinoma del colon e del retto, in : Current Problems in Cancer, vol. 11, pp. 257-356, 1987
430) Srivastava PK: Do human tumors contain shared protective antigens ? Or the necessity of remembrance of things
past, Semin. immunol., 8, pp. 295-302, 1996
431) Stavinoha, W.: Short term dietary supplementation with ganoderma lucidum slows development and growth of
microadenomatous lesions in the colon of rats treated with the carcinogen 1,2 dimethylhydrazine, Presented at the 5th
international symposium on ganoderma lucidum, Seoul, Korea on June 17, 1993.
432) Stavinoha W.: Study of the anti-inflammatory action of Ganoderma Lucidum,
Research paper presented at the Third Accademic/Industry Joint Conference in Sapporo, Japan on Aug, 18-20, 1990.
433) Stavinoha W.: Study of the antiinflammatory efficacy of Ganoderma lucidum,
In : B.-K. Kim, & Y.S. Kim (Eds.), Recent Advances in Ganoderma lucidum research, pp. 3-7, Seoul Korea: The
Pharmaceutical Society of Korea, 1995.
434) Stavinoha W.: The Antiinflammatory activity of Ganoderma lucidum, Third International Symposium on
Ganoderma lucidum, pp.: 9-21, 1991
435) Stell P.M.: Chemio-Terapia di supporto per il cancro della testa e del collo, in: Br. J. Cancer, vol. 61, pp. 779-
787, 1990
436) Stone H.B., Sensitization by SR-2508 Plus Ro 03-8799. Session 1, “Int.J. Radiat.Oncol.Biol.Phys.”, Vol.12, pp.
1097-1100, 1986.
437) Stewart L.A.: Meta analisi della letteratura o si dati clinici individuali di pazienti: c’è una diffferenza?, in : The
Lancet, vol. 341 i, pp. 418-422, 1993
438) Stewart L.A.: Una meta-analisi di dati clinici sull’uso di Chemio-Terapia nel cancro dei polmoni non a piccole
cellule, Abstract No. 1117, in: Proc. Amer. Soc. Clin. Oncology, Vol. 13, p 336, 1994
439) Suga T.: Antitumor activity of lentinan in murine syngeneic and autochthonous hosts and its suppressive effect on
3methylcholanthrene induced carcinogenesis, Cancer Res. 44, pp.:5132-7, 1994.
440) Suzuki F.: Importance of T-cells and macrophages in the antitumor activity of carboxyethylgermanium
sesquioxide (Ge 32), Anticancer Res; 5, pp: 479-483, 1985
441) Suzuki F.: Cooperation of lymphokines and macrophages in expression of antitumor activity of
carboxyethylgermanium sesquioxide (Ge 32)
Anticancer Res; 6, pp:177-182, 1986
442) Suzuky I.: Purification and characterization of two Lectins from Aloe arborescens Miller, J. Biochem (Tokyo), 85
(1), pp 163-171, 1979
443) Szarka CE: Chemoprevention of cancer, Curr Probl Cancer.; 18, pp: 6-79, 1994 .
444) Tafuto S.: A Comparison of Two GM-CSF Schedules to Counteract the Granulo-mono-cytopenia of Carboplatin –
Etoposide Chemotherapy, “Eur. J. Cancer”, Vol. 31A, pp. 46-49, 1995.
445) Tallman MS: Differentiating therapy in acute myeloid leukemia, Leukemia; 10, pp.1262-1268. 1996.
446) Tallman MS: Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia, Leukemia; 10 Suppl.
1: S12-S15, 1996.
447) Tallman MS: All-trans-retinoic acid in acute promyelocytic leukemia and its potential in other hematologic
malignancies, Semin Hematol.; 31(4 Suppl 5), pp: 38-48, 1994.
448) Tallman MS: Acute promyelocytic leukemia: a paradigm for differentiation therapy with retinoic acid, Blood
Rev.; 8: 70-78, 1994.
449) Tannock I.F.: „Uno studio randomizzato di Chemio-Terapia con due diversi dosaggi di ciclofosfamide,
methotrexate e fluorouracile per pazienti con cancro metastatico della mammella”, J.Clin. Oncol. , Vol. 6, pp.1337-
1387, 1984
450) Tattersall M.H.: „Trial randomizzato di Chemio-Terapia con epirubicina e cisplatino seguito da radiazione
pelvica in cancri avanzati del collo dell’utero”, J.Clin. Oncol., Vol. 13, pp. 444-451, 1995
451) Taylor I.: „Un inventario critico del trattamento di metastasi del fegato di carcinomi colon-rettali”, Clin. Oncol.,
Vol. 8, pp. 149-158, 1982.
452) Taylor PR: Selenium, vitamin E, and prostate cancer ready for prime time?
J Natl Cancer Inst.; 90, pp: 1184-1185, 1998
453) Teicher B.A.: Therapeutic effect of infused Fluosol-DA/Carbogen with Ephedrine, Flunarizine, or Nitroprusside,
“Int. J. Radiat. Oncol. Biol. Phys.”, Vol. 26, pp 103-109, 1993.
454) Thestrup-Pedersen K: Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in
combination with etretinate, Br J Dermatol.; 118, pp: 811-818, 1988.
455) Thigpen J.T.: : „Chemio-Terapia di cancri ginecologici avanzati e secondari”, Cancer, Vol. 60, pp. 2104-2116,
456) Thomas G.E., Gamma-interferon administration after 90 Yttrium radiolabeled antibody therapy: survival and
hematopoietic toxicity studies, “Int. J. Radiat. Oncol. Bio. Phys.”, Vol.31, pp. 529-534, 1995.
457) Tobita T: Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from
complete remission induced by all-trans retinoic acid, Blood; 90, pp: 967-973. 1997
458) Toma S: Effectiveness of beta-carotene in cancer chemoprevention, Eur J Cancer Prev. ; 4, pp: 213-224, 1995.
459) Tripathy D.: „Cancro della mammella”, in : Kirkwood and Yasko: Attuale approccio terapeutico al cancro,
Current Medicine, Philadelphia, pp. 82-86
460) Tropé C: Phase II study of spirogermanium in advanced ovarian malignancy, Cancer Treat Rep, , 65:1-2, 119-
120, 1981
461) Trump DL: Retinoids in bladder, testis and prostate cancer: epidemiologic, pre-clinical and clinical observations,
Leukemia. 1994; 8 Suppl 3, pp: S50-S54, 1994
462) Tsujitani S., Infiltation of Dendritic Cells into Regional Lymph Nodes, “Cancer”, 75, pp. 1478-1483, 1995.
463) Tsurusawa M: Treatment results in childhood acute myeloblastic leukemia–a report of clinical trials of a past
decade from the Japanese children’s Cancer and Leukemia Study Group, Rinsho Ketsueki; 38, pp: 505-512. 1997
464) Tuttle S.W.: Bioreductive metabolism of SR-4233 (win 59075) by whole cell suspensions under aerobic and
hypoxic conditions, “Int. J. Radiat. Oncol. Biol. Phys.”, Vol. 29, pp. 357-362, 1994.
465) Udupa SL: anti-inflammatory and wound healing properties of Aloe Vera, Fitoterapia, 65 (2), pp.141-145, 1994.
466) Urano M.: The advantageous use of hypoxic tumour cells in cancer therapy, “Int. J. Hyperthermia”, Vol. 11, No 5,
pp. 379-388, 1995.
467) Utles J.F., Distribution of 35S-Labeled WR-2721 in Normal and Malignant Tissues of the Mouse, “Radiation
Research”, 68, pp. 284-291, 1976.
468) Vainio H.: An international evaluation of the cancer preventive potential of carotenoids.
Cancer Epidemiol Biomarkers Prev.; 7, pp. 725-728. 1998
469) Valanis B: Mailing strategies and costs of recruiting heavy smokers in CARET, a large chemoprevention trial,
Control Clin Trials. 1998 Feb; 19, pp. 25-38; 1998
470) van der Leede BM: Retinoids: use in combating cancer, Ned Tijdschr Geneeskd.; 141, pp. 1183-1188, 1997
471) Veronesi U: Chemoprevention of breast cancer with fenretinide, IARC Sci Publ.; 136, pp. 87-94, 1996.
472) Immunobiology Vol. 156, pp. 309-319, 1979
473) Villablanca JG: Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow
transplantation, J Clin Oncol., 13, pp. 894-901, 1995
474) Visco G., “Sostanze immunomodulanti: Il levamisole “, Edizioni L. Pozzi, Roma, 1981.
475) Vogelgesang B., Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of Land
D-verapamil examined with a stable isotope technique, “Br. J. Clin. Pharmac.” 18, pp. 733-740, 1984
476) Vogelzang NJ: A phase II study of spirogermanium in advanced human malignancy, Am J Clin Oncol, 8:4, pp:
341-344, 1985
477) Voravud N: Phase II trial of 13-cis-retinoic acid plus interferon-alpha in recurrent head and neck cancer, Invest
New Drugs, Feb; 11, pp: 57-60, 1993.
478) Wadler S: All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the
uterine cervix: clinical and pharmacokinetic studies, Cancer. 15; 79, pp: 1574-1580, 1997.
479) Wali RK.: 1 alpha,25-Dihydroxy-16-ene-23-yne-26,27-hexafluoro cholecalciferol, a non-calcemic analogue of 1
alpha,25-dihydroxyvitamin D3, inhibits azoxymethane-induced colonic tumorigenesis, Cancer Res.; 55, pp: 3050-3054,
480) Walling J.M., Studies on the mechanisms of the radiosensitizing and cytotoxic properties of RSU -1069 and its
analogues. Session 1, “Int.J. Radiat. Oncol. Biol. Phys.”, Vol.12, pp. 1083-1086, 1986.
481) Walters R.: Walters R.S.: Arandomized trial of two dosage schedules of mitomycin C in advanced breast
carcinoma, Cancer,1992, Vol. 69, No.2, pp.:476-481 (Uno studio randomizzato di due protocolli con mitomicina C per
i carcinomi avanzati della mammella).
482) Warr D.: „Influenza degli errori di valutazione sulle percentuali di risposta”, Cancer Treatment Reports, Vol. 69,
pp. 1127-1130, 1985.
483) Washburn L.C., Predication of the Effective Radioprotective Dose of WR-2721 in Humans through an Interspecies
Tissue Distribution Study, “Radiation Research”, 66, pp. 100-105, 1976.
484) Washburn L.C., Distribution of WR-2721 in Normal and Malignant Tissues of Mice and Rats Bearing Solid
Tumors : Dependence on Tumor Type, Drug Dose and Species, “Radiation Research”, 59, pp. 475-483, 1974.
485) Weber W.: „Infusione diretta nel fegato di fluoracil e mitomicina per il cancro colon-rettale”, SAKK Anticancer
Research, Vol. 13, pp. 1839-1840, 1993.
486) Wendell D.: Immunoreactive lectins in leaf gel from Aloe barbadensis Miller, Phytotherapy Research , Vol. 7,
S23-S25, 1993
487) Werner L., Pharmacokinetic-Metabolic Studies with 14C-Aloe Emodin after Oral Administration to Male and
Female Rats, Pharmacology, 47, suppl. 1, pp. 110-119, 1993
488) Wheatley C.: Vitamin trials and cancer, Lancet, 21; 349: pp. 1844-1845, 1997.
489) White E: Relationship between vitamin and calcium supplement use and colon cancer, Cancer Epidemiol
Biomarkers Prev., pp: 769-774, 1997.
490) Wilder R.B., The hypoxic cytotoxin SR-4233 increases the effectiveness of radioimmunotherapy in mice with
human non-Hodgkin’s lymphoma xenografts, “Int. J. Radiat. Oncol. Biol. Phys.”, Vol. 29, pp. 119-126, 1994.
491) Wilder R.B., Local Hyperthermia and SR-4233 Enhance the Antitumor Effects of Radio-immunotherapy in Nude
Mice with Human Colonic Adenocarcinoma Xenografts, “Cancer Research”, 53, pp. 3.022-3.027, 1993.
492) Williams, C.J.: „Cancro cervicale, endometriale e vulvale” in: Slevin and Staquet, Studi randomizzati del cancro:
un inventario critico per locazioni, Raven Press, New York, pp. 417-446, 1986
493) Windbichler GH: Increased radiosensitivity by a combination of 9-cis-retinoic acid and interferon-y in breast
cancer cells, Gynecol Oncol.; 61, pp.387-394, 1996
494) Wolf R: Vitamin E: the radical protector, J Eur Acad Dermatol Venereol.; 10, pp: 103-117, 1998
495) Wood P.J., Calcium antagonists as radiation modifiers: site specificity in relation to tumor response, Int. J. Radiat.
Oncol. Biol. Phys., Vol. 16, pp. 1141-1144, 1989.
496) Yamanaka WK: Vitamin C and cancer. How convincing a connection ? Postgrad Med; 78, pp:47-9, 52-3, 1985.
497) Yihas, “Cancer Research”, 40, pp. 1519-1524, 1980.
498) Yoon T.J.: Inhibithory effect of korean mistletoe (Viscum album coloratum) extract on tumour angiogenesis and
metastasis of haematogenous and non-haematogenous tumour cells in mice
Cancer Letters, Vol. 97, pp. 83-91, 1995
499) Yoshimoto R.: Plant lectin, ATF1011, on the tumor cells surface augments Tumor-specific immunity through
activation of T cells specific for the Lectin, Cancer Immun. Immunother., 25, pp. 25-30, 1987
500) Yoshizawa H.: Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially
activated with anti-CD3 and IL-2, J. Immunology 147, pp: 729-737, 1991
501) Yu SY: Intervention trial with selenium for the prevention of lung cancer among tin miners in Yunnan, China. A
pilot study, Biol Trace Elem Res.; 24(2): 105-108, 1990.
502) Yun TK: A case control study of ginseng intake and cancer, International Journal of Epidemiology, 19, pp. 871-
876, 1990
503) Yun TK: Preventive effects of ginseng intake against various human cancers: a case-control study on 1987 pairs.
Cancer Epidemiol., Biomarkers, Prevention , 4, pp. 401, 1995
504) Yun TK: Saponin contents and anticarcinogenic effects of ginseng depending on types and ages in mice, Acta
Pharmacologica Sinica, 17, pp. 293-298, 1996
505) Yun TK: Anticarcinigenic effect of long-term oral administration of red ginseng on newborn mice exposed to
various chemical carcinigens, Cancer Detection and Prevention , 6, pp. 515-525, 1983
506) Xiaoguang C.: Cancer chemopreventive and therapeutic activities of red ginseng, J.Ethnopharmacol, 60, pp.71-78,
507) Zadra F., “Biologia dei Tumori”, Masson, Italia, 1986.
508) Zhang XK: Retinoid receptors in human lung cancer and breast cancer, Mutat Res.,19; 350, pp. 267-277, 1996.
509) Zeman E.M., Pre-and Post-irradiation radiosensitization by SR-4233,” Int.J. Radiat. Oncol. Biol. Phys.”, 16, 4,
pp. 967-971, 1989.
510) Ziegler RG: Nutrition and lung cancer, Cancer Causes Control.; 7, pp: 157-177, 1996
511) Ziegler RG: Health claims about vitamin C and cancer, J. Natl. Cancer Inst. ;86, pp:871-2, 1994
512) Zou CP: Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis
in non-small cell lung cancer cell lines, Clin. Cancer Res.; 4, pp.: 1345-1355, 1998
514) New England Journal of Medicine, 28 gennaio 1982, pp 236;
515) New England Journal of Medicine, Vol. 299, 1978, pp. 549-552
516) Workshop on alternative Medicine. Coley Toxins. Alternative Medicine: expanding Medical Horizons. A report to
the National Institutes of Health on Alternative Medical Systems and Practices in the United States , Washington, DC,
US Government Printing Office, 1992
517) Enciclopedia delle piante medicinali, Idea Libri, Rimini.
518) Shark catilage contains inihibitors of tumor angiogenesis, Science, 221, pp. 185-187, 1983
519) Ontario Breast Cancer Information Exchange Project. Guide to unconventional cancer therapies. 1st ed. Toronto:
Ontario Breast Cancer Information Exchange Project, pp. 166-169, 1994.
520) Guarneri L.: La formula di Renè Caissè, un rimedio per difendersi dal cancro e dalle malattie degenerative, Storia
di una tisana di erbe degli indiani d’America che ha guarito migliaia di persone dal cancro , raccontata dal primo
italiano che ne ha tratto beneficio, M.I.R. Edizioni, via Montelupo, 147, CAP. 50025 Montespertoli, Firenze.
521) Preziosi A.: Relazione sull’esame di cartelle cliniche relative a casi di pazienti con neoplasie mammarie e
sottopostesi volontariamente a MDB, Riflessione-Rivista Scientifica della SISTE. Anno II Numero 1 2000.
522) Preziosi A: Importante risultato positivo in un caso di recidiva di neoplasia mammaria trattata con MDB,
Riflessione-Rivista Scientifica della SISTE. Anno II Numero 1 2000
523) Preziosi A: Evidenza di efficacia terapeutica in due casi di carcinoma polmonare a piccole cellule trattati con la
sola MDB, Riflessione-Rivista Scientifica della SISTE. Anno II Numero 1 2000.
524) Norsa A: Sarcoma osteogenico con metastasi polmonari: diverse impostazioni terapeutiche e relativi risultati,
Riflessione-Rivista Scientifica della SISTE. Anno II Numero 1 2000.
525) Valeri A: Il MDB aumenta del 30% la sopravvivenza nel carcinoma del pancreas: deve quindi essere proposto
come terapia di elezione in questa neoplasia, Riflessione-Rivista Scientifica della SISTE. Anno II Numero 1 2000.
526) Preziosi A.: Relazione sull’esame di cartelle cliniche relative a casi di Linfomi sottopostisi volontariamente a
MDB, Riflessione-Rivista Scientifica della SISTE. Anno I- Numero 1 1999.
527) Preziosi A.: Trattamento con MDB di un Linfoma non Hodgkin Centroblastico-centrocitico follicolare a bassa
malignità, Riflessione-Rivista Scientifica della SISTE. Anno I- Numero 1 1999.
528) Pollak MN & Schally AV: Mechanism of the antineoplastic action of somatostatin analogs, Proceedings of the
Society for Experimental Biology and Medicine, 217, pp 143-152.
529) Abbott A: Italy pulls plug on unproven cancer ‘cure’, Nature; 394(6693) pp: 514, 1998.
530) Ippoliti C: Octreotide in the management of diarrhea induced by graft versus host disease, Oncol. Nurs. Forum.;
25, pp: 873-878, 1998.
531) Pollak M: Cancer controversy, Nature; 392(6678), pp: 752, 1998.
532) Simini B: Frenzy mounts in Italy over assessment of the Di Bella regimen, Lancet ; 351(9106) pp: 891, 1998.
533) Di Bella L.: Il Metodo Di Bella nelle patologie linfatiche oncologiche, La Med. Biol., pp: 41-45, 1998.
534) Rosenberg L.: Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and
gemcitabine, Int. J. Pancreatol.; 22, pp: 81-93, 1997.
535) Thapar K: Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary
tumors: results of a multicenter randomized trial, Mayo Clin Proc.; 72, pp: 893-900, 1997.
536) Sulkowski U.: Regression of a distal bile duct carcinoma after treatment with octreotide for 6 months, Digestion;
58: 407-409, 1997
537) Vainas G.: The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic
carcinoma, J. Exp. Clin. Cancer Res.; 16, pp: 119-126, 1997.
538) Pelley R.J.: Recent advances in diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract, Curr
Opin Oncol.; 9, pp: 68-74, 1997.
539) Rieger A.: Somatostatin receptor scintigraphy in patients with pituitary adenoma, Neurosurg Rev.; 20, pp: 7-12,
540) Kopf D.: Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant
phaeochromocytoma, Clin Endocrinol (Oxf); 46, pp: 39-44, 1997
541) Zimmer T.: Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation
of insulinomas and gastrinomas, Gut; 39, pp: 562-568, 1996.
542) Ahren B: The treatment of carcinoid of the small intestine with octreotide and alpha-interferon. A call for
participation in a randomized study, Dtsch Med Wochenschr.; 121, pp: 744-745, 1996, German.
543) Morris D.L.: A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with
asymptomatic advanced colon carcinoma, Cancer.; 77, pp: 1956-1957, 1996.
544) Arnold R.: Medical treatment of metastasizing carcinoid tumors, World J Surg.; 20, pp: 203-207, 1996
545) Feu F: Somatostatin and its analogs in the treatment of gastrointestinal and liver diseases, Gastroenterol Hepatol.;
19, pp: 68-77, 1996, Spanish.
546) Bangerter M.: New diagnostic imaging procedures in Hodgkin’s disease,Ann. Oncol.; 7 Suppl 4, pp: 55-59, 1996
547) Davies N: Therapeutic potential of octreotide in the treatment of liver metastases, Anticancer Drugs; 7 Suppl 1,
pp: 23-31, 1996.
548) Bax ND: Octreotide therapy in carcinoid disease, Anticancer Drugs; 7, Suppl 1, pp: 17-22, 1996.
549) Pandha H.S.: Octreotide in malignant intestinal obstruction, Anticancer Drugs.; 7, Suppl 1, pp: 5-10, 1996.
550) Bajetta E: The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumours,
Digestion; 57, Suppl 1, pp: 72-76, 1996.
551) Meropol N.J.: Metastatic colorectal cancer: advances in biochemical modulation and new drug development,
Semin Oncol.; 22, pp: 509-524, 1995.
552) Figg W.D.: A phase I study of the somatostatin analogue somatuline in patients with metastatic hormonerefractory
prostate cancer, Cancer; 75, pp: 2159-2164,1995.
553) Vacher P.: Gn-RH agonists in the treatment of prostatic carcinoma, Biomed. Pharmacother.; 49(7-8), pp: 325-331,
554) Kvols L.: Medical oncology considerations in patients with metastatic neuroendocrine carcinomas, Semin Oncol.;
21(5 Suppl 13), pp: 56-60, 1994.
555) Mosdell K.W.: Emerging indications for octreotide therapy, Part 1., Am J Hosp Pharm.; 51, pp: 1184-1192, 1994.
556) Phlipponneau M.: Somatostatin analogs for the localization and preoperative treatment of an
adrenocorticotropin-secreting bronchial carcinoid tumor, J. Clin. Endocrinol. Metab.; 78, pp: 20-24, 1994.
557) Bajetta E.: Medical treatment of neuroendocrine tumors, Tumori; 79, pp: 380-388, 1993.
558) Saltz L.: Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine
tumors, Cancer; 72, pp: 244-248, 1993.
559) Eriksson B.: An update of the medical treatment of malignant endocrine pancreatic tumors, Acta Oncol.; 32, pp:
203-208, 1993.
560) Barrie R.: Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent,
Journal of Surgical Research 55, pp.: 446-450, 1993.
561) Pollak M.: Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing
trial, Metabolism.; 41(9 Suppl 2), pp: 119-120, 1992.
562) Peyrat J.P.: Insulin-like growth factor 1 receptors (IGF1-R) and IGF1 in human breast tumors, J Steroid Biochem
Mol Biol.; 37, pp: 823-827, 1990.
563) Conte PF: In vivo manipulation of human breast cancer growth by estrogens and growth hormone: kinetic and
clinical results, J. Steroid. Biochem. Mol. Biol.; 37, pp: 1103-1108, 1990
564) Klijn JG: Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical
and clinical studies, J. Steroid. Biochem. Mol. Biol.; 37, pp: 1089-1095, 1990.
565) Manni A: Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced
breast cancer, Breast Cancer Res Treat.; 14, pp: 289-298, 1989.
566) Cheson BD: Clinical trials referral resource. Adjuvant treatment of colon cancer, Oncology (Huntingt); 3, pp: 98-
101, 1989
567) Vinik AI: Somatostatin analogue (SMS 201-995) in patients with gastrinomas, Surgery; 104, pp: 834-842, 1988
568) Kvols LK: Metastatic carcinoid tumors and the carcinoid syndrome. A selective of chemotherapy and hormonal
therapy, Am. J. Med.; 81(6B), pp: 49-55, 1986.
569) Eriksson B: Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon, Lancet. Dec
6; 2(8519) pp: 1307-1309, 1986.
570) Klapdor R: The effect of somatostatin on bronchial obstruction in carcinoid,
Prax Klin Pneumol. 36, pp: 202-205, 1982 German.
571) Wout A.P., Evaluation in vitro and in rats of 161 Tb-DTPA-octreotide, a somatostatin analogue with potential for
intraoperative scanning and radiotherapy, “European Journal of Nuclear Medicine”, Vol 22, No. 7, 1995.
572) Hematol. Oncol. Clin. North. Am., 11, pp.: 159-172, 1997
573) Immunity 1999, 10, pp.: 105-115);
574) Blood, 89, pp.: 227-234, 1997
575) Int. J. Hematology, 66, pp.: 367-371, 1997
576) Broumand D.M., Immunopharmacology, 3, pp. 229-235, 1997
577) Hirazumi A.: An immunomodulatory polysaccaride -rich substance from the fruit juice of Merinda citrifolia
(Nomi) with anti-tumour activity, Phytotherapy Res., 13, pp. 380-387, 1999.
578) Hiramatsu T.: Induction of normal phenotipes in ras-transformed cells by damnacanthal from Morinda citrifolia,
Cancer Lett, 73, pp. : 161-166, 1993
579) Hiwasa T.: Stimulation of ultraviolet-induced apoptosis of human fibroblast Uvr-1 cells by tyrosine kinase
inhibitors, FEBS Lett., 444, pp. 173-176, 1999
580) Della Loggia R.: Piante Officinali per infusi e tisane, Manuale per Farmacisti e Medici, OEMF, Organizzazione
Editoriale Medico Farmaceutica, Via Edolo 42, Milano, Edizione italiana TEEDROGEN
581) Bettger W.: Life Sci., 28, pp.: 1425-1438, 1981.
582) Keusch G.T.: Nutrition, host defenses, and the lymphoid system. In: Gallin J.I.: „Advances in Host Defense
Mechanisms”, Vol.2 (A.S.Eds), New York, Raven Press, 1963
583) Rossi M.: „Partenio”, Erboristeria Domani, Maggio 1990
584) Makheja A.: A platelet phospholipase inhibitor from the medicinal herb tanacetum parthenium, Prostaglandins –
Len Kotiens Med., 8, pp. 653-660, 1982.
585) Cartleman M.: Le Erbe Curative, Ed. tecniche nuove.
586) Salimath B.P.: Dietary components inhibit peroxidation in erythrocyte membrane, Nutrition Research 6: 10, pp.
1171-1178, 1986.
587) Nunez G.A.: Ascorbic acid in canned red peppers. Estimation by high performance liquid chromatography,
Alimentaria, n.228, pp. 53-56, 1992.
588) De Froment P.: Unsaponifiable substance from alfalfa for pharmaceuticals and coemetic use, French Patent 2,
187, 328, 1974.
589) Gestetner B.: Lucerne saponins. IV. Relation between their chemical constitution and hemolytic and antifungal
activities, Journal of Science, Food and Agriculture, 22, pp. 168-172, 1971
590) Autori vari: Further screening for antioxidant activity of vegetable plants and its activity principles from
zanthoxylum schinifolium, Journal of the Korean Society of Food and Nutrition, 23, pp. 466-471, 1994
591) Levy S.M., Persistently low natural killer cell activity in normal adults: immunological Hormonal and mood
correlates, in natural and immunological cell growth regulation, Vol. 8, 1988, pp. 173-186.
592) Levy S.M., Perceived social support and tumor estrogen /progesteron e receptor status as predictors of natural
killer cell activity in breast cancer patients, Psychosomatic Medicine, vol. 52, 1990, pp. 73-85
593) Irwin M., Plasma cortisol and natural killer cell activity during bereavement, Biological Psychiatry, Vol. 24,
1988, pp. 173-178
594) Irwin M., Electroencephalographic Sleep and natural killer activity in depressed patients and control subjects,
Psychosomatic Medicine, vol. 54, 1992, pp. 10-21.
595) Graham, IM.: Plasma homocysteine as a risk factor for vascular disease, JAMA, 277, pp: 1775 – 1776, 1997.
596) Messina M.: Modern applications for an ancient bean: soybeans and the prevention and treatment of chronic
disease. J. Nutr., 125, 3 Suppl. 1995, 567S-569S.
597) Giuseppe Rama: Orto. Le schede con le tecniche culturali, le malattie, i parassiti. Calendario lunare delle semine.
Demetra S.R.L. PP. 190, 2002
598) Erbe buone per la salute, Demetra s.r.l., pp. 432, 2002
599) Bosisio E.: Effect of the flavanolignans of Sylibum marianum on lipid peroxidation in rat liver microsomes and
freshly isolated hepatocytes. Pharmacol. Research 25, 147-154, 1992.
600) Ferenci P.: Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver, J. Hepatol.
9, 105-113, 1989
601) Flora K.: Milk thistle (Sylibum marianum) for the therapy of liver disease, Am. J. Gastroenterol., 93, 2, pp.: 139-
143, 1998.
602) Held C. Therapy of toxic hepathopaties: Mary’s thistle extract lowers the fibrosis activity. Therapiewoche 43,
2002-2009, 1993.
603) Hikino H.: Antihepatotoxic actions of flavonolignans from Silybum marianum fruits, Planta Med. 248-250, 1984.
604) Valenzuela A.: Selectivity of silymarin on the increase of the glutathione content in different tissuee of the rat,
Planta Med. 55, 420-422, 1989.
605) Valenzuela A.: Sylimarin protection against lipid peroxidation induced by acute ethanol intoxication in the rat,
Biochem. Pharmacol. 34, 2209-2212, 1985.
606) Wang M.: Hepatoprotective properties of Sylibum marianum herbal preparation on ethanol induced liver damage,
Fitoterapia, 67, 166- 171, 1996.
607) International Journal of Pharmacology, Vol. 35, No.4, pp. 288-296, 1997
608) Sharma H.: Maharishi Ayurveda: Modern insights into ancient sistem of medicine, JAMA, 20 May 1991, pp.:
609) Dhar M.L.: Screening of indian medicinal plants for their biological activity, Ind. Journ. Of Exp. Biology, 6, 232,
610) Sato Y.: Studies on chemical protectores against radiation XXVI. Protective effect of various extracts on crude
drugs on skin injury induced by X-irradiation, Yakugata Zasshi, Vol. 109, ISS2, pp. 113-118, 1989.
611): Limone Mele e Uva per non parlare dell’Aglio e del Peperoncino. Il libro delle tre cure, Demetra Edizioni, S.r.l.,
marzo 1996, 37012 Bussolengo, VR
612): Solis P.N.: Bioactive anthraquinone glycosides from Picramnia antidesma SPP. Fessonia, Phytochemistry 38 (2),
pp. 477-480, 1995, Jan
613): Kuzuya M.: Mechanochemical solid state reactions of natural products for medical use contaning
hydroxyanthraquinone derivatives,Yakugaki Zasshi 111 (11), pp. 665-671, 1991
614): Il miele, un miracolo della natura, proprietà curative, uso e ricette con miele, polline e pappa reale”, Demetra
S.R.L, Edizione marzo 1997, 3712 Bussolengo, VR, pp. 21-24
615) Margherita Neri: Curarsi con il limone. Con ricette al limone. Edizioni Demetra S.r.l., marzo 1997, 37012
Bussolengo, VR
616) Hayashi K.: Chem. Pharm. Bull. 28, pp.1954 , 1980
617) Hayashi K.: Chem. Pharm. Bull. 29, pp. 2725, 1981
618) Koch H.: Pharm. Act. Helv. 53, pp. 56, 1978
619) Graham I.M.: Plasma homocysteine as a risk factor for vascular disease, JAMA, 277: 1775 – 1776, 1997
620) Kapoor L.D.: CRC Handbook of Ayurvedic Medicinal Plants, CRC Press, Inc. Boca Raton, Florida
621) Bhakuni D.: Screening of Indian plants for biological activity, II, Indian J. Exp. Biol., 7, 250, 1969
622 Carlo Alberto Zaccagna: Quel gran piacere che viene dallo star bene, Stampa MARIOGROS Industrie grafiche
S.P.A, marzo 2002
623) Paolo Pigozzi: Il Cibo che cura: 100 disturbi 100 soluzioni, Demetra S.R.L, Edizione agosto 1994, 37030,
Colognola ai Colli, VR
624) Block G.: Friut, Vegetables, and cancer prevention: a review of the epidemiological evidence, Nutr. Cancer 1992,
18, pp. 1-29. ;
625) Gerster H.: The potential role of Lycopene for human health, J. Am.Coll. Nutr., 1997, 16, pp. 109-126
626) Ribaya-Mercado J.D.: Skin Lycopene is destroyed preferentially over beta-Carotene during ultraviolet irradiation
in humans, J. Nutr. 1995, 125, pp. 1854-1859
627) de Pes S.: Lack of improvement in vitamin A status with increased consumption of dark-green leafy vegetables,
Lancet 1995, 346 (8967), pp.: 75-81
628) Brown E.D.: Plasma carotenoids in normal men after a single ingestion of Vegetables or purified beta-Carotene,
Am. J. Clin. Nutr., 1989, 49, pp.: 1258-1265
629: Palozza P.: Beta-Carotene and alpha-Tocopherol are synergistic antioxidants, Arch. Biochem. Biophys 1992, 297,
pp.: 184-187
630) Inserra P.F.: La supplementazione di succhi concentrati di Frutta e verdura migliora le funzioni immunitarie,
Integrative medicine, 1999, 2, pp.: 3-10
631) Smith J.M.: La supplementazione di succhi concentrati di Frutta e Verdura riduce il danno ossidativo al DNA dei
linfociti periferici, Nutr. Research, 1999, 2, pp. 3-10
632) Graziano J.M.: Discrimination in absorption or trasport of beta-Carotene isomers after oral supplementation with
either all-trans- or 9-cis-beta Carotene, Am. J. Clin. Nutr., 1995, 61, pp.: 1248-1252
633) Giovannucci E.: Intake of carotenoids and retinol in relation to risk of prostate cancer, J. Natl. Cancer Inst., 1995,
87 (23), pp. 1767-1776
634) Lim B.P.: Antioxidant activity of Xanthophylls on peroxyl radical-mediated phospholipid peroxidation, Biochim
Biophys Acta, 1992, 1126, pp-: 178-184
635) Gerster H.: Anticarcinogenic effect of common carotenoids, Int. J. Vitam. Res., 1993, 63, pp.93-121
636) Wise J.A.: Variazione dei livelli plasmatici di Carotenoidi, alfa-Tocoferoli e Perossidi lipidici in seguito
all’integrazione dietetica con succhi concentrati di Frutta e Vegetali.
637) Leeds A.R.: disponibilità di micro-nutrienti da preparati di Frutta e Verdura essiccate e incapsulate: uno studio in
volontari sani, J. Hum. Nutr. Dietet 1999, 13, pp. 21-27
638) Abbey M.: Antioxidant vitamins and low-density-lipoprotein oxidation, Am. J. Clin. Nutr., 1993, 58, pp.: 525-532
639) Jifka C.: In vivo antitumor activity of the Bitter Melon (Momardica charantia), Cancer Research, 43, 5151-5155,
640) Bhakuni D.S.: Screening of Indian plants for biological activity, II, Indian J. Exp. Biol., 7, 250, 1969.
641) Taussing S.J.: Inhibition of Tumour Growth in vitro by Bromelain, an extract of the Pineapple Plant (Ananas
comosus), Planta Medica, 52, pp. 538-539, 1985.
642) : AA.VV.: La spesa biologica in Italia
643) Giuseppe Capano: La cucina mediterranea delle Verdure; TECNICHE NUOVE
644) Sara Honegger Chiari: Cucina naturale; TECNICHE NUOVE, pagine 344
645) Claude Aubert: I cereali nel piatto. TECNICHE NUOVE 140 pagine
646) Attilio Giacosa, Daniela Garavini, Franco Travaglini: Più gusto; più salute con 5 porzioni al giorno di Frutta e
647) AA.VV.: Cibi che guariscono;
648) Burt Berkson: l’acido alfa-lipoico; Tecniche Nuove pagine 140
649) Shalila Sharamon, Bado J.Biginski: Le virtù terapeutiche dei semi di Pompelmo; TECNICHE NUOVE 96 pagine
650) Giulia Fulghesu: Mangiare mediterraneo; TECNICHE NUOVE 96 pagine
651) Gerhard Leibold: Il digiuno terapeutico; TECNICHE NUOVE 90 pagine
652) Hans Peter Bleuel: Aceto di Mele; TECNICHE NUOVE 90 pagine
653) Hu Fan Hsiang, Marion Zerbst : Il the verde TECNICHE NUOVE 95 pagine
654) Cherie Calbom, Maureen B. Keane : La salute con i succhi di Frutta e verdura; TECNICHE NUOVE 268 pagine
655) Ghislaine Lepetit De La Bigne, Agathe Amante: L’alimentazione vegetariana; TECNICHE NUOVE 214 pagine
656) Julia Lawless : Enciclopedia degli olii essenziali; TECNICHE NUOVE 96 pagine
657) Michael Kraus : Aromaterapia per tutti i giorni; TECNICHE NUOVE 118 pagine
658) Costanza Giunti: Decotti e tisane; TECNICHE NUOVE 180 pagine
659) Michael Castleman: Le erbe curative; TECNICHE NUOVE 552 pagine
660) Piergiorgio Chiereghin : Le piante da bere; TECNICHE NUOVE, 134 pagine
661) Susan Drury: L’olio di Tea Tree; TECNICHE NUOVE, 80 pagine
662) Anna Vigoni Marciani: Manuale di Fitoterapia per i meno giovani; TECNICHE NUOVE 96 pagine
663) Natasha Trenev: Probiotici; TECNICHE NUOVE 234 pagine
664) Federico Lacche: Gli agriturismi bioecologici 2001; TECNICHE NUOVE 96 pagine
665) Penelope Ody: Erbe medicinali; TECNICHE NUOVE 72 pagine
666) Il miele, un miracolo della natura, proprietà curative, uso e ricette con miele, polline e Pappa reale”, Demetra
S.R.L, Edizione marzo 1997, 3712 Bussolengo, VR, pp. 21-24.
667) Jane Newdick: Il Miele; TECNICHE NUOVE 127 pagine
668) Bruno Brigo: Ginseng; TECNICHE NUOVE 96 pagine
669) Bruno Brigo: I micronutrienti per il benessere, II Edizione;
670) Bruno Brigo: Gemme e germogli per la salute; TECNICHE NUOVE 96 pagine
671) Fabio Firenzuoli: Le insidie del naturale;
672) Enrica Campanini: Manuale pratico di Gemmoterapia;
673) Alessandro Camporese: Oli essenziali e malattie infettive; TECNICHE NUOVE 176 pagine
674) Enrica Campanini: Ricettario medico di fitoterapia;
675) Michael T. Murray: il potere curativo dei cibi. Guida pratica e completa agli alimenti che aiutano a curare
numerosi disturbi, Demetra s.r.l., 1999.
676) Francesca Rocco : Nuove tecnologie di Bioremediation e di Phytoremediation per la decontaminazione dei suoli:
esperienze e prospettive, Progetto UTN Urban Tecnology Network, Trieste, 30 maggio 2000, Area Science Park.
677) Monica Bregante: Fito-decontaminazione: un sistema pilota per la fito-decontaminazione di suoli inquinati da
piombo, ARS No. 82, Novembre/Dicembre 2001, pp.41-44
678) Crook PA : Use of L-cavanine as a chemotherapeutic agent for the treatment of pancreatic cancer. US Patent %,
552, 440, Dic 5, 1994
679) Liauder: Beneficial effects of L-cavanine, a selective inhibitors of nitric oxyde sinthase, Clin Sci., 90, 5, 369, 1996
680) Morris : Treating HIV in South Africa: a tale of two system, Lancet, 257, 9263, 2001
681) Narayan : Pinitol : a new anti-diabetic compound from the Leaves of baoungavillea Spectabilis, Current Sciences,
56 (3), pp.: 139-141, 1987.
682) Ostlund : Pinitol and derivates therof for the treatment of metabolic disorders, US patent 5, 8827, 896, 1966
683) Van Wyke and Gericke: People’s Plants. A Guide to the Useful Plants of Southern Africa. Briza, Pretoria
684) Sgouros G., Bone Marrow Dosimetry for Radioimmunotherapy: Theoretical Considerations, “J. Nucl. Med.”, 34,
689-694, 1993.
685) P.A.Shaul : Regulation of lysine synthesis in transgenic potato plants expressing a bacterial dihydrodipicolinate
synthase inthreir chloroplasts; Rehovot, Israel; Plant Mol. Biol 1992, 19 (5) pp. 815-823
686) Gustafson ME: Large-scale production and characterization of Bacillus thuringgiensis subsp. Tenebrionis
insecticidial protein from Escherichia coli; Monsanto Company MO 631898, USA; Appl. Microbiol. Biotechnol. 1997,
47 (3), pp. 255-261
687) Chong DK: Expression of the human milk protein beta-casein in transgenic potato plants; Loma Linda CA, USA;
Transgenic Research 1997, 6 (4) pp.: 289-296
688) Chakraborty S.: Increased nutritive value of transgenic potato by expressing a nonallergenic seed albumin gene
from Amaranthus hypochondriacus; Delhi, 110067, India; Proc. Natl. Acad. Sci. USA, 2000, 97(7) pp.: 3724-3729
689) A.J. Conner: Food risks from transgenic crops in perspective, Nutrition, Vol. 16 No. 7/8, 2000 pp. 709-711
690) Zheng S.: Initial study on naturally occurring products from traditional Chinese herbs and vegetables for
chemoprevention, J.Cell. Biochem. Suppl. 1997, 27, pp.: 106-112
691) Thatte U.: Modulation of programmed cell death by medicinal plants, Cell Mol. Biol. 2000, 46 (1) pp. 199-214
692) Tseng TH: Induction of apoptosis by hibiscus protocatechuic acid in human leukemia cells via reduction of
retinoblastoma (RB) phosporylation and Bcl-2 expression, Biochem. Pharmacol. 2000, 1, 60 (3), pp. 307-315.
693) Ogata S.: Apoptosis induced by the flavonoid from lemon fruit (Citrus limon BURM f. ) and its metabolites in HL-
60 cells, Biosc. Biotechnol. Biochem. 2000, 64 (5), pp.: 1075-1078
694) Hong YS.: Effects of allyl sulfur compounds and garlic extract on the expression of Bcl-2, Bax, and p53 in non
small cell lung cancer cell lines, Exp. Mol. Med. 2000, 32 (3), pp. 127-134.
695) Kimura Y.: Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung
and tumor- induced neovascularization in Lewis lung carcinoma-bearing mice, J.Nutr. 2001, 131 (6), pp. 1844-1849
696) Pinto J.T.: Antiproliferative effects of garlic-derived and other allium related compounds, Adv Exp. Med. Biol.
2001, 492, pp.: 83-106
697) Steenkamp V.: the effect of Senecio latifolius a plant used as a South African traditional medicine, on a human
hepatoma cell line, J. Ethnopharmacol. 2001, 78 (1) pp. 51-58
698) Wang CC.: Camellin B induced apoptosis in HeLa cell line, Toxicology, 168 (3), pp.: 231-240.
699) Zhong Yao Xai: Inhibitory effect of gelsemium alkaloids extract on hepatic carcinoma HepG2 cells in vitro, 2001,
24 (8), pp.: 579-581
700) Huang J.. Experimental study on apoptosis induced by ursolic acid isolated from asparagus in HL-60 cells,
Zhongguo Zhong, 1999, 19 (%) pp.: 296-298
701) Wen J.: Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide,
J.Biol. Chem. 2002, 277 (41), pp.: 38954-64
702) Ren W. : Tartary buckwheat flavonoid activates caspase 3 and induces HL-60 cell apoptosis, Methods Find Exp.
Clin. Pharmacol. 2001 23 (8), pp.: 427-432
703) Hsieh TC: Effects of herbal preparation Equiguard on hormone – responsive and hormone – refractory prostate
carcinoma cells: mechanistic studies, Int. J. Oncol. 2002, 20 (4), pp.: 681-9
704) Wang CC.: Cytotoxic activity of sesquiterpenoids from Atractylodes ovata on leukemia cell lines, Planta Med,
2002, 68 (3), pp.: 204-208
705) Shan CM: Study of apoptosis in human liver cancers, World J. Gastroenterol. 2002, 8 (2), pp. 247-252
706) Qi Z.: Experimental study on induction of apoptosis of leukemia cells by Boswellia carterii Birdw extractive,
Hunan Yi Ke Da Xye Xue Bao, 1999, 24 (1), pp.: 23-25
707) Sandoval M.: Sangre de grado Croton palanostigma induces apoptosis in human gastrointestinal cancer cells, J.
Ethnopharmacol 2002 , 80 (2-3), pp.: 121-129
708) Zhang XL: Salvia miltiorrhiza monomer IH764-3 induces hepatic stellate cell apoptosis via caspase-3 activation,
World J. Gastroenterol. 2002, 8 (3), pp. 515-519
709) Tran QL.: Hepatoprotective effect of majonoside R2, the major saponin from Vietnamese ginseng (Panax
vietnamensis), Planta Medica 2002, 68 (5), pp.402-406
710) Ueda JY.: Antiproliferative activity of Vietnamese medicinal plants, Biol. Pharm. Bull. 2002, 25 (6), pp. 753-760
711) Chen Q.: Apoptosis of human highly metastatic lung cancer cell line 95-D induced by acutiaporberine, a novel
bisalkaloid derived from Thalictrum acutifolium, Planta Med 2002, 68 (6), pp.: 550-553.
712) Steiner M.: Carnosic acid inhibits proliferation and augments differentiation of human leukemic cells induced by
1,25dihydroxyvitamin D3 and retinoic acid, Nutr. Cancer 2001, 41 (1-2), pp. 135-144
713) Chen Y.C.: Wogonin andFisetin induction of apoptosis through activation of caspase 3 cascade and alternative
expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1, Arch Toxicol. 2002, 76 (5-6), pp. 351-349
714) Sandoval M.: anti-infiammatory and antioxidant activities of cat’s claw (Uncaria tomentosa and Uncaria
guianensis) are independent of their alkaloid content, Phytomedicine 2002, 9 (4), pp.: 325-337
715) Kuo PL.: the antiproliferative activity of aloe-emodin is through p53-dependent and p21-dependent apoptotic
pathway in human hepatoma cell lines, Life Sci, 2002, 71 (16), pp. 1879-1892.
716) Tan MQ.: the anti-leukemia effects of Sophora flavescens and its mechanism, Hunan Yi Ke Da Xue Xue Bao
2000, 25 (5) pp. 443-445
717) Lin CY: the effect of Chinese medicine on bone cell activities, Am.J. Chin. Med., 2002, 30 (2-3) , pp. 271-285
718) Ciesielska E. : anticancer, antiradical and antioxidative actions of novel Antoksyd Sand its major components,
baicalin and baicalein, Anticancer Research 2002, 22 (5), pp. 2885-2891
719) Zhang J.: Capsaicin inhibits growth of adult T-cell leukemia cells, Leuk Res. 2003, 27 (3), pp. 275-283.
720) Sheng-Teng Huang: Phyllanthus urinaria triggers the apoptosis and Bcl-2 down-regulation in Lewis lung
carcinoma cells, Life Sciences, 72, (2003), pp.. 1705-1716.
721) Russo A.: red wine micronutrients as protective agents in Alzheimer-like induced insult, Life Science, 2003, 72
(21), pp. 2369-79
722) Ferrante RJ.: therapeutic efficacyof EGb 761 (Ginkgo biloba extract) in a transgenic mouse model of amyotrophic
lateral sclerosis, J. Mol. Neuroscienc, 2001, 17 (1), pp. 89-96
723) Artemisia absinthium (referenza bibliografica perduta)
724) Dittman, Arzneim Forsch, 21, pp 1999-2002, 1971
725) Kim GS, Muricoreacin and murihexocin C, mono-tetrahydrofuran acetogenins, from the leaves of Annona
muricata. Phytochemistry 1998 Sep;49(2):565-71
726) Lopez Abraham AM,, [Plant extracts with cytostatic properties growing in Cuba. I.] Rev Cubana Med Trop,
31: 2, 1979 May-Aug, 97-104
727) Hernández L.,, Use of medicinal plants by ambulatory patients in Puerto Rico. Am J Hosp Pharm, 41: 10,
1984 Oct, 2060-4
728) Bories C., et.a., Antiparasitic activity of Annona muricata and Annona cherimolia seeds. Planta Med, 57: 5, 1991
Oct, 434-6
729) Wu FE,, Two new cytotoxic monotetrahydrofuran Annonaceous acetogenins, annomuricins A and B, from the
leaves of Annona muricata. J Nat Prod, 58: 6, 1995 Jun, 830-6
730) Wu FE,, Muricatocins A and B, two new bioactive monotetrahydrofuran Annonaceous acetogenins from the
leaves of Annona muricata. J Nat Prod, 58: 6, 1995 Jun, 902-8
731) Wu FE,, New bioactive monotetrahydrofuran Annonaceous acetogenins, annomuricin C and muricatocin C,
from the leaves of Annona muricata. J Nat Prod, 58: 6, 1995 Jun, 909-15
732) Wu FE,, Additional bioactive acetogenins, annomutacin and (2,4-trans and cis)-10R-annonacin-A-ones, from
the leaves of Annona muricata. J Nat Prod, 58: 9, 1995 Sep, 1430-7
733) Kooiman P., Structures of the galactomannans from seeds of Annona muricata, Arenga saccharifera, Cocos
nucifera, Convolvulus tricolor, and Sophora japonica. Carbohydr Res, 20: 2, 1971 Dec, 329-37
734) Bourne RK., A preliminary study of the sedative effects of Annona muricata (sour sop). West Indian Med J, 28: 2,
1979 Jun, 106-10
735) Rieser MJ.,, Bioactive single-ring acetogenins from seed extracts of Annona muricata. Planta Med, 59: 1,
1993 Feb, 91-2
736) Makleit et Bognar: Acta Pharm. Chirurg, 1968, 38, pp. 58-62
737) Iocco P. : Genetic transformation of major wine grape cultivars of Vitis vinifera L, Transgenic Res. 2001, 10(2),
pp. 105-112
738) Lindbo J.A.: Virus-mediated reprogramming of gene expression in plants; California, USA; Curr. Opin. Plant.
Biol. 2001, 4(3), pp. 181-185;
739) Mette M.F.: Endogenous viral sequences and their potential contribution to heritable virus resistance in plants,
Salzburg, Austria, EMBO J., 2002, 21(3), pp.: 461-469;
740) Harper G.: Viral sequences integrated into plant genomes; United Kingdom; Annu Rev. Phytopathol. 2002, 40,
pp.: 119-136; Epub 2002 Feb.;
741) Paul W.: Correct processing of the kiwifruit protease actinidin in transgenic tobacco requires the presence of the
C-terminal propeptide; United Kingdom; Plant Physiol. 1995, 108(1), pp. 261-268
742) Sehnke PC.: Expression of active, processed ricin in transgenic tobacco; Florida, USA; j. Biol. Chem., 1994,
269(36), pp.: 22473-6.
743) Matzke MA: Integrated pararetroviral sequences; Nat. Biotechnol. 2000, 18(6), pp. 579.
744) Hammond J.: Epidemiological risks from mixed virus infections and transgenic plants expressing viral genes;
Maryland USA; Adv Virus Res., 1999, 54, pp. 189-314.
745) Tabe LM.: A biotechnological approach to improving the nutritive value alfalfa; Australia; J. Anim. Sci., 1995,
73(9), pp.: 2752-9.
746) Nagar S.: A geminivirus induces expression of a host DNA synthesis protein in terminally differentiated plant cells;
USA; Plant Cell. 1995, 7(6), pp.: 705-719.
747) Feuerbach F.: Retrovirus-like end processing of the tobacco Tnt1 retrotransposon linear intermediates of
replication; France; J. Virol. 1997, 71(5), pp.: 4005-4015.
748) Dickman MB.: abrogation of disease development in plants expressing animal antipoptotic genes, Department of
Plant Pathology, University of Nebraska, Lincoln, USA, IN: Proc. Natl. Acad. Sci. USA, 2001, Jun 5, 98(12): 6957-62
749) “The Gerson therapy. The amazing juicing programme for cancer and other illnesses”, by Charlotte Gerson and
Morton Walker, Thorsons ed.; Charlotte Gerson, Morton Walker: La Terapia Gerson. Macroedizioni.
750) Gerson M.A.:Cancer Therapy; Results of Fifty Cases, The Gerson Institute, Bonita, California, 1999.
751) Li F: Characterization of Fortilin, a novel anti-apoptotic protein, J.Biol.Chem. 2001; 276(50), pp.:47542-9
752) Dhar M: Screening of indian plants for biological activity. Indian J. Exp. Biol., 6, 232, 1968
753) Ocampo: Uncaria tomentosa, aspectos, Ethnomedicos, Medicos, Farmacologicos, Botanicos, Agronomicos,
Comerciales, Legales, Anthropologicos, Sociales y Politicos. Lima: Instituto de Desarollo Rural Peruraro (IDDERP),
1994, 74
754) Jones K: “Cat’s Claw: Healing Vine of Peru”. Seattle: Sylvan Press,1995, 180
755) Cabieses F: “The saga of the Cat’s Claw”. Lima: Via Lactera Editores, 1994
756) KeplingerH.: ”Oxindole Alkaloides Having Properties Stimulating the Immunologic System and Preparation
Containing Same. United States Patent 5, 302, 611, april 12, 1994
757) Keplinger H.: ”Oxindole Alkaloides Having Properties Stimulating the Immunologic System and Preparation
Containing Same”. United States Patent 4, 940, 725, July 10, 1990.
758) Keplinger H.: ”Oxindole Alkaloides Having Properties Stimulating the Immunologic System and Preparation
Containing Same”. United States Patent 4, 844, 901, July 4, 1989
759) Montenegro De Matta, S.: ”Alkaloids and procyanidins of an Uncaria sp. from Peru.” Il Farmaco. Ed.Sc 31
(1976); pp: 527-535.
760) Ozaki Y.: Pharmacological studies on Uncaria and Amsonia alkaloids. Japanese Journal of Pharmacology
(suppl.) 30 (1980): 137P
761) Kreutzkamp B.: Niedermolekulare Inhalstoffe mit Immunstimulierenden Eigenschaften aus Uncaria tomentosa,
Okoubaka aubrevillei und anderen Drogen. Dissertation of the faculty of chemistry and pharmacy of Ludwig
Maximilians University, Munich, May 1984.
762) Stuppner H. :HPLC analysis of the main oxindole alkaloids from Uncaria tomentosa. Chromatographia 34, 11/12
(1992), pp.: 597-600.
763) Wagner H.: Die Alkaloide von Uncaria tomentosa und ihre Phagozytosesteigernde Wirkung. Planta Medica 51
(1985), pp.: 419-423
764) Laus G.: Separation of sterioisomeric oxindole alkaloids from Uncaria tomentosa by high performance liquid
chromatography. Journal of Chromatography A 662 (1994). pp.: 243-249.
765) Lavault M.: Alcaloides de l’Uncaria guianensis, Planta Medica, 47 (1983), pp.:244-245.
766) Hemingway, S.R.: Alkaloids from South American species of Uncaria (Rubiaceae). Journal of Pharmacy and
Pharmacology 26, suppl. (1974), pp.:113P
767) Raymond Hamet, M.: Sur l’alcaloide principal d’une rubiacee des regions tropicales de l’Amerique de Sud:
l’Ourouparia guianensis Aubelt. Comptes Rendus Hebdomadaires des Seances de l’Academie des Sciences
235(1952).pp.: 547-550.
768) Stuppner, H.: A differential sensitivity of oxindole alkaloids to normal and leukemic cell lines. Planta Medica 59,
suppl.(1993). pp.583
769) Peluso G.: Effetto antiproliferativo su cellule tumorali di estratti e metaboliti da Uncaria tomentosa. Studi in vitro
sulla loro azione DNA polimerasi, 11.o congresso Italo-Peruviano de Etnomedicina Andina, Lima, Perù, ottobre 27-
30,1993, pp.21-22.
770) Rizzi R.: Mutagenic and antimutagenic activities of Uncaria tomentosa and its extracts, Premiere Colloque
European d’Ethnopharmacologie, Metz, France, March 22-24, 1990.
771) RizziR.: Bacterial cytotoxicity, mutagenicity and antimutagenicity of Uncaria tomentosa and its extracts.
Antimutagenic activity of Uncaria tomentosa in humans, Premiere Colloque European d’Ethnopharmacologie, Metz,
France, March 22-24, 1990.
772) RizziR.: Mutagenic and antimutagenic activities of Uncaria tomentosa and its extracts, Journal of
Ethnopharmacology 38 (1993), pp:63-77.
773) Segun Hartwell, J.L.: “Plants used against Cancer”. Lloydia 30-32, pp.:379-436
781) Brief Series webpage.htm
788Nat.Toxins 1998; 6(6):219-33
789) Rev. Can. Biol. 1978 Jun; 37(2): 127-130
790) J.Clin. Microbiol. 1998 Jul, 36(7): 2138-9
791) FEMS Immunol. Med. Microbiol. 1999 May; 24(1): 43-7),
792) J.Appl.Microbiol. 2000 Jul, 89(1): 16-23.
793) Leslie Taylor: “Herbal Secrets of the Rainforest. The healing power of over 50 medicinal plants you should know
about. Prima Health”. A division of Prima Publishing.
794) Dewick PM.: “Tumor Inhibitors from Plants”, Treasend Evans, Pharmacognosy (13th.Ed.), 1989, Volumenes 1-3.
795) J. Nat. Cancer Institute, vol.83, 1994, pp.1450-1459
796) Epstein S.: Un inganno a spese delle donne, in: Los Angeles Times, 22 giugno 1992
797) The Lancet I, 1989, pp.: 117-120
798) Austin S.: Cancro della mammella: ciò che dovreste sapere (ma che potrebbero non dirvi) sulla prevenzione,
diagnosi e trattamento, Prima Publishing, Rocklin, CA-USA, 1994
799) Fisher B.: Cancro endometriale in pazienti trattate con Tamoxifene: risultati del National Surgical Adjuvant
Breast & Bowel Project (NSABP) B-14, in: J.Natl.Cancer Inst., vol. 86, 1994, pp.:527-537
800) Fisher B: Commenti sulle morti per cancro endometriale nelle pazienti trattate con Tamoxifene, in: J.Clin.Oncol.,
vol.14, 1996, pp.: 1027-1039
801) Health Letter, Public Citizens Health Research Group, Attenzione al Tamoxifene che causa cancri, in: Public
Citizens Health Research Group Health Letter, 3 luglio 1994.
802) Newbold R: Carcinoma uterino nei topi sottoposti al Tamoxifene, durante la gestazione, in: Carcinogenesis,
vol.18,(12), dicembre 1997, pp.: 2293-2298
803) Rischiare il cancro della mammella o rischiare il Tamoxifene?, in: Toronto Star Newspaper , 14 aprile 1998
804) Yager J.D.: Estrogeni sintetici e Tamoxifene come promotori di epatocarcinogenesi, in: Prev.Med., vol.20,
805) Physicians’Desk Reference, 1998; Zeneca Pharmaceuticals, pag. 3175
806) Zou J.: Modification of seed oil content and acyl composition in the brassicaceae by expression of a yeast sn-2
acyltransferase gen, Plant Cell,1997, 9(6), pp.909-923
807) Shkurupii VA.: Efficiency of the use of peppermint (Mentha piperita) essential oil inhalations in the combined
multi drug therapy for pulmonary tuberculosis, Probl. Tuberk., 2002, (4), pp.:36-39
808) Kchouk ML.: In vitro organogenesis and transgenosis aspects in globe artichoke (Cynara scolymus), Cell. Mol.
Biol. (Noisy-le-grand) 1997, 43(3), pp.:399-408
809) Bonnesen C.: Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both
stimulate apoptosis and confe protection against DNA damage in human colon cell lines. Cancer Res. 2001, 61(16),
pp.: 6120-6130
810) Bruneton J:Pharmagnosy, Phytochemistry, Medicinal Plants, Andover, England: Intercept Limited, 1995.
811) Werbach, M.R.:Botanical Influences on Illness-A Sourcebook of Clinical Research, Tarzana, CA: Third Line
Press, 1994.
812) Blumenthal M.:”Plant medicines from the New World”, Whole Foods Magazine, april 1997.
813) Kametani T.: Heterocycles 4, 1976, pp.483
814) Guinaudeau H.: L loydia 38, 1975, pp.275
815) Marini-Bettolo G.B., Acad. Geneeskund, Belg. 43, 1981, PP. 185
816) Anwer F.: Studies in medicinal plants 3. Protoberberine alkaloids from the roots of Cissampelos pareira Linn,
Experientia, october 15, 1968.
817) Bhatnagar A.K.: Chemical examination of the roots of Cissampelos pareira Linn. Structure and stereochemistry of
hayatidin, Experientia, april 15, 1967
818) Bhatnagar AK.: “Chemical examination of the roots of Cissampelos pareira Linn, IV . Structure and
stereochemistry of hayatin, J.Org. Chem., March 1967
819) Kupchan S.M.: Tumor inhibitors. VI. Cissamparene, new cytotoxic alkaloid from Cissampelos pareira.
Cytotoxicity of bisbenzylisoquinoline alkaloids, J.Pharm. Sci., april 1965
820) Basu D.K.: Studies on curariform activity of hayatinin methochloride, an alkaloid of Cissampelos pareira, J.P.N.J.
Pharmacol., June 1970
821) Kondo Y.: Inhibitory effect of bisbenzylisoquinoline alkaloids on nitric oxide production in activated
macrophages, Biochem.Pharmacol., 46, 1993, pp. 1887-92.
822) Morita H.: Conformation of tropolone ring in antileukemic tropoloisoquinoline, Chem. Pharm. Bull., Tokyo, 41, 8
(August 1993), pp. 1478-80
823) Morita H.: Structures and solid state tautomeric forms of two novel antileukemic tropoloisoquinoline alkaloids,
pareirubrines A and B, from Cissampelos pareira, Chem. Pharm. Bull., Tokyo, 41, 8 (August 1993), pp. 418-22
824) DiCarlo F.J.: Reticuloendothelial system stimulants of botanical origin, Journal of the Reticuloendothelial Society,
1964, pp. 224-232
825) Martinod P.: Isolation of tingenone and pristimerin from Maytenus chuchuhuasha, Phytochemistry 15, 1976, pp.
826) Gonzales J.: Chuchuhuasha: a drug used in folk medicine in the Amazonian and Andeas areas. A chemical study of
Maytenus laevis, Journal of Ethnopharmacology 5, 1982, pp. 73-77
827) Itokawa H.: Oligo-nicotinated sesquiterpene polyesters from Maytenus ilicifolia, Journal of Natural Products 56,
1993,, pp. 1479-1485
828) Sekar V.S.: Mayteine and 6-benzoil-6-deacetyl-mayteine from Maytenus krukovii, Planta Medica, 61, 1995, PP.:
829) Bradshaw D: Therapeutic potential of protein kinase C inhibitors, Agents and Actions 38, 1993, pp. 135-147
830) Terhune S.: B-spathulene: a new sesquiterpene in Schinus molle oil, Phytochemistry 13, 1973, pp. 865.
831) Dominguez X.: A chemical survery of seventeen medicinal Mexican plants, Planta Med., 18, 1970, 51.
832) Pozzo-Balbi T.: The triterpenoid acids of Schinus molle, Phytochemistry 17, 1978, pp.: 2107-2110.
833) Dikshit AS.: Schinus molle: a new source of natural fungitoxicant, Appl. Environ.Microbiol. 51, 5, 1986, pp.:
834) Keltawi N.: Antimicrobial activity of some Egyptian aromatic plants, Herba Pol., 26, 4, 1980, pp.: 245-250.
835) Gundidza M.: Antimicrobial activity of essential oil from Schinus molle Linn, Central African J. Med., 39, 11,
1993, pp.: 231-234
836) Ross S.: Antimicrobial activity of some Egyptian aromatic plan ts, Fitoterapia 51, 1980, pp.: 201-205
837) Simons J.: Succulernt-type as sources of plant virus inhibitors, Phytopathology, 53, 1963, pp.: 677-683
838) Bhakuni D.: Screening of Chilean plants for anticancer activity, Llydia 39, 4, 1976, pp.: 225-243
839) Lima O.G.: Substabcias anti-microbiano de plantas superiores. Comunicacao XXXI. Maaitenina, novo
antimicrobiano con acao antineoplastica, isolade de celastracea de pernambuco. Revista do Instiuto de Antibioticos
(Recife), 9, 1969, pp.: 17-25
840) Monache F.D.: Maitenin: a new anti-tumoral substance from Maytenus sp., Gazzetta Chimica italiana, 102 (1972),
pp.: 317-320
841) Wolpert- Defillipes M.K.: Initial studies on the cytotoxic action of maytansine, a novel ansa macrolide,
Biochemical Pharmacology 24, 1975, pp.: 751-754.
842) Spjut Rj: Plant folklore: a tool for prediciting sources of antitumor activity? Cancer treatment reports 60, 1976,
pp.: 979-985
843) De Santana C.F.: Primeiras observacoes sobre o emprego da maitenina en pacientes cacerosos, Revista do
Instituto de Antibioticos (Recife), 11, 1971, pp.: 37-49.
844) Melo A.M.: First observations on the topical use of primin, plumbagin and maytenin in patiens with skin cancer,
Revista do Instituto de Antibuioticos (Recife), december 1974.
845) Cabanillas F.: Phase I study of maytansine using a 3-day schedule, Cancer Treatment Reports 60, 1976, pp.: 1127-
846) Chabner B.A.: initial clinical trials of mayansine, an antitumor plant alkaloid, Cancer Treatment Reports 62,
1978, p.: 429-433
847) O’Connell M.J.: Phase II trial of maytansine in patients with advanced colorectal carcinoma, Cancer Trteratment
Reports, 62, 1978, pp. : 1237-38
848) Suffnes M.J.: Current status of the NCI plant and animal product program, Journal of Natural Products 45, 1982,
pp.: 1-14
849) Crovetto P.M.: Las plantas utilizadas en medicina popular en el norestde corrientes, Miscelanea 69, Tucuman,
Argentina, Ministeris de Cultura y Educacion, Foundacion Miguel Lillo, 1981, 69
850) Jones K: Pau d’Arco immune power from the Rainforest, Rochester , VT, Healing Arts Press, 1995, 63
851) Freise, F.W.: Plants medicinais Brasileiras, Boletim de Agricultura 34, 1933, pp.: 410
852) Souza – Formigoni M.L.: Anti-ulcerogenic effects of two Maytenus species in laboratory animals, J.
Ethnopharmacol., august 1991
853) Oliveira M.G.: Pharmacologic and toxicologic effects of two Maytenus species in laboratory animals, J.
Ethnopharmacol, august 1991
854) Shirota O.: Cytotoxic aromatic triterpenes from Maytenus ilicifolia and Maytenus chuchuhuasca, J.Nat.Prod.,
december 1994.
855) Mesquita A: Flavonoids from four compositae species, Phytochemistry 25, 5, 1986, pp.: 1255-1256
856) Simoes C.M.: Anti-inflammatory action of Achyrocline satureoides extracts applied topically, Fitoterapia 59, 5,
1988, pp.: 419-421
857) Simoes C.M.: Pharmacological investigations on Achyrocline satureoides , J.Ethnopharmacol. 22, 3, 1988, pp.:
858) de Souza C.P.: Chemoprophylaxis of Schistosomiasis: molluscicidal activity of natural products, An. Acad. Brasil.
Cienc. 56, 3, 1984, pp.: 333-338
859) Vargas V.M. : Mutagenic and genotoxic effects of aqueous extracts of Achyrocline satureoides in prokaryotic
organisms, Mutat. Res. 240, 1, 1990, pp.: 13-18
860) Wagner H.: Immunostimulating polysaccharides (heteroglycans) of higher plants, Arzneim-Forsch., 35, 7, 1985,
pp.: 1069-75
861) Wagner H.: Immunostimulating polysaccharides (heteroglycans) of higher plants, preliminary communication ,
Arzneim-Forsch., 34, 6, 1984, pp.: 659-661.
862) Arisawa M.: Cell growth inhibition of KB cells by plant extracts, Nat. Med. 48, 4, 1994, pp.: 338-347
863) Abdel-Malek S.: Drug leads from the Kallawaya herbalists of Bolivia, 1.Background, rationale, protocol and anti-
HIV activity, J.Ethnopharmacol. 50, 1996, PP.: 157-166
864) Vasina O.E.:Withasteroids of Physalis, VII, 14-alpha-hydroxyixocarpanolide and 24,25-epoxywithanolide D.,
Chem. Nat. Comp. 22, 5, 1987, pp.: 560-565
865) Chen C.M.: Withangulatin A, a new withanolide from Physalis angulata, Heterocycles 31, 7, 1990, pp.: 1371-1375
866) Shingu K.: Physagulin C, a new withanolide from Physalis angulata Chem. Pharm. Bull. 39, 6, 1991, pp.: 1591-93
867) Shingu K. : Three new withanolides, physagulins E,F,G from Physalis angulata, Chem.Pharm. Bull., 40, 9, 1992,
pp.: 2448-2451
868) Basey K.: Phygrine, an alkaloid from Physalis spcies, Phytochemistry, 31, 12, 1992, pp.: 4173-76
869) Lin Y.S.: Immunomodulatory activity of various fractions derived from Physalis angulata extract, Amer. J.
Chinese Med., 20, 3/4 1992, pp.: 233-243
870) Chiang H.: Antitumor agent, physalin F, from Physalis angulata, Anticancer Res., 12, 3, 1992, pp.: 837-843
871) Chiang H.: Inhibitory effects of physalin B and physalin F on various human leukemia cells in vitro, Anticancer
Res., 12, 4, 1992, pp.: 1155-1162
872) Anonymous: Biological assay of antitumor agents from natural products, Abstr. Seminar on the Development of
Drugs from Medicinal Plants, Organized by the Department of Medical Science Department at Thai Farmer Bank,
Bangkok Thailand, 1982, 129
873) Veira J.E.: Pharmacologic screening of plants from nrtheast Brazil. II., Rev. Brasil. Farm., 49, 1968, pp.: 67-75
874) Caceres A.: Plants used in Guatemala for the treatment of gastrointestinal disorders 1. Screening of 84 plants
against enterobacteria, J.Ethnopharmacol., 30, 1, 1990, pp.: 55-73
875) Heinrich M.: Parasitological and microbiological evaluation of Mixe Indian medicinal plants, (Mexico),
J.Ethnophatrmacol., 36, 1, 1992, PP.: 81-85
876) Caceres A.: Plants used in Guatemala for the treatment of respiratory diseases.2: evaluation of activity of 16
plants against gram-positive bacteria, J.Ethnopharmacol., 39, 1993, pp.: 77-82
877) Caceres A: Plants used in Guatemala for the treatment of gastrointestinal disorders.3: confirmation of activity
against enterobacteria of 16 plants, J.Ethnopharmacol. 38,1, 1993, pp.31-38
878) Cancers A.: Anti-gonorrhoel activity of plants used in Guatemala for the treatment of sexually transmitted
diseases, J. Ethnopharmacol. 48, 2, 1995, , pp. 85-88
879) Pinheiro De. Sousa: Molluscicidal activity of plants from northeast Brazil, Rev. Brasil. Pesq. Med. Biol., 7, 4,
1974, pp.: 389-394
880) Nascimento S.C.: Antimicrobial and cytotoxic activities in plants from Pernambuco, Brazil, Fitoterapia, 61, 4,
1990, pp.: 353-355
881) Tseng C.E.: Inhibition of in vitro prostaglandin and leukotriene biosyntheses by cinnamoyl-beta-phenethylamine
and N-acyldopamine derivatives, Chem.Pharm.Bull., 40, 1992, 2, pp.: 396-400
882) Hor M.: Inhibition of intestinal chloride secretion by proanthocyanidins from Guazuma ulmifolia, Planta Medica,
61, 3, 1995, pp.: 208-212.
883) Hor M.: Proanthocyanidin polymers with antisecretory activity and proanthocyanidin oligomers from Guazuma
ulmifolia bark, Phytochemistry 42, 1, 1996, pp:109-119
884) Jones K: Pau d’Arco: Immune Power from the Rain Forest , Rochester, VT: Healing Arts Press, 1995, pp.: 54-58
885) Gentry A.: A synopsis of bignoniaeae ethnobotany and economic botany, Annals of the Missouri Botanical Garden
79, 1992, pp.: 53-64
886) Rao K.V.: Recognition and evaluation of lapachol as an antitumor agent, Cancer Res., 28, 1968, pp.: 1952-54
887) Block J.B.: Early clinical studies with lapachol (NSC-11905), Cancer Chemother. Rep., 4, 1974, pp.: 27-28
888) Linardi M.D.C.: A lapachol derivative active against mouse lympocyte leukemia P-388, J.Med.Chem., 18, 11,
1975, pp.: 1159-1162
889) Santana C.F.: Preliminary observation with the use of lapachol in human patients bearing malignant neoplasms,
Revista do Instituto de Antibioticos 20, 1971, pp.61-68
890) Beckstrom-Sternberg: the Phytochemical Database, ACEDB version 4.3, July 1994, National Germplasm
Resources Laboratory (NGRL), Agricultural Research Service (ARS), U.S. Department of Agricolture
891) de Lima O.G.: Primeiras observacoes sobre a acao antimicrobiana do lapachol, Anais da Sociedade de Biologica
de Pernambuco, 14, 1956, pp.: 129-135
892) de Lima O.G.: Una nova substancia antibiotica isolada do “Pau d’Arco”, Tabebuia sp., Anais da Sociedade de
Biologica de Pernambuco, 14, 1956, pp.: 136-140
893) Burnett A.R.: Naturally Occuring quinones; the quinonoid constituents of tabebuia avellanedae, J.Chem. Soc., C,
1967, pp.: 2100-2104
894) Gershon H.: Fungitoxicity of 1,4-naphthoquinonoes to Candida albicans and Trichophyton menta grophytes, Can.
J. Microbiol. 21, 1975, pp.: 1317-1321
895) Binutu O.A.: antimicrobial potentials of some plant species of the Bignoniaceae family, Afr. J. Med.Sci., 23, 3,
1994, PP.: 269-273
896) Linhares M.S.: Estudo sobre of efeito de substancias antibioticas obitdas de Streptomyces e vegatais superiores
sobre o herpesvirus hominis, Revista Instituto Antibioticos, Recife 15, 1975, pp.: 25-32
897) Lagrota M.: Antiviral activity of lapachol, Rev. Microbiol. 14, 1983, pp.: 21-26
898)Schuerch A.R.: B-Lapachone, an inhibitor of oncornavirus reverse transcriptase and eukarotic DBA polymerase-a.
Inhhibitory effect, thiol dependency and specificity, Eur. J. Biochem., 84, 1978, pp.: 197-205
899) Austin F.R.: Schistosoma mansoni chemoprophylaxis with dietary lapachol, Am.J.Trop. Med.Hyg., 23, 1979, pp.:
900) Gilbert B.: Schistosomiasis. Protection against infection by terpenoids, An. Acad. Brasil. Cienc. 42, (Suppl.),
1970, pp.: 397-400
901) Oga S.: Toxicidade e atividade anti-infiammatoria de Tabebuia avellanedae Lorentz (“Ipe Roxo”), Rev. Fac.
Farm. Bioquim., 7, 1969, pp.47-53
902) Awang DVC: Commercial taheebo lacks active ingredient, Information Letter 726, August 13, 1987, Can. Pharm.
J., 121, 1991, pp.: 323-326
903) Perdue G.P.: South American plants II: Taspine isolation and anti-inflammatory activity, J.,Pharmac.Sci., January
904) Vlietinck A.J.: Dommisse R.A., Eds, Advances in Medicinal Plant Research, Stuttgart, Wiss, Verlag, 1985
905) Vaisberg A.J.: Taspine is the cicatrizant principle in Sangre de Drago extracted from Croton lechleri, Planta
Med., april 1989.
906) Porras-Reyes B.H.: Enhancement of wound healing by the alkaloid taspine defining mechanism of action, Proc.
Soc. Exp. Biol. Med. 203, 1, 1993, pp.: 18-25
907) Itokawa H.: A cytotoxic substance from sangre de drago, Chem. Pharm. Bull., Tokyo, 39, 4, 1991, pp.: 1041-42.
908) Pieters L.: Isolation of a dihydrobenzofuran lignan from South American dragon’s blood (Croton spp) as an
inhibitor of cell proliferation, J.Nat. Prod., June 1993
909) Chen Z.P.: Studies on the anti-tumour, anti-bascterial, and wound-healing properties of dragon’s blood, Planta
Med., december 1994
910) Hobbs C.: Sarsaparilla, a literature review, Herbal Gram 17, 1988
911) Lung A,and Steven F.: Encyclopedia of Common Natural Ingredients, New York , John Wiley & Sons, Inc., 1996
912) Thurman F.M. : The treatment of psoriasis with sarsaparilla compound, New England Journal of Medicine 337,
1942, pp.: 128-133
913) D’Amico M.L.: Ricerche sulla presenza di sostanze ad azione antibiotica nelle piante superiori, Fitoterapia, 21, 1,
1950, pp.: 77-79
914) Fitzpatrick F.K.: Plant substances active against mycobacterium tuberculosis, Antibiotics and Chemotherapy, 4, 5,
1954, pp.: 528-536.
915) Rollier r.: treastment of lepromatous leprosy by a combination of DDS and sarsaparilla (Smilax ornata),
Int.J.Leprosy, 27, 1959, pp.: 328-340
916) Ageel A.M.: Experimental studies on antirheumatic crude drugs used in Saudi traditional medicine, Drugs Exp.
Clin. Rers., 15, 1989, , pp.: 369-372
917) Rafatulah S.: Hepatoprotective and safety evaluation studies on Sarsaparilla , Int. J. Pharmacognody, 29, 1991,
pp.: 296-301.
918) Harnischfeger G.: Smilax species -Sarsaparilla, in Bewahrte Pfanzendrogen in Wissenschaft und Medizin, Bad
Homburg/Melsungen, Notamed Verlag, 1983, pp.: 216-225
919) Tschesche R.: Advances in the chemistry of antibiotic substances from higher plants, In: H. Wagner and L.
Horhammer, Pharmacognosy and Phytochemistry, New York , Springer Verlag, 1971, pp.: 274-276
920) Willard T.: The wild Rose Scientific Herbal, Alberta: wild Rose College of natural Healing, 1991, PP.307
921Botanical Monograph, “Sarsaparilla (Smilax sarsaparilla)”, American Journal of Natural Medicine, 3, 9, 1996
922) Newal C.: Herbal Medicine: a Guide for Health -care Professionals, Cambridge, England: the Pharmaceutical
Press, 1996
923) Anesini C: Screening of plants used in Argentine folk medicine for antimicrobial activity, Catedra de
Farmacologia, Facultad de Odontologia, Univeridad de Buenos Aires, Argentina, J. Ethnopharmacol.. 39, 1993, pp.:
924) Ogungbamila F.O.. Smooth muscle-relaxing flavonoids from Alchornea cordifolia, Acta Pharm. Nord. 2,6, 1990,
pp.: 421-422
925) Robineau L: Towards a Caribbean Pharmacopoeia, TRAMIL-4 Workshop, UNAH, Enda Caribe, Santo Domingo,
926) Calixto J.B.: Antispasmodic effects of an alkaloid extracted from Phyllanthus sellowianus: a comparative study
with papaverine, Braz. Biol. Res., 17, 3,-4, 1984, pp.313-321
927) Syamasundar K.V.: Antihepatotoxic principles of Phyllanthus niruri herbs, J. Ethnopharmacol., 14, 1, 1985, pp.
928) Shimizu M.: Studies on aldose reductase inhibitors from natural products. II. Active components of a Paraguayan
crude drug, paraparai mi, Phyllanthus niruri, Chem. Pharm. Bull., Tokyo, 37, 9, 1989, pp.: 2531-2532
929) Ueno H.: Chemical and pharmaceutical studies on medicinal plants in Praguay. Geraniin, an angiotensinconverting
enzyme inhibitor from “paraparai mi”, Phyllanthus niruri, J.Nat. Prod., 51, 2, 1988, pp. 357-359.
930)Santos A.R.: analgesic effects of allus culture extracts from selected species of Phyllanthus in mice, J.Pharm.
Pharmacol., 46, 9, 1994, pp.: 755-759
931) Santos a.r.: Analysis of the mechanisms underlying the anti-nociceptive efect of the extracts of plants from the
genus Phyllanthus, Gen.Pharmacol. 26, 7, 1995, pp.: 1499-1506
932) Srividya N.: Diuretic, hypotensive and hypoglycaemic effect of Phyllanthus amarus, Indian J. Exp. Biol. 33, 11,
1995, pp.: 861-864
933) Dixit S.P.: J.Natl.Integ.Med. Assoc. 25, 8, pp.: 269, 1983
934) Thyagarajan S.P.: In vitro inactivation of HBsAg by Eclipta alba Hassk and Phyllanthus niruri Linn, Indian J.Med.
Res., 76, 1982, pp.: 124-130
935) Effects of an extract from Phyllantus niruri on hepatitis B and woodchuck hepatitis viruses: in vitro and in vivo
studies, Proc. Natl. Acad. Sci., USA, 84, 1, 1987, pp.: 274-278.
936) Wang M.: Herbs of the genus Phyllanthus in the treatment of chronic hepatitis B: observations with
three preparations from different geographic sites, J.Lab.Clin. Med., 126, 1995, pp.: 350-352
937) Wang M.: Efficacy of Phyllanthus spp. in treating patients with chronic hepatitis B., Chung Kuo Chung Yao Tsa
Chih, 19, 12, 1994, pp.: 750-751
938) Yeh S.F.: Effect of an extract from Phyllanthus amarus on hepatitis B surface antigen gene expression in human
hepatoma cells, Antiviral Research 20, 1993, pp.: 185-192
939) Mehrotra R: In vitro studies on the effect of certain natural products against hepatitis B virus, Indian J.Med.Res.,
92, 1990, pp.: 133-138
940) Ogata T.: HIV-1 reverse transcriptase inhibitor from Phyllanthus niruri, AIDS Res. Hum. Retroviruses 8, 11,
1992, pp.: 1937-1944
941) Qian -Cutrone J.: Niruriside, a new HIV REV/RRE binding inhibitor from Phyllanthus niruri, J.Nat.Prod., 59, 2,
1996, pp.: 196-1999.
942) Beral V.: Use of HRT and the subsequent risk of cancer, J.Epidemiol.Biostat.4, pp.191-210, 1999
943) Verheul H.A.: Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of
breast cancer therapy, Maturitas 36, pp.1-17, 2000
944) Armostrong K.: Beliefs about breast cancer risk and use of postmenopausal hormone replacement thepapy,
Med.Decis.Making 20, pp.208-313, 2000
945) Boyle P.: Update on cancer control in women, Int.J.Gynaecol. Obstet 70, pp.263-303, 2000
946) Henrich J.B.: The postmenopausal estrogen/breast cancer controversy, J.Am.Med.Assoc., 268, pp.1900-1902,
947) Miksicek R.J.: Commonly occuring plant flavonoids have estrogenic activity, Mol.Pharmacol. 44, pp.37-43, 1993
948) Miksicek R.J.: Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human
estrogen receptor, J.Steroid Biochem.Mol.Biol., 49, pp.153-160, 1994
949) Graumann K.: Monitoring of estrogen mimics by a recombinant yeast assay: synergy between natural and
synthetic compounds?, Sci Total Environ. 225, pp.: 69-79, 1999
950) Bennetts H.W.: A specific breeding problem of sheep on subetranean clover pastures in Western Australia,
Aust.Vet.J. 22, PP.2-12, 1946.
951) Brzezinski A: Phytoestrogens: the “natural” selective estrogen receptor modulators?, Eur. J.Obstet. Gynecol.
Reprod. Biol. 85, pp.47-51, 1999
952) Reinli K.: Phytoestrogen content of foods – a compendium of literature values, Nutr. Cancer, 26, pp.123-148, 1996
953) Zava D.T.: Estrogen and progestin bioactivity of foods, herbs, and spices, Proc. Soc.Exp.Biol.Med. 217, 369-378,
954) Xu X.: Bioavailability of soybean isoflavones depends upon gut microflora in women, J.Nutr. 125, pp. 2307-2315,
955) Setchell K.D.: Dietary isoflavones: biological effects and relevance to human health, J.Nutr. 129, 758AS-767S,
956) Lichtenstein A.H.: Soy protein, isoflavones and cardiovascular disease risk, J.Nutr.128, pp.1589-1592, 1998
957) Verma S.P.: The inhibition of the estrogenic effects of pesticides and environmental chemicals by curcumin and
isoflavonoids, Environ.Health Perspect, 106, pp.807-812, 1998
958) Peterson G.: Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer
cells, Cell Growth Differ. 7, pp.1345-1351, 1996
959) Constantinou A.I.: Genistein induces mautration of cultured human breast cancer cells and prevents tumor growth
in nude mice, Am.J.Clin.Nutr. 68, 1426S-1430S, 1998
960) Fotsis T.: Genistein, a dietary-derived inhibitor of in vitro angiogenesis, Proc.Natl.Acad.Sci.USA 90, 2690-2694,
961) Wei H.: Antioxidant and antipromotionsl effects of the soybean isoflavone genistein, Proc.Soc.Exp.Biol.Med. 208,
pp.124-130, 1995
962) Ruiz-Larrea M.B.: Antioxidant activity of phytoestrogenic isoflavones, Free Radic.Res. 26, pp.63-70, 1997
963) Kim H.: Mechanisms of action of the soy isoflavone genistein:emerging role for its effects via transforming growth
factor beta signaling pathways, Am. J. Clin. Nutr. 68, 1418S-1425S, 1998
964) Hsieh C.Y.: estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer
(MCF-7) cells in vitro and in vivo, Cancer Res. 58, pp.:3833-3838, 1998
965) Dixon-Shanies D.: Growth inhibition of human breast cancer cells by herbs and phytoestrogens, Oncol. Rep. 6,
pp.: 1383-1387, 1999
966) Dornstauder E: Attività estrogenica di due estratti standardizzati di trifoglio pratense. Uso nella terapia ormonale
sostitutiva, Medicina Naturale, gennaio2003, pp.68-73
967) Christiansen P.: Transgenic Trifolium repens with foliage accumulating the hi sulphur protein, sunflower seed
albumin, Transgenic Res., 2000, 9 (2), pp.: 103-113
968) Kuvshinov VV: Transgenic crop plants expressing synthetic cry9Aa gene are protected against insect damage,
Plant Sci 2001, 160 (2), pp: 341-353
969) Walji, Vitamins, Minerals and Dietary supplements, Headway Hodder and Stoughton, pp.100, 1995
970) Walji, Vitamins, Minerals and Dietary supplements, Headway Hodder and Stoughton, pp.100, 1995
971) Waldron KW.: Food and cancer prevention: chemical and biological aspects, I.T.Johnson AFRC
972) Kendler B.S.: Garlic (Allium sativum) and Onion (Allium cepa) : a reviuw of their Relationship to
cardiovascular disease, Preventive Medicine 16, pp.: 670-685, 1987
973) Fulder S.: Scorn not garlicke, Pharmacy update, october, pp.: 327-329
974) Abdullah TH: Garlic revisited: therapeutic for the major diseases of our times? J.Natl. Med. Assoc.
80, pp.: 439-445, 1988
975) Lammon DL: The potential application of Allium sativum (garlic) for the treatment of bladder
cancer, Urol. Clin. North Am., 27, pp.: 157-162, 2000
976) Lau BH.: Garlic compounds modulate macrophage and T-lymphocyte functions, Mol. Biother 3, pp.:
103-107, 1991
977) Nagabhushan M.: Anticarcinogenic action of diallyl sulfide in hamster buccal pouch and
forestomach, Cancer lett., 6, pp.: 207-216, 1992
978) Lin XY: Dietary garlic suppresses DNA adducts caused by N-nitroso compounds, Carcinogenesis
15, pp.: 349-352, 1994
979) Song K.: The influence of heating on the anticancer properties of garlic, J.Nutr. 131S: 1054S-
1057S, 2001
980) Lamm d.l.: Enhanced immunocompetence by garlic: role in bladder cancer and other malignacies,
J.Nutr. 131s: 1067s-1070s, 2001
981) Kyo E.: Immunomodulatory effects of aged garlic extract, J.Nutr. 131s: 1075s-1079s, 2001
982) Alvarez I., Lysine-rich gamma -zeins are secreted in transgenic Arabidop plants, Planta, 1998, 205(3), pp: 420-
427Barcelona, Spain
983) Markkanen T.: Antiherpetic agent from Juniper Tree (Juniper communis), its purification,
identification, and testing in primary human amnion cell cultures, Drug exp. Clin. Res., 1981, 7, pp.: 691-
984) Dombradi A.:Anti-tumor activity of A.lappa, ext. tumori, 52, pp.:173-175, 1966); (Morite K.:
Chemical nature of a desmutagenic factor from burdock (Arctium lappa), Agric. Biol.Chem. 49, pp.: 925-
985) Gibson GR.: Non-digestible oligosaccharides and bifido bacteria-implications for health,
International Sugsr Journal, 96 (1150), pp.: 381-387.
986) Della Loggia: Piante officinali per infusi e tisane, OEMF, 1993, pp.: 99-101). 987)Pedretti M.:
Chimica e farmacologia delle piante, Studio Edizioni, 1990)
987) Polacheck: Activity of compound G2 isolated from alfaalfa roots against medically importannt
yeasts, Antimicrobial agents Chem other, 30, pp: 290.34, 1986.
988) Pedretti M.: Colesterolo e aterosclerosi , Clesav, 1992
989) Story JA: interactions of alfalfa plant and sprout saponins with cholesterol in vitro and in
cholesterol-fed rats, Am J.Clin. Nutr. 39, pp.: 917-929, 1984
990) Malinow MR: comparative effects of alfalfa saponins and alfalfa fiber on cholesterol absorption in
rats, Am. J. Clin. Nutr. 32(9), PP.: 1810-1812, 1977
991) Malinow MR: Effect of alfalfa saponins on intestinal cholesterol absorption in rats, Am. J. Clin.
Nutr. 30 (12), pp.: 2062-67
992) Mallinow MR.: Effect of alfaalfa meal on shrinkage (regression) of atherosclerotic plaques during
cholesterol feeding in monkeys, Atherosclerosis 30 (1), pp.: 27-43
993) Della Loggia R.: Piante officinali per infusi e tisane, OEMF, pp.200.202, 1983. 994)Mcintyre A.:
Woman’s herbal, Gaia Book, pp.: 189-190, 1994
995) Poletti A.: Fiori e piante medicinali, Vol.II, Musumeci, 1994.
996) Benigni: Piante medicinali, Ed. Inverni & della Beffa, pag. 847, R.N. Brodgen et al., Drugs, 8, pp.:
330, 1964).
997) Le monografie tedesche, Vol. 2, pp.25, Studio Edizioni, 1990.
998) Castleman M.: Le erbe curative, Tecniche nuove, pp.242-247, 1994.
999) Hamilton L.: La via della natura, Sinai Edizioni, 1995.
1000) Mcintyre A.: Woman’s Herbal, Gaia Books, pp.34, 1994.
1001) Bone K., British J. Phytother., 2, pp.55-60, 1994.
1002) Wilson L: Equilibrio nutrizionale e analisi minerale tissutale, Sinai Edizione, 1995
1003) Kampf R.: Schweizerische apotheker zeitung, 114, pp. 337-342, 1976.
1004) (Pedretti M: Chimica e farmacologia delle piante, Studio edizioni, 1990.
1005) Suglia L: Natura antalgica, Erboristeria Domani, 12, pp: 34-40, 1995
1006) Wagner H.: Immunostimulans from medicinal plants, in: Chang HM. et al, editors, Advancesin
Chinese Medicinal Materials Research, Singapore: Word Scientific, 159, 159; 1985.
1007) Wagner H.: Immunstimulierend wirkende polysaccaride (heteroglykane) aus hoheren pflanzen,
Arzneimittelforschung 35, 1069; 1985.
1008)Yun-Choi HS: Potential inhibitors of platelet aggregation from plant sources, III, J.Natl. Prod. 50;
pp: 1059-64, 1987.
1009) Medon P.J.: Hypoglycaemic effect and toxicity of Eleuteroccocus senticosus following acute and
chronic administration in mice , Acta Pharmacol. Sinica, 2, pp: 281-285, 1981.
1010) Hikino H: Isolation and hypoglycaemic activity of Eleutherans A, B, C, D, E, f and G: Glycans of
Eleutherococcus senticosus roots, J. Natl.Prod., 49, pp: 293-297, 1986.
1011) Chowrira GM: Coat protein-mediated resistance to pea enation mosaic virus transgenic Pisum
sativum L., Transgenic Res., 1998, 7(4), pp.: 265-271
1012) Vincent R: Overexpression of a soybean gene encoding cytosolic glutamin synthetase in shoots of transgenic
Lotus corniculatus L plant triggers changes in ammonium assimilation and plant development, Planta, 1997, 201 (4),
pp.: 424-433
1013) Malinowski T.: Preliminary report on the apparent breaking of resistance of transgenic plum by chip bud
inoculation of plum pox virus PP S, Acta Virol., 1998, 42(4), pp.: 241-243
1014) Febres VJ: Characterization of grapefruit plants (Citrus paradisi Macf.) transformed with citrus tristeza
closterovirus genes, Plant Cell Rep. 2003, 21(5), pp.: 421-428
1015) Mostefa-Kara N; Pauwels A; Pines E;et al.: Fatal hepatitis after herbal tea. Lancet 1992; V340,(Sep12), p.674
1016) Larrey D; Vial T; Pauwels A ;et al.: Hepatitis after germander (Teucrium chamaedrys) administration: another
instance of herbal medicine hepatotoxicity. Ann Intern Med 1992; 117(2):129-32.
1017) Castot A; Larrey D.:Hepatitis observed during a treatment with a drug or tea containing Wild Germander.
Evaluation of 26 cases reported to the Regional Centers of Pharmacovigilance. Gastroenterol Clin Biol 1992; 16: 916-
1018) Kouzi SA; McMurty RJ; Nelson SD.: Hepatoxicity of Germander (Teucrium-chamaedrys l) and one of its
constituent neoclerodane diterpenes teucrin-a in the mouse. Chem Res Tox 1994;7:850-856.
1019) Loeper J; Descatoire V; Letteron P;et al.: Hepatotoxicity of Germander in mice. Gastroenterology 1994; 106:464-
1020) Lekeral M; Pessayre D; Lereau JM;et al.: Hepatotoxicity of the herbal medicine germander metabolic-activation
of its furano diterpenoids by cytochrome-p450 3a depletes cytoskeleton-associated protein thiols and forms plasmamembrane
blebs in rat hepatocytes. Hepatology 1996;24:212-218.
1021) Ben Yahia M; Mavier P; M´etreau JM;et al.:Chronic active hepatitis and cirrhosis induced by wild germander. 3
cases. Gastroenterol Clin Biol 1993; 17: 959-62.
1022) Bello R, et al.: Evaluation of the acute toxicity, analgesic and CNS activities of different species of Teucrium
genus. Phytoter Res 1995;9:277-280.
1023) Tanira MOM; Wasfi IA; Al Homsi M; et al.: Toxicological effects of Teucrium stocksianum after acute and
chronic administration in rats. J Pharmacy Pharmacol 1996; 48: 1098-1102.
1024) Piozzi F; Bruno M; Cirimina R; et al.: Putative hepatotoxic neoclerodane diterpenoids from Teucrium species.
Planta Medica 1997; 63: 483-484.
1025) Soylu AR; Sivri B; Bayraktar Y.: Hepatotoxicity of Teucrium poliu.: Turkish Journal of Gastroenterology
1998;9/2: 196-197.
1026) Bruno M; Cruciata M; Bondi ML; et al.: Neo-clerodane diterpenoids from Scutellaria lateriflora. Phytochemistry
1998; 48: 687-691.
1027) Labbe C; Castillo M; Hernandez M. Diterpenoids from Baccharis lejia. Phytochemistry 1991; 30: 1607-1611
1028) De Smet P.A.G.M. Adverse of Herbal Drugs. Vol. 3, Springer Verlag, Berlin, 1997
1029) Firenzuoli F.: Ogni rosa ha la sua spina. L’ Erborista 1994; 7: 14-19.
1030) Firenzuoli F. Le insidie del Naturale. Tecniche Nuove, Milano, 1996: p. 70.
1031) Firenzuoli F. Fitoterapia II Ed. Masson, Milano, 1998: p. 36, 39, 145.
1032) Firenzuoli F. Le 100 erbe della salute. Tecniche Nuove, Milano, 2000
1033) Ministero della Sanità, Gazzetta Ufficiale, nr.181, August 3rd 1996.
1034) Larrey D. Liver involvement in the course of phytotherapy .Presse Med 1994, 23:691-3.
1035) McLendon RE: Is the long-term survival of patients with intracranial glioblastoma multiforme overstated?
Cancer, 98 (8), pp.: 1745-1748, 2003
1036) Fulda S, Friesen C, Los M, et al. Betulinic Acid triggers CD95 (APO-1Fas)- and p53-independent apoptosis via
activation of caspases in neuroectodermal tumors. Cancer Res. 1997;57:4956-4964.
1037) Fulda S.: Betulinic Acid: A new cytotoxic agent against malignant brain-tumor cells. Int J Cancer. 1999;82:435-
1038) Fulda S.: Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res.
1039) Jeong HJ, Chai HB, Park SY, Kim DS. Preparation of amino acid conjugates of betulinic acid with activity
against human melanoma. Bioorg Med Chem Lett. 1999;9:1201-1204.
1040) Pisha E, Chai H, Lee IS, et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that
functions by induction of apoptosis. Nat Med. 1995;1:1046-1051.
1041) Schmidt ML.: Betulinic acid induces apoptosis in human neuroblastoma cell lines. Eur J Cancer. 1997;33:2007-
1042) Kitanaka C.: increased RAS expression and caspase- independent Neuroblastoma cell death: possible
mechanism of spontaneous Neuroblastoma regression, Journal of the National Cancer Institute,Vol.94,No.5,pp.358-
368,2002 [358.pdf]
1043) Tomonori H.: Induction of normal phenotypes in RAS transformed cells by damnacanthal from Morinda
citrifolia, Cancer-Letters 73, 1993, pp.161-166.
1044) Gobe:GC.: Apoptosis in brain and gut tissue of mice fed a sedd preparation of the cycad Lepidozamia
peroffskyana, Biochem.Biophys Res. Commun 1994, 205-pp.:327-333
1046) Jang MH: Protective effects of Puerariae flos against ethanol induced apoptosis on human neuroblastoma cell
line SK-N-MC, Jpn J.Pharmacol., 2001, 87(4), pp..338-342
1047). Foldeak S and Dombradi G. Tumor-growth inhibiting substances of plant origin. I. Isolation of the active
principle of Arctium lappa. Acta Phys Chem.1964;10:91-93.
1048). Dombradi C and Foldeak S. Screening report on the antitumor activity of puriÞed Arctium lappa extracts.
1049). Morita K, et al. A desmutagenic factor isolated from burdock (Arctium lappa Linne). Mutat Res.1984;129:25-31.
1050). WHO. In vitro screening of traditional medicines for anti-HIV activity: memorandum from a WHO meeting. Bul.
WHO (Switzerland), 1989;67:613-618.
1051). Belkin M and Fitzgerald D. Tumor damaging capacity of plant materials. 1. Plants used as cathartics. J Natl
Cancer Inst.1952;13:139-155.
1052) US Congress, OfÞce of Technology Assessment (OTA). Unconventional cancer treatments. Washington, DC: US
Government Printing OfÞce, 1990.
1053). Pettit GR, et al. Antineoplastic agents. The yellow jacket Vespula pensylvanica. Lloydia.1977;40:247-52.
1054) Rhoads P, et al. Anticholinergic poisonings associated with commercial burdock root tea. J Toxicol.1984-
1055)Gray RE, Fitch M, Greenberg M, Perspectives of cancer survivors interested in unconventional therapies. Journal
of Psychosocial Oncology. 1997; 15:149-171
1056)Yats P, Patients with terminal cancer who use alternative: their beliefs and practices. Sociology of Health abd
Illness. 1993; 15: 199-217
1057) National Research Council. Food Chemical codex. Food and Nutrition Board, Division of Biological Sciences,
Assembly of Life Sciences. Washington D: National Academy Press; 1981
1058) Flora Manufacturing and Ditributing files, Academy of Agricultural Sciences pof the Russian Federation
Research & Manufacturing Association. Research & Development Institute of Medical & Aromatic Plants. Unpublished
report, 1997
1059) The University of Texas Houston Center for Alternative Medicine Research in Cancer. Essiac Summary.
1060) Richardson MA, Ramirez T, Nanney K, Singletary SE. Alternative/ complementary medicine: implications for
patients-provider communication. Proceedings ofAmerican Society of Clinical Oncology. 1999; 18: 590A abstr 2279
1061) Yun-Ching Chang: Induction of apoptosis by penta-acetyl geniposide in rat C6 glioma cells, Chemico-
Biological Interactions, 141, 2002, pp.: 243-257,%20contenuto%20nel%20frutto%20di%20Gardenia,%20fa%
1062) Steiner M.: Carnosic acid inhibits proliferation and augments differentiation of human leukemic cells induced
by 1,25-dihydroxyvitamin D3 and retinoic acid, Nutr.Cancer 2001,41(1-2):135-144
1063) Tanaka T.: Suppression ofazoxymethane induced colon carcinogenesis in male F344 rats by mandarin juices
rich in beta-Cryptoxanthin and Hesperidin, Int.J.Cancer- 88(1), pp.:146-150, 2000.
1064) Ren W. : Tartary buckwheatflavonoid activates caspase 3 and induces HL-60 cell apoptosis, Methods Find Exp.
Clin. Pharmacol. 2001 23 (8), pp.: 427-432
1065) Day P.R.: Genetic modification of plants: significant issues and hurdles success, Am.J.Clin.Nutr., 63(4), pp.:
651S-656S, 1996
1066) Christiansen P.: Transgenic Trifolium repens with foliage accumulating the high sulphur protein, sunflower seed
albumin, Transgenic Res., 2000; 9(2); pp.:103-113
1067) Singh R.: The natural history of breast carcinoma in the elderly: implications for screening and treatment,
Cancer, 100 (9), pp.:1807-1813, 2004
1068) Fumoleau P.: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline
and taxane-pretreated metastatic breast cancer, Eur. J.Cancer, 2004; 40(4), PP:536-542
1069) Polyzos A.: Full dose paclitaxel plus vinorelbine as salvage chemotherapy anthracycline-resistant advanced
breast cancer: a phase II study, J.Chemother. 2003,15(6),pp.:607-612
1070) Humphreys AC.: Phase II study of docetaxel in combination with epirubicin an protracted venous infusion 5-
fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group
study, Br.J.Cancer, 2004, 90(11),pp.:2131-2134
1071) Gradishar WJ.: Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a
multicenter phase II study, J.Clin.Oncol.2004,22(12),pp: 2321-2327
1072) Ejlertsen B.: Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in
patients with advanced breast cancer: a Scandinavian Breast Group Trial, J.Clin.Oncol.2004, 22(12),pp.:2313-2320].
1073) Wist EA: Oral capecitabine in anthracycline and taxane-pretreated advanced/metastatic breast cancer, Acta
Oncol.,2004,43(2), pp.:186-189
1074). Judith G. Dausch and Daniel W. Nixon, Garlic: A Review of Its Relationship to Malignant Disease, Preventive
Medicine 19:346-361 (1990), 350.
1075). Moss, Cancer Therapy, 148-9.
1076). N. Caporaso, S.M. Smith and R.H. Eng, Antifungal Activity in Human Urine and Serum after Ingestion of Garlic
(Allium sativum), Antimicrob Agents Chemother 23(5):700-702 (1983).
1077). Draft, Status Report of Year One Operations, University of Texas Center for Alternative Medicine Research,
September 9, 1996, 45.
1078). G. Li et al., Anti-Proliferative Effects of Garlic Constituents in Cultured Human Breast Cancer Cells, Oncology
Reports 2:787-91 (1995).
1079). A.K. Maurya and S.V. Singh, Differential Induction of Glutathione Transferase Isoenzymes of Mice Stomach by
Diallyl Sulfide, a Naturally Occurring Anticarcinogen, Cancer Letters 57(2):121-9 (1991 May 1).
1080). Boik, Cancer and Natural Medicine, 29.
1081). E. Lee, M. Steiner and R. Lin, Thioallyl Compounds: Potent Inhibitors of Cell Proliferation, Biochimica et
Biophysica Acta 1221(1):73-7 (10 March 1994)
1082). Boik, Cancer and Natural Medicine, 30.
1083). A. Koch et al., Inhibition of Production of Monocyte/macrophage derived Angiogenic Activity by Oxygen Freeradical
Scavengers, Cell Biology International Reports 16(5):415-25 (May 1992).
1084). Boik, Cancer and Natural Medicine, 24-5.
1085). C. Legnani et al., Effects of a Dried Garlic Preparation on Fibrinolysis and Platelet Aggregation in Healthy
Subjects, Arzneimittel Forschung 43(2):119-22 (February 1993).
1086). R.C. Arora, S. Arora and R.K. Gupta, The Long-Term Use of Garlic in Ischemic Heart Disease–An Appraisal,
Atherosclerosis 40(2):175-9 (October 1981).
1087). H. Kiesewetter et al., Effect of Garlic on Thrombocyte Aggregation, Microcirculation, and Other Risk Factors,
International Journal of Clinical Pharmacology, Therapy, & Toxicology 29(4):151-5 (April 1991).
1088). Z.H. Feng et al., Effect of Diallyl Trisulfide on the Activation of T Cell and Macrophage-Mediated Cytotoxicity,
Journal of Tongji Medical University 14(3):142-7 (1994).
1089). J.Y. Xie, Y.M. Gao and L.C. Shen, Flow Cytometric Analysis of the Garlic Oil Effect on DNA Content of
Cancer, Chung-Kuo Chung Hsi i Chieh Ho Tsa Chih 12(2):92-4, 69-70 (1992 February).
1090). J.Y. Xie, M.F. Liu and Q.H. Hu, Experimental Study on Effect of Kang ai-bao II to Cancer Cells with Cell CT
Analysis in Mice, Chung-Kuo Chung Hsi i Chieh Ho Tsa Chih 15(5):293-5 (1995 May).
1091). P. Xiyu, Comparison of the Cytoxic Effect of Fresh Garlic Diallyl Trisulfide, 5-Fluorouracil (5-FU), mitomycin
(MMC), and cis-DDP on Two Lines of Gastric Cancer Cells, Chung Hua Chung Liu Tsa Chih 7(2):103-5 (1985). Cited
in Dausch and Nixon, „Garlic,” 356.
1092). G. Li et al., Anti-Proliferative Effects of Garlic Constituents in Cultured Human Breast Cancer Cells, 789.
1093). Hiromitsu Takeyama, Growth Inhibition and Modulation of Cell Markers of Melanoma by S-Allyl Cysteine,
Oncology 50:63-9 (1993).
1094). David S.B. Hoon, Modulation of Cancer Antigen and Growth of Human Melanoma by Aged Garlic Extract, First
World Congress on the Significance of Garlic and Garlic Constituents. Washington, D.C., 1990.
1095). Sujatha G. Sundaram and John A Milner, Impact of Organosulfur Compounds in Garlic on Canine Mammary
Tumor Cells in Culture, Cancer Letters 74:85-90 (1993).
1096). Y. Kimura and K. Yamamoto, Cytological Effects of Chemicals on Tumors. XXIII. Influence of Crude Extracts
from Garlic and Some Related Species on MTK-sarcoma III, GANN 55:325-29 (1964). Cited in Dausch and Nixon,
„Garlic,” 355.
1097). M. Fujiwara and T. Natata, Induction of Tumor Immunity with Tumor Cells Treated with Extract of Garlic,
Nature 216:83-4 (1967). Cited in Dausch and Nixon, „Garlic,” 355.
1098). T. Nakata, Effect of Fresh Garlic Extract on Tumor Growth, Japanese Journal of Hygiene 27(6):538-43 (1973).
Cited in Dausch and Nixon, „Garlic,” 356.
1099). H. Cheng and T. Tung, Effect of Allithiamine on Sarcoma-180 Tumor Grown in Mice, Journal of the Formosan
Medical Association 80:385-93 (1981). Cited in Dausch and Nixon, „Garlic,” 356.
1100). G. Dhillon et al., Inhibitor in the in vivo and in vitro Guanylate Cyclase Activity from Garlic, In Proceedings,
72nd Annual Meeting AACR 1981, Abstract 69:17. Cited in Dausch and Nixon, „Garlic,” 356.
1101). W.E. Criss et al., Inhibition of Tumor Growth with Low Dietary Protein and with Dietary Garlic Extracts. In
Proceedings, 66th Annual Meeting FASEB 1982. Abstract 74:281. Cited in Dausch and Nixon, „Garlic,” 355.
1102). Y.M. Choy, T.T. Kwok and C.Y. Lee, Effects of Garlic, Chinese Medicinal Drugs and Amino Acids on Growth
of Erlich Ascites Tumor Cells in Mice, American Journal of Chinese Medicine 11(1-4):69-73 (1983). Cited in Dausch
and Nixon, „Garlic,” 355.
1103). B.H.S. Lau, F. Lam and R. Wang-Cheng, Effect of an Odor-modified Garlic Preparation on Blood Lipids,
Nutrition Research 7:139-49 (1987).
1104). C.L. Marsh et al., Superiority of Intravesical Immunotherapy with Corynebacterium Parvum and Allium Sativum
in Control of Murine Bladder Cancer, Journal of Urology 137(2):359-62 (1987 February).
1105). Dr. Donald L. Lamm, et al., Intralesional Immunotherapy of Murine Transitional Cell Carcinoma Using Garlic
Extract, First World Congress on the Significance of Garlic and Garlic Constituents. Washington, D.C., 1990.
1106). M.C Unnikrishnan and R. Kuttan, Tumor Reducing and Anticarcinogenic Activity of Selected Spices, Cancer
Letters 51(1):85-9 (1990 May 15).
1107). XY Pan et al, Experimental Chemotherapy of Human Gastric Cancer Cell Lines in Vitro and in Nude Mice,
Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology] 10(1):15-8 (January 1988).
1108). S.A. Yellin et al., Relationship of Glutathione and Glutathione-S- transferase to Cisplatin Sensitivity in Human
Head and Neck Squamous Carcinoma Cell Lines, Cancer Letters 85(2):223-32 (14 October 1994).
1109). Z.Z. Zhao and M.T. Huang, A SOS Induction Test Screening Study for Vegetables Inhibiting Mutagenicity
Caused by Antineoplastic Drugs, Chung-Hua Yu Fang i Hsueh Tsa Chih [Chinese Journal of Preventive Medicine]
26(2):92-3 (March 1992).
1110). M. Takada et al., Enhancing Effects of Organosulfur Compounds from Garlic and Onions on
Hepatocarcinogenesis in Rats: Association with Increased Cell Proliferation and Elevated Ornithine Decarboxylase
Activity, Japanese Journal of Cancer Research 85(11):1067-72 (November 1994).
1111). Robert I. Lin, Ph.D., Theories and Facts about Garlic’s Health Benefits, First World Congress on the Health
Significance of Garlic and Garlic Constituents. Washington, D.C., 1990.
1112). Sujatha G. Sundaram and John A. Milner, Impact of Organosulfur Compounds in Garlic on Canine Mammary
Tumor Cells in Culture, Cancer Letters 74:85-90 (1993).
1113). J.S. Pruthi, L.J. Singh and G. Lag, Determination of the Critical Temperature of Dehydration of Garlic, Food
Science 8:436-41 (1959).
1114). S. Nakagawa et al., „Effect of Raw and Extracted-aged Garlic Juice on Growth of Young Rats and Their Organs
after Per Oral Administration,” Journal of Toxicological Sciences 5:91-112 (1980).
1115) Capasso R.: Planta Medica, 70 (2), 2004, pp.: 185-188
1116) Bisio A.: Ann. Bot. 1999, 83(4) pp.: 441-452
1117) Yagi, Planta medica 2002, 68, pp.: 957
1118) Oleszek W.: Resveratrol and other phenolics from the barb of Yucca schidigera, J. Agric. Food Chem, 49, 2001,
pp.: 747-752
1119) Joung JY.: An overexpression of chalcone reductase of Pueraria Montana var. lobata alters biosynthesis of
anthocyanin and 5’-deoxyflavonoids in transgenic tobacco, Biochem Biophys Res. Commun 2003, 303, pp.: 326-331.
1120) Varrelmann M.: Transgenic or plant expression vector-mediated recombination of Plum Pox virus, J. Virol.
2000, 74 (16), pp.: 7462-7469
1121) Kuo PL.: Resveratrol induced apoptosis in mediated by p53-dependent pathway in Hep G2 cells, Life Sci 2002,
72(1), pp.: 23-34 [05070315580403622.pdf
1122) Ren W.: Flavonoids: promising anticancer agents, Med Res. Rev. 2003, 23(4), pp.: 519-534
1123) Fujiki H.: Two stages of cancer prevention with green tea, J.Cancer Res. Clin. Oncol. 1999, 125(11), pp.: 589-
1124) Hibasami H.: Induction of programmed cell death (apoptosis) in human lymphoid leukaemia cells by catechin
compounds, Anticancer Res. 1996, 16(4A9, pp.: 1943-1946
1125) Salmaan H.: Altholactone, avovel styryl-lactone induces apoptosis via oxidative stress in human HL-60 leukemia
cells, Toxicology Letters 131, 2002, pp.153-159.
1126) Naoko Miura: Inhibition of Thymocyte apoptosis by Berberine, Biochemical Pharmacology, Vol. 53, pp. 1315-
1322, 1997. [PDF]
1127) D.V.Raghuvar Gopal: Betulinic acid induces apoptosis in human chronic myelogenous leukaemia (CML) cell
line K-562 without altering the levels of Bcr-Abl, Toxicology Letters 155, 2005, pp. 343-351. )
1128) Eun Mi Ju: Antioxidant and anticancer activity of extract from Betula platyphylla var. japonica, Life Sciences,
74, 2004, pp.: 1013-1016.
1129) Diane F. Birt: Dietary agents in cancer prevention: flavonoids and isoflavonoids, Pharmacology and
Therapeutics 90, 2001, pp.: 157-177. 1129
20dei%20bioflavonoidi_1.pdf ,
1130) Jun Matsui: Dietary bioflavonoides induce apoptosis in human leukaemia cells, Lekemia research 29, 2005, 573-
1131) Wanzhou Zhao: Boswellic acid acetate induces differentiation and apoptosis in highly metastatic melanoma and
fibrosarcoma cells, Cancer Detection and prevention 27, 2003, PP.: 67-75.
1132) L. Lopez: Cupressus lusitanica (Cupressaceae) leaf extract induces apoptosis in cancer cells, Journal of
Ethnopharmacology, 80, 2002, pp.: 115-120.
1133) G. Radhakrishna Pillai: Induction of apoptosis in human lung cancer cells by curcumin, Cancer Letters 208,
2004, pp.: 163-170.
1134) S. Moalic : A plant steroid, diosgenin, induces apoptosis, cell cycle arrest and COX activity in osteosarcoma
cells, FEBS Letters 506, 2001, 225-230.’OSTEOSARCO
1135) Po-Lin Kuo: The mechanism of ellipticine –induced apoptosis and cell cycle arrest in human breast MCF-7
cancer cells, Cancer Letters, 223, 2005, pp.: 293-301.
1136) Macho A.: Calcium ionophoretic and apoptotic effects of ferutinin in the human Jurkat T-cell line, Biochemical
Pharmacology, 68, 2004, 875-883. [05042618293528758.pdf]
1137) Ian T. Johnson: Glucosinolates in the human diet. Bioavailability and implications for health, Phytochemistry
Reviews, 1, pp.: 183-188, 2002.
1138) Salmaan H.: Caspases-3 and -7 are activated in goniothalamin – induced apoptosis in human Jurkat T-cells,
FEBS Letters 456, 1999, pp.: 379-383.
1139) S.H. Inayat-Hussain: Loss of mitochondrial transmembrane potential and caspase-9 activation during apoptosis
induced by the novel styryl-lactone goniothalamin in HL -60 leukemia cells, Toxicology in Vitro 17, 2003, pp.: 433-
1140) Furukawa F.: Chemopreventive effects of Aloe arborescens on N-nitrosobis (2-oxopropyl)amine – induced
pancreatic carcinogenesis in hamsters, Cancer Lett. 2002, 178(2), 117-22. PDF
1141) Dana Tatman: Volatile isoprenoid constituents of fruit, vegetables and herbs cumulatively suppress the
proliferation of murine B16 melanoma and human HL-60 leukemia cells, Cancer Letters 175, 2002, pp.: 129-139.
1142) F. Reno: Mimosine induces apoptosis in the HL-60 human tumor cell line, Apoptosis, Vol. 4, No.6, 1999, pp.:
1143) Young – Sam Keum : Induction of apoptosis and caspase-3 activation by chemopreventive [6]-paradol and
structurally related compounds in KB cells, Cancer Letters 177, 2002, pp.: 41-
1144) M.L.Tan: Methanolic extract of Pereskia bleo (Kunth) DC. (Cactaceae) induces apoptosis in breast carcinoma,
T47-D cell line, Journal of Ethnopharmacology 96, 2005, pp.: 287-
1145) Sachiko Nasu: Enhancement of radiotherapy by oleandrin is a caspase-3 dependent process, Cancer Letters 185,
2002, pp.: 145-151. [05042618173526874.pdf]
1146) Bela Csokay: Molecular mechanisms in the antiproliferative action of Quercetin, Life Sciences, Vol. 60, No. 24,
pp.: 2157-2163, 1997. )
1147) Kenneth Anye Chinkwo: Sutherlandia frutescens extracts can induce apoptosis in cultured carcinoma cells,
Journal of Ethnopharmacology 98, 2005, pp.: 163-170.
1148) R. M. Niles: Resveratrol is a potent inducer of apoptosis in human melanoma cells, Cancer Letters, 190, 2003,
pp.: 157-163.
1149) Dae Joong Kim: Chemoprevention of colon cancer by Korean food plant components, Mutation Research, 523-
524, (2003), pp.: 99-107. [05070317244123467.pdf]
1150) Young-Joon Surh: Dietary and medicinal antimutagens and anticarcinogens: molecular mechanisms and
chemopreventive potential-highlights of a symposium, Mutation Research, 523-524, (2003), pp.: 1-8.
1151) O. Aruoma: Methodological considerations for characterizing potential antioxidant actions of bioactive
components in plants foods, Mutations Research, 523-524, (2003), 9-20. [05070317044819633.pdf]
1152) I.T. Johnson : new approaches to the role of diet in the prevention of cancers of the alimentary tract, Mutation
Research, 551, 2004, pp.: 9-28
1153) R.C.Cambie: Potential functional foods in the traditional Maori diet, Mutation Research, 523-524, (2003), 109-
117. [05070317215322671.pdf]
1154) Nyska A. : Topical and oral administration of the natural water-soluble antioxidant from spinach reduces the
multiplicity of papillomas in the Tg.AC mouse model, Toxicology Letters 122 (2001), pp.: 33-44.
1155) H. Tapiero: The antioxidant role of Selenium and seleno-compounds, Biomedicine and Pharmacotherapy, 57,
(2003), pp.: 134-144.
1156) Eunyong Lee: Effects of Alpinia oxyphylla (zingiberaceae) in human promielocytic leukaemia (HL-60) cells and
tumor promoter-induced inflammation in mice, PXVII, B.20.
elocitica.pdf ).
1157) Ming-Jie Liu: Mitocondrial dysfunction as an early event in the process of apoptosis induced by woodfordin I in
human leukaemia K562 cells, Toxicology and Applied Pharmacology 194 (2004), pp.: 141-155.
1158) C.A.Blum: Promotion versus suppression of rat colon carcinogenesis by chlorophyllin and chlorophyll:
modulation of apoptosis, cell proliferation, and Beta-catenin/Tcf signalling, Mutation Research, 523-524, (2003), pp.:
1159) M. Roy: Anticlastogenic, antigenotoxic and apoptotic activity of epigallocatechin gallate: a green tea
polyphenol, Mutation Research, 523-524 (2003) , pp.: 33-41. [05070317133920883.pdf]
1160) J. D. Lambert: Cancer chemopreventive activity and bioavailability of tea and tea polyphenols, Mutation
Research, 523-524, (2003), pp.: 201-208.
1161) N. Frank: No prevention of liver and kidney tumors in Long-Evans Cinnamon rats by dietary curcumin, but
inhibition at other sites and of metastases, Mutation Research, 523-524, (2003), pp.: 127-135.
1162) Zigang Dong: Molecular mechanism of the chemopreventive effect of resveratrol, Mutation Research, 523-524
(2003), pp.: 145-150.
1163) Sanchez-Lamar A.: Phyllanthus orbicularis aqueous extract: cytotoxic, genotoxic, and antimutagenic effects in
the CHO cell line, Toxicology and Applied Pharmacology, 161, (1999), pp.: 231-239. [05042618251728448.pdf]
1164) Azam S.: Prooxidant property of green tea polyphenols epicatechin and epigallocatechin-3-gallate : implications
for anticancer properties, Toxicology in Vitro, 18, (2004), pp.: 555-561.
1165) Ya-Ling Hsu: Acacetin inhibits the proliferation of Hep G2 by blocking cell cycleprogression and inducing
apoptosis, Biochemical Pharmacology, 67, (2004), pp.: 823-829.
1166) Zhao-Ning Ji: 23-Hydroxybetulinic acid-mediated apoptosis is accompanied by decreases in bcl-2 expression
and telomerase activity in HL-60 Cells, Life Sciences 72 (2002), pp.: 1-9.
1167) J.Fernandes: Pentacyclic triterpenes from Chrysobalanaceae species: cytotoxicity on multidrug resistant and
sensitive leukaemia cell lines, Cancer Letters, 190, (2003), pp. 165-169.
1168) Lan Yuan: Inhibition of human breast cancer growth by GCPTM (genistein combined polysaccharide) in
xenogeneic athymic mice: involvement of genistein biotransformation by Beta-glucoronidase from tumor tissues,
Mutation Research, 523-524, (2003, pp.: 55-62
1169) C.C.Chou: Pharmacological evaluation of several major ingredients of Chinese herbal medicines in human
hepatoma Hep3B cells, European Journal of Pharmaceutical Sciences 19 (2003), pp.: 403-412.
1170) Taik-Koo Yun: Experimental and epidemiological evidence on non-organ specific cancer preventive effect of
Korean ginseng and identification of active compounds, Mutation Research, 523-524, (2003), pp.: 63-74.
1171) Young-Sam Keum: Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2
expression, NF-kB activation and tumor promotion, Mutation Research, 523-524, (2003), pp.: 75-85.
1172) C.A.Hornick: Inhibition of angiogenic initiation and disruption of newly established human vascular networks by
juice from Morinda citrifolia (noni), Angiogenesis, 6, 2003, pp.: 143-149.
1173: Shunji Chi: Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death
program in human cancer cells, Oncogene, 1999, Vol. 18, No. 13, pp. 2281-2290.
1174: Gattinoni L.: Renal cancer treatment: a review of the literature, Tumori, 2003, 89(5), pp.: 476-484.
1175: Flaningan RC.: Metastatic renal cell carcinoma, Curr. Treat. Options Oncol. 2003, 4(5), pp.: 385-390
1176) T. Robak: The effect of subsequent therapies in patients with chronic lymphocytic leucemia previously treated
with prednisone and either cladribine or chlorambucil, Haematologica, 90, pp.: 994-996, 2005.
1177) F.R.Mauro: Fludarabine + prednisone + alfa-interferon followed or not by alfa-interferon maintenance therapy
for previously untreated patients with chronic lymphocytic leucemia: long term results of a randomized study,
Haematologica 88(12), pp.1348-1355, 2003. [ ]
1178) Camera A.: GIMELA ALL –Rescue 97: a salvage strategy for primary refractory or relapsed adult acute
lymphoblastic leucemia, Haematologica, 89(2), pp.145-155, 2004. [ ]
1179) R. Consolini: Clinical relevance of CD10 expression in childhood ALL, Haematologica 83, pp.: 967-973, 1998[ ]
1180) De Souza: Validation of the EBMT risk score in chronic myeloid leucemia in Brazil and allogeneic transplant
outcome, Haematologica, 90, pp.: 232-237, 2005. [ ]
1181) Pulsioni A.: Survival of elderly patients with acute myeloid leukaemia, Haematologica, 89, pp.: 296-303, 2004 [ ]
1182) Oriol A.: Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in
patients over 60 years old. Results of the CETLAM AML-99 protocol, Haematologica, 89, pp.: 791-800, 2004 [ ]
1183) Kenneth C. Anderson: Management of Multiple Myeloma Today, Seminars in Hematology, vol. 36, No.1,
suppl.3, 1999.
1184) P.L. Zinzani: High-dose therapy with autologous transplantation for Hodgkin’s disease: the Bologna experience,
Haematologica, 88,(05), pp.: 522-528, 2003 [ ]
1185) M.van Agthoven: Cost determinants in aggressive non-Hodgkin’s lymphoma, Haematologica, 90(5), pp.: 661-
672, 2005.
1186) Tomonori Nakazato: Catechin, a green tea component, rapidly induces apoptosis of myeloid leukemic cells via
modulation of reactive oxygen species production in vitro and inhibits tumour growth in vivo, Haematologica, 90(3),
pp.317-325, 2005
1187) Phillip Day: “Cancro, se vuoi la vita prepara la verità”, Credence Publications, 2003
1188) Inosmetzeff,T: Gazette Medicale de Paris, 1845, No. 13, pp.: 577-582
1189) Inosmetzeff, T.: Journal Chirurgie und Augenheilkunde, 1846, No. 35, pp.. 7-28
1190) Oke: “the role of hydrocyanic acid in nutrition”, in “World Review of Nutrition and Dietetics”, Vol. II, Bourne
G.H., ed. Basel: S.Karger, 1969, pp.: 170-198; Krebs E.: “The Nitrilosides in Plants and Animals”, New Rochelle:
Arlington House, 1974, pp.: 145-164.
1191) Fishman W: The presence of high beta-glucuronidase activity in cancer tissue, J. Biol. Chem No. 169, pp.: 449-
1192) Fishman W: A comparison of beta-glucoronidase activity of normal, tumor and lymph node surgical patients,
Science, No. 106, pp.: 66-67, 1947
1193) Kochi M.: Antitumor activity of Benzhaldehyde, Cancer Research, 64, pp.: 21-23, 1980);
1194) Kochi M.: Antitumor activity of Benzhaldehyde Derivative, Cancer Research, 69, pp.: 533, 1985
1195) Tatsumura T.: 4,6-O-Benzylidene-glucopyranose (BG) in the treatment of solid malignant tumour – an extended
Phase I Study, Br. J. Cancer, 62, pp.: 436-439, 1990
1196) Heinerman J.: “An Encyclopedia of Nature’s Vitamins and Minarals”, Prentice Hall, 1998
1197) Moss R.: “Questioning chemotherapy: a critique of the use of toxic drugs in the treatment of cancer”, Equinox
press, 1995, ISBN 188192525x
1198) Anderson J.R.: Analysis and interpretation of the comparison of survival by treatment outcome variable in
cancer clinical tirals, in: Cancer Treatment Rep., vol. 69, pp.: 1139-1144, 1985
1199) Becker N.: Time trends in cancer mortality in the Federal Republic of Germany: progress against cancer?, in :
Int. J. Cancer, vol. 43, pp.: 245-249, 1989
1200) Berlin J.A.: An assessment of publication bias using a sample of published clinical trials, in: J.AM.Statistic
Assoc., vol. 84, pp.: 381-392, 1989
1201) Cohen M.H.: Prognostic factors may account for the increase survival of advanced ovarian cancer patients
receiving high dose intensity chemotherapy, Abstract No. 614, in: Proc. Am. Soc. Clin. Oncol. Vol. 9, pag. 158, 1990
1202) Enstrom J.E.: Interpreting cancer survival rates, in : Scince, vol. 195, pp.: 847-851, 1977
1203) Hankey B.F.: Black/white differences in bladder cancer patient survival, in: J. Chron Dis., vol. 40, pp.: 65-73
1204) Hughes M.D.: Stopping rules and estimation problems in clinical trials, in : Statist. In Med., vol. 7, pp.: 1231-
1205) Longtin R.: The pomegranate: nature’s power fruit ? , J.Natl. Cancer Inst., 5; 95, pp.: 346-348, 2003
1206) V.E.Prescott: Transgenic expression of bean-amylase inhibitor in peas results in altered structure and
immunogenicity, J. Agric. Food Chem., 53, (23), pp.: 9023-9030, 2005. Disponibile in PDF
1207)Epstein S.: “Safe, Shopper’s Bible”, pag. 342
1208) Epstein S.: “The Politics of Cancer Revisited”, East Ridge Press, 1998, pp. 479.
1209) D’Raye T.: “The facts about Fluoride” PO. BOX 21075, Keizer, OR 97307, USA
1210) Health damaging effects of Fluoride, Journal of the American Medical Association, october 1994.
1211) National Toxicology Program (NPT), 1990, National Cancer Institute, HHS Fluoride Report 2/91
1212) La John R. Lee, Medical Letter, febbraio 1999.
1213) Journal of the American Medical Association, mar/8/1995
1214) Journal of the American Medical Association, august/11-12/1992
1215) Journal of the American Medical Association, july/25/1991
1216) Journal of the American Medical Association, june/19/1991
1217) Journal of the American Medical Association, july/25/1990
1218) American Journal of Epidemiology, 4/91
1219) American Journal of Public Health, 7/90
1220) Morris MC.: Vitamin E and vitamin C supplements use and risk of incident Alzheimer disease, Alz. Dis. Assoc.
Disord. 1998, 12, 121-126).
1221) Burton GW: Human plasma and tissue alpha-tocopherol concentrations in response to supplementation with
deuterated and synthetic vitamin E, Am.J. Clin. Nutr., 1998, 67, pp.: 669-684
1222) Muscio P.: Antioxidant defence systems: the role of carotenoids, tocopherols and thiols, Am. J. Clin. Nutr. 1991,
53, Suppl., pp.: 194S-200S.
1223) Palozza P.: Beta carotene and alpha tocopherol are synergistic antioxidants, Arch. Biophys. Biochem, 1992,
297, pp.. 184-187
1224) Palozza P.: The inhibition of radical-initiated peroxidation of microsomal lipids by both alpha tocopherol and
beta carotene, Free Radical Biol. Med., 1991, 11, pp.: 401-414
1225) Ribaya-Mercado J.D.: Skin lycopene is destroyed preferentially over beta-carotene during ultraviolet irradiation
in humans, J.Nutr. 1995, 125, 125, pp.: 1854-1859.
1226) Stefan J.: Increased bioavailability of Nitric Oxide after lipid-lowering therapy in Hypercholesterolemic patients,
Circulation, 1998, 98, pp.: 211-216.
1227) Welch GN: Mechanisms of disease: Homocysteine and atherothrombosis, N.Engl.J.Med., 1998, 338, pp.: 1042-
1228) Welch GN: Homocysteine, oxidative stress and vascular disease, Hospital Practice, 1997, 32, pp.: 81-92.
1229) Zock PL.: Diet, LDL oxidation and coronary artery disease, Am.J.Clin.Nutr., 1998, 68, pp.. 759-760.
1230) Burke AP.: Coronary risk factors and plaque morphology in men with coronary disease who died suddenly,
N.Engl.J.Med., 1997, 336, pp.: 1276-1280
1231) Diaz MN.: Mechanisms of disease. Antioxidants and atherosclerotic heart disease, N.Engl.J.Med., 1997, 337,
pp.. 408-417
1232) Esterbauer H.: The role of lipid peroxidation and antioxidants in oxidative modification of LDL, Free Radic Biol.
Med., 1992, 13, pp.. 341-390
1233) Esterbauer H.: Continuous monitoring of in vitro oxidation of human low density lipoprotein, Free Radic Res.
Commun., 1989, 6, pp.. 67-75
1234) Greenberg ER.: Antioxidant vitamins, cancer, and cardiovascular disease, N.Engl.J.Med., 1996, 334, pp.: 1189-
1235) Loscalzo J.: The oxidative stress of hyperhomocysteinemia, J.Clin.Invest., 1998, 196, pp.: 5-7.
1236) Parks EJ: Reduced oxidative susceptibility of LDL from patients participating in an intensive atherosclerosis
treatment program, Am.J.Clin.Nutr., 1998, 68, pp.: 778-785
1237) Banks DA: Telomeres, Cancer, and Aging, JAMA, 1997, 278, pp.. 1345-1348
1238) Leff JA: Serum antioxidants as predictors of adult Respiratory Distress Syndrome in patients with sepsis, Lancet,
1993, 341, pp.: 777-778
1239) Rosenberg IH: Nutrition and Senescence, Nutrition Reviews, 1997, 55, pp: S69-S81
1240) Weindruch R.: Caloric intake and aging. Seminars in medicine, N.Engl.J.Med., 1977, 337, pp.: 986-994
1241) Allsopp RC.: Telomere length predicts replicative capacity of human fibroblast, Prec. of Nat. Acad. of Sci., 1992,
89, pp.: 10114-10118.
1242) Haber DA: Clinical implications of basic research, telomeres, cancer, and immortality, N.Engl. J.Med., 1995,
332, pp.:955-956
1243) Gillman MW.: Protective effect of fruits and vegetables on development of stroke in men, JAMA, 1995, 273, pp.:
1244) Knekt P.: Serum antioxidant vitamins and risk of cataract, BMJ, 1992, 305, PP.. 1392-1394.
1245) Snodderly DM: Evidence for protection against age-related macular degeneration by carotenoids and
antioxidant vitamins, Am.J.Clin.Nutr., 1995, 62(Suppl.),pp.: 1448S-1461S.
1246) Barr DB: Exposure to Contemporary-Use Pesticides, J.Med.Assn.Georgia, 1999, 88, pp.. 34-37
1247) Jonas CR: Nutrition support and antioxidant defenses: a cause for concern, Am.J.Clin.Nutr., 1998, 68, pp.: 765-
1248) Centers for Disease Control and Prevention: Lactic acidosis traced to thiamine deficiency related to nationwide
shortage of multivitamins for total parenteral nutrition, United States, 1997, JAMA, 1997, 278, pp.: 380 (Letter)
1249) Galley HF: The effects of intravenous antioxidants in patients with septic shock, Free Radic Biol. Med., 1997, 23,
pp.: 768-774
1250) Barton RG.: Nutrition support in critical illness, invited review, Nutr. Clin. Prac., 1994, 9, pp.: 127-139
1251) Tanswell AK: Antioxidant therapy in critical care medicine, New Horizons, 1995, 3, pp.: 330-341.
1252) Antony A. Miller: Accumulation of very-long-chain fatty acids in membrane glycerolipids is associated with
dramatic alterations in plant morphology, The plant Cell, Vol. 11, pp. 1882-1902, 1998,
1253) International Application Published Under The Patent Cooperation Treaty (PTC), 43 International Publication
Date 6 December 2001, International Publication Number WO01/91735 A2, International Patent Classification:
A61K31/00. International Application Number: PCT/EP01/06135, Title: USE OF ALOE-EMODIN IN THE
TREATMENT OF NEUROECTODERMAL TUMORS. Inventor’s/Applicants: Palù Giorgio, Carli Modesto, Pecere
1254) Ichiro Mitsuhara: Animal cell-death suppressors Bcl-x and Ced-9 inhibit cell death in tobacco plants, Current
Biology, Vol. 9, No. 14, pp.775-778, [05042617202612198.pdf]
1255) Debasis Bagchi: Molecular mechsanism of cardioprotection by a novel grape seed proanthocyanidin extract,
Mutation Research, 523-524, 2003, pp.: 87-97. [05070317181121772.pdf]
1256) Moertel CG: A clinical trial of amygdalin (laetrile) in the treatment of human cancer, N.Engl.J.Med., 306, pp.:
201-206 ;
1257) vedi note: 1, 3, 10, 13, 14, 17, 18, 23, 24, 28, 34, 35, 36, 45, 56, 59, 69, 73, 76, 94, 92, 93, 100, 106, 111, 120, 121, 129, 128, 131, 137,
138, 137, 138, 165, 187, 200, 202, 203, 208, 209, 212, 213, 214, 216, 218, 222, 235, 255, 256, 257, 263, 264, 265, 266, 280, 282 286, 287, 288, 298,
303, 304, 305, 307, 313, 315, 322, 324, 325, 326, 334, 338, 340, 341, 347, 348, 352, 354, 362, 363, 365, 382, 383, 385, 390, 398, 402, 404, 405, 409,
410, 420, 425, 426, 427, 445, 446, 447, 448, 454, 457, 461, 463, 468, 469, 470, 471, 473, 477, 478, 488, 493, 508, 512.
1258) vedi note: 6, 19, 20, 30, 45, 91, 95, 112, 125, 129, 142, 165, 167, 190, 202, 228, 229, 246, 261, 280, 332, 404, 405, 452, 494.
1259) vedi note: 1, 2, 7, 9, 12, 15, 18, 19, 23, 26, 31, 32, 33, 35, 36, 42, 44, 46, 50, 53, 54, 57, 60, 64, 65, 67, 68, 70, 72, 77, 80, 81, 82, 84, 88,
89, 90, 91, 92, 93, 95, 99, 100, 102, 104, 105, 109, 107, 110, 111, 113, 115, 117, 118, 121, 125, 127, 128, 133, 135, 137, 139, 140, 149, 150, 151,
152, 160, 162, 164, 166, 167 169,170, 171, 172, 173, 178, 180, 181, 183,1035,1067-1073, 1174-1184
1260) vedi note: 4, 5, 102, 123, 135, 155, 173, 217, 224, 274, 309,1123,1124,1186
1261) vedi note: 25, 33, 47, 54, 83, 91, 122, 129, 181, 197, 202, 218, 244, 246, 270, 299, 311, 335, 339, 367, 404, 405, 414, 415, 416, 496, 489,
510, 511;
1262) vedi note: 28 , 157, 160, 188, 208, 209, 231, 240, 246, 254, 302, 323, 479, 489
1263) vedi note: 79, 108, 112, 129, 133, 136, 143, 156. 228, 229, 276, 338, 339, 364, 367, 404, 405, 407, 443, 452, 458, 501, 510, 511,1155
1264) vedi note: 107, 110, 119, 139, 174, 193, 237, 249, 269, 336, 357, 386, 399, 440, 441, 460, 476
1265) vedi note: 9, 11, 32, 44, 50, 53, 61, 67, 82, 105, 126, 132, 144, 145, 146, 180, 196, 198, 225, 236, 278, 279, 306, 310, 319, 331, 346, 351,
359, 368, 372-381, 387, 388, 394, 395, 406, 412, 418, 419, 430, 444, 456, 462, 472, 474, 500, 516, 517, 520, 577
1266) V. H. Engelhard: “Come le cellule elaborano gli antigeni”, Le Scienze, n.314, pp. 42-50, ottobre 1994;
1267) J.Ding: “Come agiscono le cellule killer”. Le Scienze, 1994, pp.: 28-34
1268) Anderson J.W.: High –carbohydrate, high fiber diets for insulin-treated men with diabetes mellitus, Am. J. Clin.
Nutr. 1979, 32, pp.: 2312-2321;
1269) Anderson J.W.: Metabolic effects of high-carbohydrate high-fiber diets for insulin-dependent diabetic
individuals, Am. Nutr. 1991, 54,pp.: 936-943
1270) Sharma KK.: Antihyperglycemic effect of onoin: effect on fasting blood sugar and induced hyperglycemia in man,
Indian J.Med. Res., 1977, 65, pp.: 422-429;
1271) Jain RC.: Hypoglycaeic action of onion and garlic, Lancet, 1973, 2, pp: 1491;
1272) Silagy C.: Garlic as a lipid lower agent a meta-analysis, J. R. Coll. Physicians London, 1994, 28, pp: 39-45;
1273) Phelps S: Garlic supplementation and lipoprotein oxidation susceptibility, Lipids, 1993, 28, pp.: 475-477;
1274) Legnani C.: Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects,
Arzneimittelforsch, 1993, 43, pp.: 119-121;
1275) Silagy CA: A meta-analysis of the effect of garlic on blood pressure, J.Hypertens. 1994, 12, pp.: 463-468;
1276) Kawasakishi S.: New inhibitor of platelet aggregation in onion oil, Lancet, 1988, 2, 330;
1277) Louria DB.: Onion extract in treatment of hypertension and hyperlipidemia: a preliminary communication, Curr.
Ther. Res., 1985, 37, pp.: 127-131
1278) “Marketing in pillole”. L’Espresso, 13 gennaio 2005, pag.132-136;
1279) “Statine miracolose assassine”, L’Espresso, 26 agosto 2004, pp.146-149.
1280) Green, Perspect Biol. Med., 1978
1281) Dayuan LI: y-Tocopherol decreases OX-LDL-mediated activation of nuclear factor –kB and apoptosis in human
coronary artery endothelial cells, Biochemical and Biophysical Research Communications, 259, pp.: 157-161, 1999.
1282) Debasis Bagchi: Molecular mechsanism of cardioprotection by a novel grape seed proanthocyanidin extract,
Mutation Research, 523-524, 2003, pp.: 87-97.
1283) Amedeo Santosuosso: Libertà di cura e libertà di terapia. La medicina tra razionalità scientifica e soggettività
del malato, Il Pensiero Scientifico Editore, 1998
1284) The Lancet, Vo. 366, Issue 9492, 1 October 2005, pages 1165-1174
1285) Effectiveness of inactivated trivalent influenza vaccine in long-term care institutions, Toronto, 2003-2004,
Canada Communicable Disease Report, Vol.30, No.12, 15 june 2004, pp.109-116
1286) Eelko H.: Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical
conditions, Arch. Int. Med., Vol. 165, No. 3, February 14, 2005
1287) Giorgio Mangiarotti: Lineamenti di Biologia, UTET, 1978, Unione Tipografico-Editrice Torinese, Capitolo 35:
Evoluzione molecolare ed evoluzione biologica (pagg.: 725-766). Evoluzione della mioglobina e dell’emoglobina
1288) R.J.Blumenshine: Comportamento alimentare ed evoluzione umana, Le Scienze, No. 292, dicembre 1992
1289) Mc Lachlan D.R. : Aluminum and the risk of Alzheimer’s disease, Environmetrics, 6, 1995, S, pp.: 233-238
1290) Buzzi S.: CRM 197 and cancer: effects of intratumoral administration, Therapy 2004, 9, pp.: 61-66
1291) Buzzi S.: CRM 197 (non toxic diphtheriae toxin) : effects in advanced cancer patients, Cancer Immunol.
Immunother. 53
1292) J.Kurtin: Interfollicolar Hodgkin’s disease, Society for Hematopathology, Hematopathology Specialty
Conference, 1996, Discussion, – Case # 5, Mayo Clinic, Rochester, Minnesota,USA
1293) Wilson CS: Malignant lymphomas that mimic benign lymphoid lesion: a review of four lymphomas, Semin. Diag.
Pathos. 1995, 12(1), pp: 77-86;
1294) Fellbaum C.: Monoclonal antibodies k1B3 and Leu-M1 discriminate giant cells of infectious mononucleosis and
of Hodgkin’s disease, Hum Pathos. 1988, 19, pp: 1168-1173.
1295) Doggett R.: Interfollicular Hodgkin’s disease, Am. J. Surg. Pathos. 1983, 7, pp.: 145-149;
1296) Child CC: Infectious Mononucleosis. The spectrum of morphologic changes simulatine lymphoma in lymph nodes
and tonsils. Am.J.Surg.Pathol. 1987; 11(2), pp.: 122-132;
1297) Hartsock RJ.: Postvaccinial lymphadenitis: Hyperplasia of lymphoid tissue that simulates malignant lymphomas,
Cancer 1968, 21, pp.: 632-649;
1298) Valente RM: Characterization of lymph node histology in adult onset Still’s disease. J.Rheumatol. 1989, 16, pp.:
1299) Abbondanzo SL: Dilantin-associated lymphadenopathy. Spectrum of histopatholologic features, Am. J. Surg.
Pathol. 1995, 19(6), pp.: 675-686;
1300) Saltstein SL: Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically
malignant lymphomas, Cancer 1959, 12, pp: 164-182.
1301) Reynolds DJ: New characterization of infectious mononucleosis and a phenotypic comparison with Hodgkin’s
disease, Am J. Pathos. 1995, 146(2), pp.: 379-388
1302) Wei-Sing Chu: Inconsistency of the immunophenotype of Reed-Sternberg cells in simultaneous and consecutive
specimens from the same patients, American Journal of Pathology, vol. 141, No.1, 1992, pp: 11-17.

1303) Bitsori M.: Reed-Sternberg cells in atypical primari EBV infection, Acta Pediatrica, Vol. 90, No.2, 2001, pp: 227-
1304) Sewell HF: Reaction of monoclonal antiLeu M1 – a myelomonocytic marker (CD15) –with normal and neoplastic
epithelia 1987, Journal of pathology, Vol. 151, No.4, pp.: 279-284
1305) Dickerman Hollister: Sarcoidosis mimicking progressive Lymphoma, Journal of Clinical Oncology, 2005, pp.:
1306) Chemotherapy of advanced epithelial cancer: a critical survey. Hippokrates Verlag, Stuttgart, 1990; Healing
Journal, No.1-2, Vol.7, 1990, Gerson Institute ].
1307) Savagno L.: I linfomi Non Hodgkin, Piccin Editore
1308) Amedeo Santosuosso: Libertà di cura e libertà di terapia. La medicina tra razionalità scientifica e soggettività
del malato, Il Pensiero Scientifico Editore, 1998, pagina 57
1309) Ridwelski K.: Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and
unresectable, locally advanced pancreatic carcinoma, Eur. J. Surg. Oncol., 2006, 32, pp.: 297-302, ELSEVIER full-text
1310) Santasusana JM: A phase II trial of gemcitabine and weekly high-dose 5 fluorouracil in a 48 hours continuousinfusion
schedale in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for
Gastroinstinal Tumour Therapy, Clin. Transl. Oncol. 2005, 7, 493-498, Full Text Article at Clin. Transl. Oncol.
1311) Lutz MP. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma:
randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal
Group, J. Clin. Oncol., 2005, 23, pp.: 9250-6, Full text article at
1312) Ko A: Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the
pancreas, J. Clin. Oncol. 2006, 24, pp.379-385.
1313) Aigner KR: Celiac axis infusion and microembolization for advanced stage III/IV pancreatic cancer – a phase II
study on 265 cases, Anticancer Res., 2005, 25, pp.: 4407-12.
1314) Oman M.: Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in nonresectable
pancreas cancer, Cancer Chemother. Pharmacol., 2005, 56, pp. 603-609; Full text article at SpringerLink.
1315) Oettle H.: A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or
metastatic pancreatic cancer, Ann. Oncol., 2005, 16, pp.: 1639-1645; Full text article at :
1316) Rothenberg ML: Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in
patients with recurrent colorectal adenocarcinoma, J. Clin. Oncol., 2005, 23, pp.: 9265-74, Full Text article at: ]
1317) Yoshida M.: Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with
chemotherapy in the Japan Clinical Oncology Group study, Jpn J. Clin. Oncol. 2004, 34, pp.: 654-9, FREE full text
article at :
1318) Enzinger PC. : A phase II trial of irinotecan in patients with previously untreated advanced esophageal and
gastric adenocarcinoma, Dig. Dis. Sci. 2005, 50, pp.: 2218-2223.
1319) Felici A.: Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluiorouracil continuous infusion
plus g-csf in advanced gastric cancer: a multicentric phase II study, Cancer Chemother. Pharmacol., 2006, 57, pp.: 59-
64; Full Text article at : SpringerLink.
1320) Lee SH: Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent,
unresectable gastric cancer, Br. J. Cancer, 2004, 91, pp.: 18-22.
1321) Burris HA: Phase II Trial of Oral Rubitecan in previously treated pancreatic cancer patients, The Oncologist
2005, 10, pp.. 183-190.
1322)Alberts SR.: Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic
adenocarcinoma: a North Central Cancer Treatment Group Phase II Trial, vol. 22, No.24, 2004, pp.: 4944-4950.
1323) Roth AD: 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel
(Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial, Ann. Oncol. 2004, 15, pp.: 759-764, FREE full
text article at :
1324) Do-Youn: Docetaxel + 5-Fluorouracil + Cisplatin 3 day combination chemotherapy as a first-line treatment in
patients with unresectable Gastric Cancer, Japanes Journal Clin. Oncol., 2005, 35, pp.: 380-385 .
1325) Eun Kyung Cho: Epirubicin, Cisplatin, and Protracted venous infusion of 5-Fluorouracil for advanced gastric
carcinoma, Journal Korean Med. Sci., 2002, 17, pp.. 348-52
1326) Ikuo Semine: Phase II study of twice-daily high-dose thoracic radiotherapy alternating with Cisplatin and
Vindesine for unresectable stage III Non-Small-Cell Lung Cancer : Japan Clinical Oncology Group Study 9306,
Journal of Clinical Oncology, Vol. 20, No.3, 2002, pp.: 797-803.
1327) Yukito Ichinose: Uracil/Tegafur plus Cisplatin with concurrent Radioterapy for locally advanced Non-Small-
Cell Lung Cancer: a Multi-institutional Phase II Trial, Clinical Cancer Research, Vol. 10, 2004, pp.: 4369-4373.
1328) F.M. Wachters: Phase II Study of docetaxel and carboplatin as second-line treatment in NSCLC, Lung Cancer,
2004, Vol. 45, pp.255-262
1329)Lechner P.: Erfahrungen mit dem Einsatz der Diat-Therapie in der chirurgischen Onkologie, Aktuel
Ernahungmedizin, Vol.2, 1990, pp.72-88.
1330) Lechner P: “Dietary regime to be used in oncological post-operative care, Proceedings of the Oesterreicher
Gesellschaft fur Chirurgie, 21-23 giugno 1984.
1331) Chasseaud L.F.: The role of glutathione S-Transferase in the metabolism of chemical carcinogens and other
electrophilic agents, Advanced Cancer Research, Vol. 29, 1979, pp.: 175-274
1332) Jakoby W.B.: A group of multifunctional detoxification proteins, Advanced enzymology and related areas of
Molecular biology, Vol. 46, 1978, pp.: 383-414.
1333) Sparnins V.L.: Enhancement of glutathione S-transferase activity of the mouse forestomach by inhibitors of
benzo[a]pyrene-induced neoplasia of forestomach, Journal of the National Cancer Institute, vol. 66, 1981, pp. 779-781
1334) Sparnins V.L.: Effects of dietary constituents on (GST) Glutathione S-Transferase activity, in Proceedings of the
American Association of Cancer Resarchers and the American Society of Clinical Oncologists, Vol. 21, Estratto 319,
1980, pp.80
1335) Sparnins V.L.: Effects of coffee on glutathione S-Transferase (GST) activity and 7-12 dimethylbenz(a)anthracene
(DMBA)- induced neoplasia, Proceedings of the American Association of Cancer Resarchers and the American Society
of Clinical Oncologists, Vol. 22, Estratto 453, 1981, pp.: 114.
1336) Lam L.K.T.: Isolation and identification of kahweol palmitate and cafestol palmitate as active constituents of
green coffee beans that enhance glutathione S-transferase activity in the mouse, Cancer Research, Vol. 42, 1982, pp.:
1337) U. Abel, Lancet, 10 agosto 1991.
1338) Walter Last, “The Ecologist”, Vol. 28, No. 2, marzo/aprile 1998.
1339) A. Braverman: Medical Oncology in the 90s, Lancet, 1991, vol. 337, pp. 901
1340) Morgan G.: The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies, Clinical Oncol.,
2004, 16, pp.: 549-560 MORGAN
1341) Xu S.S. : Efficacy of tablet Hyperzine A on memory, cognition and behavior in Alzheimer’s disease. Acta
Pharmacologica Sinica, 1995, 16, pp.: 391-395.
1342) Yen S.S.: Replacement of DHEA in aging men and women. Potential remedial effects. Ann. N.Y. Acad. Sci.
1995, 774, pp.: 128-142.
1343) Morales A.J.: Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age, J.
Clin. Endocrinol. Metab. 1994, 78, pp.: 1360-1367
1344) Kleijnen J.: Ginkgo biloba. Lancet, 1992, 340, pp.. 1136-1139
1345) Kanowski S.: Proof of the efficacy of the Ginkgo biloba special extract Egb 761 in outpatients suffering from
mild to moderate primary degenerative dementia of the Alzheimer type of multi-infarct dementia. Phytomedicine 1997,
4, pp.: 3-13.
1346) Le Bars P.L.: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia.
JAMA 1997, 278, pp.: 1327-1332.
1347) Skolnick A.: Old Chinese herbal medicine used for fever yields possible new Alzheimer disease therapy, JAMA,
1997, 277, pp.: 776.
1348) Cope FW.: A medical application of the ling associaton-induction hypothesis: the high potassium, low sodium
diet of the Gerson cancer therapy, in Physiological Chemistry and Physics, NMR, Vol. 10, 1978, pp. 465-468
1349) Waterhouse C.. Craig A.: Body-composition and changes in patients with advanced cancer, Cancer, vol. 11(6),
november-december 1957.
1350) Koh SH: The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice, Neurosci
Lett., 395(2), pp.: 103-107, 2006
1351) Lehmann S., Cancer Research, 2006 (non ancora disponibile, su Peperoncino).
1352) Akio Mori: Capsaicin, a component of Red Peppers, inhibits the growth of androgen-independent, p53 Mutant
Prostate Cancer Cells, Cancer Research, 66, 2006

Dă clic pentru a accesa curcuma%20longa%20e%20isotiocianati%20(Crucifere).pdf

1353) Longtin R.: The pomegranate: nature’s power fruit ?, J. Natl. Cancer Inst., 95 (5), pp. 346-348, 2001.
1354) P. Brennan: The Lancet 366, pp.: 1558-1560, 2005.
1355) Lancet, 14 giugno 2006 (non ancora disponibile).
1356 ) Morrone J.: Chemotherapy of inoperable Cancer. Preliminary report of 10 cases trated with Laetrile, Exp. Med.
Surg., 20, pp.: 299-308, 1962, VEDI ALLEGATO: Morrone

Dă clic pentru a accesa morrone.pdf

1357) Clinical Toxicology, 1984 (non ancora disponibile).
1358) Nicholson: Doxycycline treatment and Desert Storm, JAMA, 1995, 273, pp. 618-619
1359) Longwer Chen: Oxidative DNA damage in prostate cancer Patients consuming tomato sauce-based entrees as a
whole-food intervention, Journal of the National Cancer Institute Vol. 93, No. 24, pp.. 1872-1879, 2001

1360) Gerson M.: Effects combined dietary regime on patients with malignant tumors, Experimental Medicine and
Surgery, Vol. 7, No. 4, 1949
1361) Gerson M.: Dietary considerations in malignant neoplastic disease; preliminary report, Rev. Gastroenterol.
1945-11/12; 12; pp.: 419-425
1362) Gerson M: The cure of advanced cancer by diet therapy: a summary of 30 years of clinical experimentation,
Physiol. Chem. Phys. 1978, 10(5); pp.: 449-464
1363) Cope FW.: A medical application of the Ling Association-Induction – Induction Hypothesis: the high potassium,
low sodium diet of the Gerson Cancer therapy, Physiol. Chem. Phys. 1978, 10(5), pp.: 465-468
1364) Haught J. Hildenbrand GLG (Editor). Censured for curing cancer: the American experience of Dr. Max Gerson.
San Diego CA, Gerson Institute, 1991
1365) Kahlos K.: Proliferation, apoptosis and Manganese superoxide dismutase in malignant mesothelioma, Int. J.
Cancer, 88, pp.: 37-43, 2000.
1366) Shine Chang: Relationship between plasma carotenoids and prostate cancer, Nutrition and Cancer, 53, pp.. 127-
134, 2005
1367) Riccardi A.: Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at
progression of the disease: a multicentre randomized study, British Journal of Cancer, 82, pp.: 1254-1260, 2000
1368) Pei-Ni Chen: Cyanidin 3-Glucoside and Peonidin 3-Glucoside inhibit tumor cell growth and induce apoptosis in
vitro and suppress tumor growth in vivo, Nutrition and Cancer, 53, pp.: 232-243, 2005
1369) Gunadharini D.N.: Antiproliferative effect od diallyl disulfide (DADS) on prostate cancer cell line LNCaP, Cell
Biochemistry and Function , 24, pp.: 407-412, 2006
ATA_2.pdf ;
1370) Maricela Haghiac : Quercetin induces necrosis and apoptosis in SCC-9 Oral Cancer Cells, Nutrition and Cancer,
53, pp.. 220-231, 2005
1371) Amr E. Edris: Pharmaceutical and therapeutic potentials of Essential Oils and their individual volatile
constituents: a review, Phytotherapy Research, 2007

Dă clic pentru a accesa gli%20olii%20essenziali%20.pdf

1372) Guidetti Ettore: Observations preliminaires sur quelques cas de cancer trates par un glycuronoside
cyanogenetique. Acta Unio Internationalis Contra Cancrum, XI No. 2, pp. 156-158, 1955, Read at the sixth international
Cancer Congress, Sao Paulo, July, 1954. pp.: Edizioni Minerva Medica 1958. Med., 9, 468-471, 1954.
1373) Tasca Marco: Osservazioni cliniche sugli effetti terapeutici di un Glicuronoside cianogenetico in casi di
Neoplasie Maligne umane. Gazzetta Medica italiana (19 pp). Edizioni Minerva Medica, 1958.
1374) Navarro Manuel: Laetrile – The Ideal anti-cancer Drug? Santo Tomas J. Med., 9; pp.: 468-471, 1954
1375) Navarro Manuel: Laetrile in Malignancy. Santo Tomas J. Med., 10, pp.: 113-118, 1955
1376) Moral G. : Metastatic pulmonary carcinoma treated with Laetrile (Report of a Case), Unitas, 28; pp.: 606-618,
1377) Lagman L.. Breast Carcinoma with Lung and Bone metastases treated with Laetrile (Case Report), Santo Tomas
J. Med., 11, PP.: 196-203, 1956; J. Philippine Med. Assn., 33, pp.. 16-29, 1957.
1378) Biochemistry of Laetrile Therapy in cancer, Papyrus, 1; pp.: 8-9, pp.: 27-28, 1957.
1379) Mechanism of Action and Therapeutic effects of Laetrile in cancer, J. Philippine Med. Assn., 33; pp.: 620-627,
1380) Gamez G.: Chemotherapy of Cancer, Laetrile in cancers of the Throat, Philippine J. of Cancer 1; pp.: 131-137,
1381) Five Years experience with Laetrile therapy in advanced cancer, Acta Unio Internationalis contra Cancrum, XV
(bis); pp.: 209-221, 1959. Read at the Symposium on cancer Chemotherapy for Pacific Asian Area, International Union
Against Cancer, Tokyo, october 1957. Report on Proceedings of International Symposium on Cancer Chemotherapy at
Tokyo, October 1957, Santo Tomas J. Med., 12, pp.: 244-453, 1957
1382) Rossi Benedetto, Guidetti Ettore: Clinical Trial of Chemotherapeutic Treatment of advanced cancers with 1-
Mandelonitrile-Beta-diglucoside. Presented at the Ninth International Cancer Congress in Tokyo, October 1966
1383) Beasley H. E.: Twenty Months’ Review of the Effects of Laetrile in the Palliative Treatment of Cancer, Read
before the American College of Osteopathic Internists Convention at Philadelphia, 1954
1384 Cohen J.: Glucocorticoid activation of a calcium-dependent endonuclease in thymocytes nuclei leads to cell death,
J. Immunol. 132, pp. 38-42, 1984
1385 McConkey D.J.: Rapid turnover of endogenous endonuclease activity in thymocytes effects of macromolecular
synthesis inhibitors, Arch. Biochem. Biophys., Vol. 278, pp.: 284-287, 1990
1386) Buttyan R.: Cascade induction of c-fos, c-myc, and heat shock 70 k transcripts during regression of the rat
ventral prostate gland, Mol. Endocrinol., 2, pp: 605-657, 1988.
1387) Nagata S.: Fas death factor, Science, 267, pp.: 1449-1456, 1995
1388) A.L. Van Eenennaam: Engineering Vitamin E contenent: from Arabidopsis mutant to Soy Oil, The Plant Cell,
Vol. 15, pp.: 3007-3019, 2003
1389) Yabuta Y.: Thylakoid membrane-bound ascorbate peroxidase is a limiting factor of antioxidative systems under
photo-oxidative stress, Plant J. 32, pp: 915-925, 2002
1390) Grasses T.: Loss of alfa-tocopherol in tobacco plants with decreased geranylgeranyl reductase activity does not
modify photosynthesis in optimal growth conditions but increases sensitivity to high-light stress, Planta, 213, pp.: 620-
628, 2001
1391) D. Hofius: RNAi –mediated tocopherol deficiency impairs Photo-assimilate export in transgenic ptato plants,
Plant Physiology, Vol. 135, pp. 1256-1268, 2004
1392: Beal MF.: Coenzyme Q10 administration and its potential for treatment of neurodegerative diseases, Biofactors,
9 (2-4), pp.: 261-266, 1999
1393) Packham G.: c-myc and apoptosis, Biochem. Soc. Acta, 1242, pp.: 11-28, 1995
1394) Cotter T.G.: Genes and apoptosis, Biochem. Soc. Transact., 22, pp. 591-593, 1994
1395) Richter C.: Oxidative stress in mitochondria: its relationship to cellular Ca 2+ homeostasis, cell death,
proliferation, and differentiation, Chem. Biol. Interact., 77, pp.: 1-23, 1991
1396) Bertrand R.: Induction of a common pathway of apoptosis by staurosporine, Exp.Cell.Res., 211, 314-321, 1994
1397) Fesus L.: Induction and activation of tissue transglutaminase durino programmed cell death. FEBS Lett., 224,
pp.: 104-108, 1987.
1398) Nemes Z.: Identification of cytoplasmatic actin a san abundant glutaminyl substrate for tissue transglutaminase
in HL-60 and U937 cells undergoing apoptosis, J.Biol.Chem., 272, pp.: 20577, 1997
1399) Oliverio : Tissue transglutaminase-dependent post-translational modification of the retinoblastoma gene product
in promonocytic cells undergoing apoptosis, Mol. Cell. Biol. 17, pp.: 6040-6048, 1997
1400) Porter A.G.: Death substrates come alive, Bioessay, 19, pp.: 501-507, 1997
1401) Zou H.: APAF-1 , a human protein homologous CED-4 , participates in cytochrome c-dependent activation on
caspase-3, Cell, 90, pp.: 405-413, 1997.
1402) Vaux D.L.: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-beta
cells, Nature, 335, pp.. 440-442, 1988
1403) Reed J.C.: Bcl-2 and the regulation of programmed cell death, J.Cell Biol. , 124, pp.: 1-6, 1994
1404) Fernandez Sarabia M.: Bcl-2 associates with the ras-related protein R-ras p23, Nature, 366, pp.. 274-275, 1993
1405) Wang H.G.: Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase, Oncogene, 9, pp.: 2751-2756,
1406) Cory S.. Regulation of lymphocytes survival by the bcl-2 gene family , Annu. Rev. Immunol. 13, pp. 513-543,
1407) Korsmeyer S.J.: Regulators of cell death, Trends Gen., 11, pp.: 101-105, 1995
1408) Monaghan P.: Ultrastructural localization of Bcl-2 protein, J.Histochem. Cytochem., 40, pp.: 1819-1825, 1992
1409) Yang The antitumor activity of Elemene is associated with apoptosis, Zhonghua.Zhong LiuZaZhi.1996.18(3),
pp.: 169-172.
1410) La Curcuma e la Quercitina si sono comunque dimostrati efficaci nell’indurre la apoptosi delle cellule di polipi
intestinali adenomatosi
1411) Peat P.: Surviving against all odds: analyis case stdies of patients with cancer followed the Gerson Therapy,
Integrative cancer therapies, Vol. 6, No.1, pp: 80-87, 2007 ;
1412) Peplow M: Vitamin Research: Why is so confusine ? , in Medicine Today, settembre 2003
1413) Podda M.: Simulateous determination of tissue tocopherols, tocotrienols, ubiquinols and ubiquiones, Lipid. Res.
1996, 37, pp.. 893-901
1414) Stefano Scoglio: ESSIAC: Il famoso rimedio contro il Cancro, 2003
1415) Roberto Romiti: Aloe e Melatonina: esperienze cliniche di 99 casi di pazienti affetti da malattia neoplastica in
fase avanzata, ed. 2001
1416) Waterhouse C.: Craig A.: “Body-composition and changes in patients with advanced cancer”, Cancer, 11(6),
Novembre/December 1957
1417) The Mosby Medical Encyclopedia. New York : New American Library, 1985, pp.: 589
1418) Whitaker J.: Minerals, Part 3: Lower your blood pressure with the “K factor”, Healt and Healing, 9, pp.: 1-3,
June 1999
1419) Bruce Halstead, Amygdalin (Laetrile) Therapy, Los Altos, CA: Choice Publications. 1978. In Culbert, „Apricot
Power,” pp.: 72.
1420) Ralph W. Moss, The Cancer Industry: Unravelling the Politics (New York: Paragon House, 1989), 134-5.
1421) N.M. Ellison et al., Special Report on Laetrile: The NCI Laetrile Review, New England Journal of Medicine
299(10) pp: 549-552 (1978). In Office of Technology Assessment, Unconventional Cancer Treatments, pp.. 102.
1422) Michael L.Culbert, D.Sc., Apricot Power: Laetrile as the Marine Corps of the `Alternative’ Revolution,
Townsend Letter for Doctors (June 1995), pp.: 71.
1423) Ralph W. Moss, The Cancer Industry: Unravelling the Politics (New York: Paragon House, 1989), pp. 135.
1424) Michael L.Culbert, D.Sc., Apricot Power: Laetrile as the Marine Corps of the `Alternative’ Revolution,
Townsend Letter for Doctors (June 1995), pp.: 77.
1425) Michael L.Culbert, D.Sc., Apricot Power: Laetrile as the Marine Corps of the `Alternative’ Revolution,
Townsend Letter for Doctors (June 1995), pp.: 77.
1426) Michael L.Culbert, D.Sc., Apricot Power: Laetrile as the Marine Corps of the `Alternative’ Revolution,
Townsend Letter for Doctors (June 1995), pp.: 78.
1427). N.M. Ellison et al., Special Report on Laetrile: The NCI Laetrile Review, New England Journal of Medicine
299(10) pp.:549-552 (1978).
1428) C.G. Moertel et al., A Pharmacologic and Toxicological Study of Amygdalin, Journal of the American Medical
Association 245(6), pp.:591-4 (1981).
1429) Office of Technology Assessment, Unconventional Cancer Treatments, 107.
1430) M.L. Culbert, correspondence, New England Journal of Medicine 307(2) pp.:119 (1982).
1431) Office of Technology Assessment, Unconventional Cancer Treatments, 107.
1432) Michael L.Culbert, D.Sc., Apricot Power: Laetrile as the Marine Corps of the `Alternative’ Revolution,
Townsend Letter for Doctors (June 1995), pp.: 81.
1433) Walters, Options, 184.
1434) Michael L.Culbert, D.Sc., Apricot Power: Laetrile as the Marine Corps of the `Alternative’ Revolution,
Townsend Letter for Doctors (June 1995), pp.: 79-80.
1435)Anonymous, „The Committee for Freedom of Choice.” In Townsend Letter for Doctors, pp.: 196-7.
1436) Michael L.Culbert, D.Sc., Apricot Power: Laetrile as the Marine Corps of the `Alternative’ Revolution,
Townsend Letter for Doctors (June 1995), pp.: 78.
1437) Luther Bohanon, „Opinion in the Case of Glen L. Rutherford vs. U.S.A. In the U.S. District Court for the Western
Region of Oklahoma.” No. CIV-75-0218-B. December 5, 1977. In Moss, The Cancer Industry, 150.
1438) Richard Thomas, The Essiac Report: Canada’s Remarkable Unknown Cancer Cure (Los Angeles: The Alternative
Treatment Information Network, 1993), 12.
1439) Gary Glum, The Calling of An Angel (Los Angeles: Silent Walker Publishing, 1988).
1440) Richard Thomas, The Essiac Report: Canada’s Remarkable Unknown Cancer Cure (Los Angeles: The Alternative
Treatment Information Network, 1993).
1441) Richard Thomas, The Essiac Report: Canada’s Remarkable Unknown Cancer Cure (Los Angeles: The Alternative
Treatment Information Network, 1993; pp.: 13.
1442) Walters, Options, 107.
1443) Richard Thomas, The Essiac Report: Canada’s Remarkable Unknown Cancer Cure (Los Angeles: The Alternative
Treatment Information Network, 1993; pp: 15-28.
1444) Walters, Options, 112.
1445) Draft, „Status Report of Year One Operations,” University of Texas Center for Alternative Medicine Research,
1446) Charles Brusch, M.D., memo, 1982. In Thomas, The Essiac Report, 37.
1447) Draft, „Status Report of Year One Operations,” University of Texas Center for Alternative Medicine Research,
1448) Richard Thomas, The Essiac Report: Canada’s Remarkable Unknown Cancer Cure (Los Angeles: The Alternative
Treatment Information Network, 1993; pp.: 38-39.
1449) D.J. Hutchinson, Memorial Sloan-Kettering Cancer Center, Rye, New York, personal communication, September
1988 and March 1989. In Office of Technology Assessment, Unconventional Cancer Treatments, 73 4.
1450) Draft, „Status Report of Year One Operations,” University of Texas Center for Alternative Medicine Research,
1451) S.S. Fraser and C. Allen, „Could Esssiac Halt Cancer?” Homemaker’s (June/July/August 1977). In Thomas, The
Essiac Report, 42-45.
1452) I.W.D. Henderson, Director, Bureau of Human Prescription Drugs, Health Protection Brance, Health and Welfare
Canada, Vanier, Ontario, letter to J.W. Meakin, Executive Director, Ontario Cancer Treatment and Research
Foundation, Toronto, Ontario, November 19, 1982. In Office of Technology Assessment, Unconventional Cancer
Treatments, 74.
1453) D.J. Hutchinson, Memorial Sloan-Kettering Cancer Center, Rye, New York, personal communication, September
1988 and March 1989. In ibid., 73-4.
1454) N.H. Greenberg, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute,
National Institutes of Health, U.S. Department of Health and Human Services, Memo to J.A.R. Mead, Acting Associate
Director, Developmental Therapeutic Program, Division of Cancer Treatment, National Cancer Institute, November 1,
1455) J.A.R. Mead, Acting Associate Director, Developmental Therapeutic Program, Division of Cancer Treatment,
National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, Letter to J.D.
Sproul, Health Protection Branch, Health and Welfare Canada, Vanier, Ontario, December 1, 1983.
1456) R. Linkous, Food and Drug Administration, U.S. Department of Health and Human Services, Rockville,
Maryland, personal communication, September 27, 1988. In ibid., 75.
1457) Walters, Options, pp.: 113.
1458) I.W.D. Henderson, Director, Bureau of Human Prescription Drugs, Health Protection Brance, Health and Welfare
Canada, Vanier, Ontario, letter to J.W. Meakin, Executive Director, Ontario Cancer Treatment and Research
Foundation, Toronto, Ontario, November 19, 1982. In Office of Technology Assessment, Unconventional Cancer
Treatments, pp.: 74.
1561) Walters, Options, pp.: 113.
1460) Office of Technology Assessment, Unconventional Cancer Treatments, pp.: 75.
1461) Glum, Calling of an Angel, i.
1462) Draft, „Status Report of Year One Operations,” University of Texas Center for Alternative Medicine Research,,
1463) C.A. Dombradi and S. Foldeak, „Screening Report on the Antitumor Activity of Purified Arcitum Lappa
Extracts,” Tumori 52:173 (1966).
1464). S. Foldeak and C.A. Dombradi, „Tumor-Growth Inhibiting Substances of Plant Origin. I. Isolation of the Active
Principle of Arcitum Lappa,” Acta Phys Chem 10:91-3 (1964).
1465) In Office of Technology Assessment, Unconventional Cancer Treatments, 73 and Boik, Cancer and Natural
Medicine, pp.: 121.
1466) H. Itokawa et al., „Screening Test for Antitumor Activity of Crude Drugs (2),” Shoyakugaku Zasshi 36:145-9
1467) W.S. Woo, E.B. Lee and I. Chang, „Biological Evaluation of Korean Medicinal Plants. II,” Yakhak Hoe Chi
21:177-83 (1977).
1468) In Office of Technology Assessment, Unconventional Cancer Treatments, pp.: 73.
1469)Y. Into, S. Maeda and T. Sugiyama, „Suppression of 7,12- dimethylbenz[a]anthracene-induced Chromosome
Aberrations in Rat Bone Marrow Cells by Vegetable Juices,” Mutation Research 172(1):55-60 (1986).
1470) K. Morita, T. Kada and M. Namiki, „A Desmutagenic Factor Isolated from Burdock (Arctium Lappa Linne),”
Mutation Research 129(1) pp.:25- 31 (1984).
1471) K. Umehara et al., „Studies on Differentiation-Inducers from Arctium Fructus,” Chemical and Pharmaceutic
Bulletin 40(10) pp.:1774-9 (1993). In Boik, Cancer and Natural Medicine, pp.: 159.
1472) T. Hirano, M. Gotoh and K. Oka, „Natural Flavenoids and Lignans are Potent Cytostatic Agents Against Human
Leukemic HL-60 Cells,” Life Sciences 55(13):1061-9 (1994). In ibid., 159.
1473) P. Bryson et al., „Burdock Root Tea Poisoning. Case Report Involving a Commercial Preparation,” Journal of
the American Medical Association 238:20 (1978).
1474) P. Rhodes et al., „Anticholinergic Poisonings Associated with Commercial Burdock Root Tea,” Journal of
Toxicology 22:581-4 (1984/5).
1475) In Moss, Cancer Therapy: The Independent Consumer’s Guide to Non-Toxic Treatment and Prevention (New
York: Equinox Press, 1992), 165.
1476) P. Rodriguez et al, „Allergic Contact Dermatitis Due to Burdock (Arctium lappa)” Contact Dermatitis 33:134-5
1477) P. Rhodes et al., „Anticholinergic Poisonings Associated with Commercial Burdock Root Tea,” Journal of
Toxicology 22:581-4 (1984/5).
1478) W. Grimminger and K. Witthohn, „Analyics of Senna Drugs With Regard to the Toxicological Discussion of
Anthranoids,” Pharmacology 47:98-109 (1993).
1479) In Draft, „Status Report of Year One Operations,” University of Texas Center for Alternative Medicine Research,
1480) Office of Technology Assessment, Unconventional Cancer Treatments, 73.
1481) H. Into, „Effects of the Antitumor agents from Various Natural Sources on Drug-Metabolizing System,
Phagocytic Activity and Complement System in Sarcoma 180-Bearing Mice, Japanese Journal of Pharmacology
40(3):435-43 (1986).
1482) Office of Technology Assessment, Unconventional Cancer Treatments, 73.
1483) M. Belkin and D.B. Fitzgerald, „Tumor-Damaging Capacity of Plant Materials. 1. Plants Used as Cathartics,”
Journal of the National Cancer Institute 13: pp: 139-55 (1952).
1484) J. Konopa et al., „Screening of Antitumor Substances from Plants,” Arch Immunol Ther Exp 15:129 (1957). In
ibid., 73.
1485) R. Anton and M. Haag-Berrurier, „Therapeutic Use of Natural Anthraquinone for Other than laxative Actions,”
Pharmacology 20(suppl 2):104-12 (1980).
1486) C.A. Friedmann, „Structure-Activity Relationships of Anthraquinones in Some Pathological Conditions,”
Pharmacology 20(suppl 1):113-22 (1980).
1487) In Boik, Cancer and Natural Medicine, pp.: 117.
1488) F. Iosi, M.T. Santini and J.W. Malorni, „Membrane and Cytoskeleton are Intracellular Targets of Rhein in A431
Cells, Anticancer Research 13(2):545-54 (1993).
1489) A. Floridi et al., „Effect of Rhein on the Glucose Metabolism of Ehrlich Ascites Tumor Cells,” Biochemical
Pharmacology 40(2):217-22 (1990).
1490) A. Delpino et al., „Protein Synthetic Activity and Adenylate Energy Charge in Rhein-Treated Cultured Human
Glioma Cells,” Cancer biochem Biophys 12(4) pp:241-52 (1992).
1491) M. Lu and Q. Chen, „Biochemical Study of Chinese Rhubarb; Inhibitory Effects of Anthraquinone Derivatives on
P388 Leukemia in Mice,” Zhongguo Yaoke Daxue Xuebao 20(3)::155-7 (1989).
1492) H.M. Chang and P.P.H. But, Pharmacology and Applications of Chinese Materia Medica (Teaneck, NJ: World
Scientific Publishing Company, 1986).
1493) Walters, Options, pp.: 114-115.
1494) Richard Thomas, The Essiac Report: Canada’s Remarkable Unknown Cancer Cure (Los Angeles: The Alternative
Treatment Information Network, 1993; pp.: 59-61.
1495) Walters, Options, pp.: 116.
1496) Draft, Status Report of Year One Operations, University of Texas Center for Alternative Medicine Research, pp.:
1497) Bruce Halstead, Amygdalin (Laetrile) Therapy, Los Altos, CA: Choice Publications. 1978. In Culbert, „Apricot
Power,” 72.
1498) Moss, The Cancer Industry, 133.
1499) Doyle JD, Stotzky G, McClung G & Hendricks C W (1995) „Effects of Genetically Engineered Microorganisms
on Microbial Populations and Processes in Natural Habitats, Advances in Applied Microbiology,” Vol. 40 Academic
1500) P.B. Chowka, „Does Mildred Nelson Have an Herbal Cure for Cancer?” Whole Life Times January-February
1984, 16.
1501) Harry M. Hoxsey, You Don’t Have to Die (New York:Milestone Books, Inc.:1956), 44-5.
1502) Chowka, „Does Mildred Nelson Have An Herbal Cure for Cancer?” Whole Life Times, 16.
1503) Hoxsey, You Don’t Have to Die, 90-1.
1504) Walters, Options, 100.
1505) Hoxsey, You Don’t Have to Die, 59.
1506) J.M. Mather et al., “Report Concernning the Hoxsey Treatment for Cancer”. Vancouver, University of British
Columbia, December 19, 1957.
1507) Hoxsey, You Don’t Have to Die, 47.
1508) Ibid., 49.
1509) F.E. Mohs, Chemosurgical Treatment of Cancer of the Skin. A Microscopically Controlled Method of Excision,
Journal of the American Medical Association 138(8):564-9 (1948). In Office of Technology Assessment,
Unconventional Cancer Treatments, 77.
1510) Office of Technology Assessment, Unconventional Cancer Treatments, 77-8.
1511) Draft, Status Report of Year One Operations, University of Texas Center for Alternative Medicine Research, 78.
1512) Walters, Options, 96.
1513) Surgery, Gynecology and Obstetrics, vol. 114, 1962, pp. 25-30 and Walter Lewis and Memory P. F. Elvin-Lewis,
Medical Botany: Plants Affecting Man’s Health (New York: John Wiley and Sons, 1977). In Walters, Options, 96.
1514) Hoxsey, You Don’t Have to Die p 45-6.
1515) Draft, Status Report of Year One Operations, University of Texas Center for Alternative Medicine Research, 76.
1516) Office of Technology Assessment, Unconventional Cancer Treatments, 77.
1517) James Duke, Ph.D., The Synthetic Bullet vs. the Herbal Shotgun Shell, HerbGram No. 18/19 (Fall 1988/Winter
1518) Draft, Status Report of Year One Operations, University of Texas Center for Alternative Medicine Research,
1519) M. Belkin and D.B. Fitzgerald, Tumor-Damaging Capacity of Plant Materials. 1. Plants Used as Cathartics,
Journal of the National Cancer Institute 13:139-55 (1952).
1520) Office of Technology Assessment, Unconventional Cancer Treatments, 78.
1521) Draft, Status Report of Year One Operations, University of Texas Center for Alternative Medicine Research, 78.
1522) W.S. Woo, E.B. Lee and I. Chang, Biological Evaluation of Korean Medicinal Plants. II., Yakhak Hoe Chi
21:177-83 (1977). In Office of Technology Assessment, Unconventional Cancer Treatments, 78.
1523) K. Yokoyama et al., Purification and Biological Activities of Pokeweed (Phytolacca americana) Mitogens,
Biochem Biophys Acta 427:443-52 (1976).
1524) M.P. Bodger et al., Mitogenic Proteins of Pokeweed, I. Purification, Characterization and Mitogenic Activity of
Two Proteins from Pokeweed (Phytolacca octandra), Immunology 37:785-92 (1979).
1525) M.P. Bodger et al., Mitogenic Proteins of Pokeweed, II. The Differentiation of Human Peripheral Blood B
Lymphocytes Stimulated with Purified Pokeweed Mitogens (Po-2 and Po-6) from Pokeweed, Phytolacca Octandra,
Immunology 37:793-9 (1979).
1526) In Moss, Cancer Therapy, pp.: 162.
1527) TY Basham et al, A Series of Murine Interleukin Molecules which Stimulate both Murine and Human
Lymphocytes. Production by Phytolacca Americana (Pokeweed) Lectin 2 (Pa-2)-Stimulated Thymus and Thymus-
Derived Cells, Cell Immunology 63:118-33,1981.
1528) R.G. Petersdorf et al., eds., “Harrison’s Principles of Internal Medicine”, 10th ed., (New York: McGraw Hill,
1529) J.P. Zhang et al., Effects of Phytolacca Acinosa Polysaccharides I on Cytotoxicity of Macrophages and Its
Production of Tumor Necrosis Factor and Interleukin 1, Chung Kuo Yao Li Hsueh Pao 11:375-7, 1990.
1530) Duke, ed., Handbook of Medicinal Herbs. In Office of Technology Assessment, Unconventional Cancer
Treatments, 79.
1532) T.Y. Owen, et al.,A New Antitumor Substance–Lycobetaine, K’o Hsueh T’ung Pao,” 21(6):258-87 (1976). In ibid.
1533) Boik, Cancer and Natural Medicine, 113.
1534) R.X. Zhang, Laboratory Studies of Berberine Used Alone and in Combination with 1,3-cis(2-chlorothyl)-1-
nitrosourea to Treat Malignant Brain Tumors, Chinese Medical Journal 103(8):658-65 (1990). In Boik, Cancer and
Natural Medicine, 113.
1535) K.K.S. Chang, C. Gao and L.C. Wang, Berberine-Induced Morphologic Differentiation and Down-Regulation of
c-Ki-ras2 Protooncogene Expression In Human Teratocarcinoma Cells, Cancer Letters 55:1038 (1990). In Boik,
Cancer and Natural Medicine, 113.
1536) C.W. Chi et al., Flowcytometric Analysis of th Effect of Berberine on the Expression of Glucocorticoid Receptors
in Human Hepatoma Hep-g2 Cells, Life Sciences 54(26):2099-2107 (1994).
1537) I.F. Shvarev and A.L. Tsetlin, Antiblastic Properties of Berberine and Its Derivatives, Farmalol Tsoilol 35(1):
73-5 (1972). In Boik, Cancer and Natural Medicine, 113.
1538) B. Hladon et al., Cytotoxic Activity of Some Chelidonium Maius Alkaloids on Human and Animal Tumor Cell
Cultures In Vitro, Annals of Pharmacology 13:61-8 (1978). In Boik, Cancer and Natural Medicine, 113.
1539) Zhang, Laboratory Studies of Berberine Used Alone and in Combination with 1,3-cis(2-chlorothyl)-1-nitrosourea
to Treat Malignant Brain Tumors. In Boik, Cancer and Natural Medicine, 113.
1540) N. Bodor and M.E. Brewster, Improved Delivery Through Biological Membranes; XV-Sustained Brain Delivery
of Berberine, European Hournal of Medical Chemistry 18(3):235-40 (1983). In Boik, Cancer and Natural Medicine,
1541) Y. Kumazawa et al., Activation of Peritoneal Macrophages by Berberine-Type Alkaloids in Terms of Induction of
Cytostatic Activity, Priority Journals 6(6):587-92 (1984). In Boik, Cancer and Natural Medicine, 113.
1543) Hartwell, Plants Used Against Cancer. In ibid., 77.
1544) Moss, Cancer Therapy, 166.
1545) M. Belkin and D.B. Fitzgerald, Tumor-Damaging Capacity of Plant Materials. I. Plants Used as Cathartics,
Journal of the National Cancer Institute 13:139-55 (1952).
1546) J.A. Duke, Weeds? Or Wonder Drugs? Organic Gardening 41(6): 38-40 (1994).
1547) H.Y. Hsu, Y.P. Chen and M. Hong, The Chemical Constituents of Chinese Herbs Vol. 1 (Long Baech, CA:
Oriental Healing Arts Institute: 1982).
1548) In Boik, Cancer and Natural Medicine, 157.
1549) B.N. Dhawan et al., Screening of Indian Plants for Biological Activity. VI., Indian Journal of Experimental
Biology 15:208 (1977). In ibid., 78.
1550) U.S. vs. Hoxsey Cancer Clinic and Harry M. Hoxsey, US District Court, Northern District of Texas, filed US
Court of Appeals, Fifth Circuit, May 7, 1951, No 13645.
1551) In Anonymous, „Hoxsey Method/Bio-Medical Center,” CA–A Cancer Journal for Clinicians 40:1
(January/February 1990) 51-5.
1552) G. Stewart, Modulation of Antibody Response in Mice to Bovine Serum Albumin. In Draft, „Status Report of Year
One Operations,” University of Texas Center for Alternative Medicine Research, 74.
1553) Bio-Medical Center literature.
1554) Steve Austin, N.D. et al., Long Term Follow-Up of Cancer Patients Using Contreras, Hoxsey and Gerson
Therapies, Townsend Letter for Doctors August/September 1995.
1555) Office of Technology Assessment, Unconventional Cancer Treatments, 79.
1556) Clark S..: Antileukemia effects of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signalling
through Mek in a Ras – and Raf-independent fashion, Clin.Cancer Res., 9, 4494-4504, 2003

Dă clic pentru a accesa Anti-leukaemia%20effects%20of%20Perillyl%20alcohol.pdf

1557) Burke Y.: Effects of the isoprenoids perillyl alcohol and Farnesol on apoptosis biomarkers in pancreatic cancer
chemoprevention, Anticancer Res., 22, 3127-3134, 2002
on%20CARCINOMA.pdf )
1558) Yuri T.. Perillyl alcohol inhibits human breast cancer cell growth in vitro and in vivo, Breast Cancer Research
Treat., 84, pp.: 251-260, 2004

Dă clic pentru a accesa Perillyl%20alcohol%20inhibits%20human%20breast%20cancer.pdf

1559) Elegbede J.. Perillyl alcohol and perillaldehyde induced cell cycle arrest and cell death in BroTo and A549 cells
cultured in vitro , Life Sci., 73, pp.. 2831-2840, 2003

Dă clic pentru a accesa Perillyl%20alcohol%20(Monoterpene)%20against%20cancer.pdf

1560) Cheong E.: Synthetic and naturally occurring COX-2 inhibitors suppress proliferation and induce apoptosis in a
human esophageal adenocarcinoma cell line (OE-33) , Gastroenterology 122, A63, 2002
1561) Larocca L.M.. Quercetin and the growth of leukemic progenitors, Leuk. Lymphoma, 23, 1996, pp.: 49-53
1562): Depeint F.: Evidence for consistent patterns between flavonoids structures and cellular activities, Proc. Nutr.
Soc., 61, 2002, pp.: 97-107
1563) Chan F.L.. Induction of apoptosis in prostate cancer cell lines by a flavonoid, baicalin, Cancer Lett., 160, PP..
219-228, 2000
1564) Thompson CB.: Apoptosis in the pathogenesis and treatment of disease , Scence, 267, pp: 1456-1462
1565) Guang L.. d-limonene induces apoptosis of gastric cancer cells, Chin. J. Oncol., 25 325-327, 2003
1566) Kaji I.: Inhibition by d-limonene of experimental hepatocarcinogenesis in Sprague-Dawley rats does not involve
p21 (ras) plasma membrane association, Int. J. Cancer 93, pp.: 441-444, 2001
1567) De Sousa A.: Melissa officinalis essential oil: anti-tumoral and antioxidant activities , J. Pharm. Pharmacol. 56,
pp. 677-681, 2004
1568) Cavalieri E.: a Bisabolol, a non toxic natural compound, strongly induces apoptosis in glioma cells, Biochem.
Biophys. Res. Commun. 315, pp.: 589-594, 2004
1569) J. West China Univ. Med. Sci.) 35, pp. 337-339, 2004
1570) Moteki H.: Specific induction of apoptosis by 1,8 –cineole in two human leukaemia cell lines, but not a in human
stomach cancer cell line, Oncol. Rep., 9, pp.: 767-760, 2002
1571) Calcabrini A.: Terpinen 4-ol, the main component of Melaleuca alternifolia (tea three) oil inhibits the in vitro
growth of human melanoma cells, J. Invest. Dermatol. 122, pp.: 349-360, 2004
1572) Buhagian J.: The induction of apoptosis in human melanoma, breast and ovarian cancer cell lines using an
essential oil extract from the conifer Tetraclinis articulata, Anticancer Res., 19, pp.. 5435-5443, 1999
1573) Seo WG: Ethyl acetate extract of the stem bark of Cudrania tricuspidata induces apoptosis in human leukaemia
HL-60 cells, American Journal of Chinese Medicine 2001, 29, pp. 313-320
1574) Tan P.: Clinical study on treatment of 40 cases of malignant brain tumor by Elemene emulsion injection Chin. J.
Integ. Trad. Western Med, 20, pp.: 645-648
1575) Yoon Y.: Tanshinone II A isolated from Salvia miltiorrhiza Burger induced apoptosis in HL-60 human
premyelocytic leukaemia cell line, Journal of Ethnopharmacology 1999, 68, pp. 121-127
1576) Kim N.D.: Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human
breast cancer, Breast Cancer Res. Treat., 71, pp. 203-217, 2002
1577) Guang : Inhibition of growth and metastasis of human gastric cancer implanted in nude mice by d-limonene
World J. Gastroenterol. 10, 2140-2144, 2004
1578) Reviewed by Dr Arpad Pusztai for the German environment agency BfN, in September and November 2004, on :
1579) Malatesta M.: Fine structural analyses of pancreatic acinar cell nuclei from mice fed on GM soybean. Eur. J.
Histochem., 47:385-388, 2003;
1580) Malatesta M.: Ultrastructural morphometrical and immunocytochemical analyses of hepatocyte nuclei from mice
fed on genetically modified soybean. Cell Struct. Funct., 27: 173-180, 2002; Disponibile in PDF
1581) Malatesta M.: Ultrastructural analysis of pancreatic acinar cells from mice fed on genetically modifed soybean.
J. Anat., 201:409-416, 2002;
1582) Malatesta M.: Reversibility of hepatocyte nuclear modifications in mice fed on genetically modified soybean. Eur.
J. Histochem., 49:237-242, 2005;
1583) Malatesta M., Martin T.E., Biggiogera B.: Ultrastructural analysis of testes from mice fed on genetically
modified soybean. Eur. J. Histochem., 48: 449-453, 2004.
1584) Ermakova IV, “Genetically modified soy leads to the decrease of weight and high mortality of rat pups of the first
generation”, preliminary studies. EcosInform 2006, 1, 4-9 (in Russian). Un documento completo è in fase di stampa:
Ermakova IV, Genetics and ecology, in: Actual problems of science , Moscow , 2005, pp.53-59 (in Russian).
1585) Food Standards Agency News, No. 48, June 2005
1586) Netherwood et al, Assessing the survival of transgenic plant DNA in the human gastrointestinal tract, Nature
Biotechnology, 2004;
1587) Duggan et al, Fate of genetically modified maize DNA in the oral cavity and rumen of sheep, British Journal of
Nutrition, 89(2): 159-166, 2003
1588) Ewen and Pusztai, Effects of diets containing genetically modified potatoes expressing Galanthus nivalis lectin
on rat small intestine, The Lancet, 354, 1353-1354, 1999; Disponibile in PDF
1589) El-Sayed, A.K., “Fine structural changes in the ileum of mice fed on endotoxin-treated potatoes and transgenic
potatoes.” Natural Toxins, 6, 219-233, 1998.
1590) Ray Vaden: Recombination sites in Cauliflower Mosaic Virus DNAs; implications for Mechanisms of
recombination, Virology, No.177, pp: 717-726, 1990

Dă clic pentru a accesa ray%20vaden%20.pdf

1591) Gal S.: Agroinfection of transgenic plants leads to viable Cauliflower Mosaic Virus by intermolecular
recombination, Virology, No.187, pp.: 525-533, 1992
1592) Greene A.: Recombination between viral RNA and transgenic plant transcripts, Science, Vol. 263, 11 march
1593) Boyer J.C.: Infectious transcripts and cDNA clones of RNA Viruses, Virology, No. 198, pp.: 415-426, 1994

Dă clic pentru a accesa boyer.pdf

1594) Allison R.F.: Recombination in plants expressing viral transgenes, Seminars in Virology, Vol. 7, pp.: 417-422,
1595) Wintermantel W.M.: Isolation of recombinant viruses between Culiflower Mosaic Virus and a viral gene in
transgenic plants under conditions of moderate selection pressure, Virology, No. 223, pp.: 156-164, 1996

Dă clic pentru a accesa wintermantel.pdf

1596) Vlasak J.: Comparison of hCMV immediate early and CaMV 35S promoters in both plant and human cells,
Journal of Biotechnology No. 103, pp.: 197-202, 2003
1597) Latham J.: GM Gene Flow (B): Horizontal gene transfer of viral inserts from GM plants to viruses, Technical
paper, February 2004.
1598) Akio Mori: Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant
prostate cancer cells, Cancer Research, No. 66, pp.. 3229- 323 2006
1599) Chen H.W.: Effect of alisol B acetate, a plant triterpene, on apoptosis in vascular smooth muscle cells and
lymphocytes, Eur. J. Pharmacol., 419, pp.: 127-138, 2001

Dă clic pentru a accesa ALISMA%20PLANTAGO-AQUATICA.pdf

1600) Lee S.: Cytoxic triterpenoides from Alismatis rhizome, Arch. Pharm. Res., No.24, pp: 524-526, 2001
1601) Motoo Y.: antitumor effects of saikosaponins, baicalin and baicalein on human hepatoma cell lines, Cancer Lett.,
86, 91-95
1602) M. Soffritti, F. Belpoggi, E. Tibaldi, D. Degli Esposti, M. Lauriola: L’Esposizione ad Aspartame a Basse
Dosi, dalla Vita Fetale e per Tutta la Vita, Aumenta gli Effetti Cancerogeni sui Ratti (Lifespan Exposure to Low Doses
of Aspartame Beginning During Prenatal Life Increases Cancer Effects in Rats) Environmental Health Perspectives
1603) Fulda S: Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors,
Medical and Pediatric Oncology, No.35, pp.. 616-618, 2000
1604) Lautrari H.: Perillyl alcohol is an angiogenesis inhibitor, J. Pharmacol. Exp. Ther. 311, pp.: 568-575, 2004.

Dă clic pentru a accesa Perilly%20alcohol%20inhibitor%20of%20ANGIOGENESIS.pdf

1605) Jan Dorie: Resveratrol extensive apoptosis by depolarizing mitochondrial membranes and activating Caspase-9
in Acute Lymphoblastic Leukaemia Cells, Cancer Research, 61, pp.: 4731-4739, 2001

Dă clic pentru a accesa Resveratrolo%20induce%20apoptosi%20sulla%20Leucemia.pdf

1606) Ji Suk Lee: Inhibition of Phospholipase Cy1 and cancer cell proliferation by triterpene esters from Uncaria
rhynchophylla, J.Nat. Prod. 63, pp: 753-756, 2000
1607) Joe A.: Resveratrol induces growth inhibition, S-phase arrest, apoptosis and changes in biomarker expression in
several human cancer cell lines, Clinical Cancer Research, Vol. 8, pp.: 893-903, 2002
1608) Damianaki A.: Potent inhibitory action of Red Wine polyphenols on human breast cancer cells, Journal of
cellular biochemistry, No. 78, pp: 429-441, 2000
1609) Caltagirone S.: Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential, Int. J.
Cancer, No. 87, pp.: 595-600, 2000
1610) Huang X.: Mechanism of the anti-cancer activity of Zizyphus jujuba in HepG2 cells, Am. J. Chin. Med., 35, pp.:
517-532, 2007
1611) Zech L.: Characteristic chromosomal abnormalities in biopsies and lymphoid cell lines from patients with Burkitt
and non-Burkitt lymphomas, Int. J. Cancer, 1976, No.17, pp: 47-56
1612) Croce CM.: Molecular genetics of human B-cell neoplasia, Adv Immunol. 1986, No. 38, pp: 245-274
1613 Rowley JD: Identification of the constant chromosomal regions involved in human hematolgic malignant disease,
Science 1982, No. 216, pp: 749-751
1614 Tsujimoto Y.: Involvement of the bcl-2 gene in human follicular lymphoma, Science 1985, No. 228, pp: 1440-
1615) Raffeld M.: bcl-1, t(11;14), and mantle cell-derived lymphomas, Blood 1991, No. 78, pp.: 259-263
1616) Erikson J.: The chromosome 14 breakpoint in neoplastic B cells with the t(11;14) traslocation involves the
immunoglobulin heavy chain locus, Proc. Natl. Acad. Sci. USA 1984, No. 81, pp.: 4111-4147
1617) Kagan J: alpha chain locus of the T-cell antigen receptor is involved in the t(10;14) chromosome traslocation of
T-cell acute lymphocytic leukaemia, Proc. Natl. Acad. Sci. USA 1987, No. 84, pp.: 4543-4546
1618) Zutter M.: The t(10;14) (q24;q11) of T-cell acute lymphoblastic leukaemia juxtaposes the delta T cell receptor
with tcl-3, a conserved and activated locus at 10q24. Proc. Natl. Acad. Sci. USA 1990; 87, PP.: 3161-3165
1619) Le Beau MM: The t(2;5) (p23;q35) : a recurring chromosomal abnormality in Ki-1 positive anaplastic large cell
lymphoma, Leukemia 1989, No.3, pp: 866-870
1620) Morris SW : Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in NON-Hodgkin’s lymphoma,
Science 1994, No. 263, pp: 1281-1284
1621) Mc Keithan : Molecular cloning of the breakpoint junction of a human chromosomal 8;14 traslocation involving
the T-cell receptor alpha chain gene and sequences an the 3’ side of myc, Proc. Natl. Acad. Sci. USA 1986, No. 83, pp:
1622) Julisson G. Chromosomal aberrations in B-cell chronic lymphocytic leukaemia: Pathogenetic and clinical
implications, Cancer Genet. Cytogenet., 1990, No. 45, pp.: 143-160
1623) Mc Keithan: Cloning of thre chromosome translocation breakpoint junction of the t(14;19) in chronic
lymphocytic leukaemia. Proc. Natl. Acad. Sci. USA 1987, No. 84, pp: 9257-9260
1624) Erikson J.: Deregulation of c-myc by translocation of the alpha-locus of the T-cell receptor in T-cell leukemias,
Science, 1986, No. 232, ppp: 884-886
1625) Denny CT : A chromosome 14 inversion in a T-cell lymphoma is caused by site specific recombination between
immuno-globulin and T-cell receptor loci, Nature 1986, No. 320, pp.: 549-551
1626) Van den Berghe: High incidence of chromosome abnormalities in IgG3 myeloma, Cancer Genet Cytogenet. 1984,
No. 11, pp: 381.387
1627) Sadamori N.: Abnormalities of chromosome 14 at band 14q11 in Japanese patients with adult T-cell leukaemia,
Cancer Genet. Cytogenet., 1985, No. 17, pp: 279-282
1628) Sadamori N.: Significance of chromosome 14 anomaly at band 14q11in Japanese patients with adult T-cell
leukaemia, Cancer 1986, No. 58, pp: 2244-2250
1629) Miyamoto K.: Specific abnormalities of chromosome 14 in patients with acute type of adult T-cell
leukaemia/lymphoma, Int. J. Cancer 1987, No. 40 pp: 461-468
1630) Sadamori N.: Cytogenetic implication in adult T-cell leukaemia. A hypothesis of leukemogenesis, Cancer Genet
Cytogenet., 1991, No. 51, pp: 131-136
1631) Orscheschet K.: Large-cell anaplastic lymphoma-specific translocation (t[2;5][p23;q35] in Hodgkin disease:
indication of a common pathogenesis ? Lancet 1995, No. 345, pp: 87-90
1632) Nowell: a minute chromosome in human chronic granulocytic leukaemia, Science 1960, No. 132 pp: 1497
1633) Manolov G: Marker band in one chromosome 14 from Burkitt’s lymphomas, Nature, 1972, No. 237, pp: 33-34
1635) Taub R.: Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma
and murine plasmocytoma cells, Proc. Natl. Acad. Sci. USA 1982, No. 79, pp.: 7837-7841
1636) Rappold G.A.: C-myc and immunoglobulin kappa light chain constant genes are on the 8q+ chromosome of
three Burkitt lymphoma lines with t(2;8) translocations , EMBO J. 1984, No. 3, pp: 2951-2955
1638) Korsmeyer SJ: Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death, Sem. Cancer Biol.
1993, No. 4, pp: 327-332
1640) Rowley JD: Chromosome abnormalities in human leukaemia, Annu. Rev. Genet. 1980, No. 14, pp: 17-39
1641) Andriamampandry M.: Diets enriched in (n-3) fatty acids affect rat coagulation factors dependent on vitamin K,
C.R.Acad.Sci.III 1998, 321, pp.: 415-421
1642) Matzinger D.: The role of long chain fatty acids in regulating food intake and cholecystokinin release in humans,
Gut, 46, pp.: 689-694, 2000
1643) Julup O.: Comparison of short-term effects of insulin and essential fatty acids on the slowed nerve conduction of
streptozoticin diabetes in rats, J.Neurol. Sci., 106, pp.: 56-59, 1991).
1644) Horrobin D.F.: Essential fatty acid metabolism and its modification in atopic eczema, Am.J.Clin.Nutr., 71,
Suppl.1, pp.: 367S-372S, 2000
1645) Lee R.M.: Fish oil, esssential fatty acids, and hypertension, Can. J. Physiol. Pharmacol., 72, pp.: 945-953, 1994
1646) Ziegler D.: Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from
clinical trias, Exp.Clin. Endocriniol.Diabetes, 107, pp.: 421-430, 1999
1647) Pardini R.S.: Nutritional Intervention with Omega-3 Fatty Acids in a case of Malignant Fibrous Histiocytoma of
the Lungs, Nutrition and Cancer 2005, 52 (2) , pp.: 121-129 (VEDI ALLEGATO 28)
1648) Tierney L.M.: Current diagnosis and treatment, Stamford CT, Appleton Lange, 1997, pp.: 1138-1142
1649) Rubenstein E,: Scientific American Medicine, New York, NY, Scientific American, 1983, pp.:1-19
1650) Werbach M.R.: Nutritional influences on illness, 2nd edn., Tarzana, CA: Third Line Press., 1993
1651) Ruz M.: Erytrocytes, erytrocyte membranes, neutrophils and platelets as biopsy materials for the assessment of
zinc status in humans. Br.J. Nutr., 1992, 68, pp.: 515-527
1652) Lanza G.: Anatomia Patologica Sistematica, Vol.1, Seconda Edizione, Piccin Editore, pagina 366
1653) Lanza G.: Anatomia Patologica Sistematica, Vol.1, Seconda Edizione, Piccin Editore, pagina 367
1654) Noguchi M.: Oncology, No. 52, pp.. 265-271,1995
1655) Dandekar D.S. : An orally active Amazonian plant extract (BIRM) inhibits prostate cancer growth and
metastasis, Cancer Chemother. Pharmacol., No. 52, pp.: 59-66, 2003
1656) Galletti S.: Glucobrassicin enhancement in woad (Isatis tintoria) leaves by chemical and physical treatments,
Journal of the Science of Food and Agricolture, No. 86, pp: 1833-1838, 2006
1657) de Feo, V. 1992. Medicinal and magical plants in the northern Peruvian Andes. Fitoterapia 63: 417-440, 1992
1658) Vasquez, M. R.: 1990 Useful Plants of Amazonian Peru. Second Draft. Filed with USDA’s National Agricultural
Library. USA
1659) Grenand, P.: Pharmacopees taditionnels en Guyane: Créoles, Palikur, Wayãpi. Editorial l-ORSTROM, Coll.
Mem No. 108. Paris, France, 1987
1660) Branch, L.C. and da Silva, I.M.F. 1983. „Folk Medicine of Alter do Chao, Para, Brazil.” Acta Amazonica
1661) de Almeida, E.R., 1993. Plantas Medicinais Brasileiras, Conhecimentos Populares E Cientificos. Hemus Editora
Ltda.: Sau Paulo, Brazil.
1662) Asprey, GF. & Thornton, P.: Medicinal Plants of Jamaica. III West Indian Med J 4: 69-92, 1955
1663) Ayensu, ES.: Medicinal Plants of the West Indies. Unpublished manuscript: 110P-(1978) Office of Biological
Conservation Smithsonian Institution, Washington, DC, 1978
1664) Weniger B.: Popular Medicine of the Central Plateau of Haiti. 2. Ethnopharmacological Inventory J
Ethnopharmacol 17 1: 13-30 (1986)
1665) Alali FQ.: Annonaceous acetogenins: recent progress. J Nat Prod. 1999 Mar;62(3):504-40. Review.
1666) Feng, P.C.: Pharmacological Screening of Some West Indian Medicinal Plants, J Pharm Pharmacol 14 : 556-561
1667) Meyer, TM.: The Alkaloids of Annona Muricata. Ing Ned Indie 8 6: 64- (1941)
1668) Carbajal, D.: Pharmacological Screening of Plant Decoctions Commonly Used in Cuban Folk Medicine. J
Ethnopharmacol 33 1/2: 21-24 (1991)
1669) Misas, CAJ: Contribution to the Biological Evaluation of Cuban Plants. IV. Rev Cub Med Trop 31 1: 29-35
1670) Sundarrao, K.: Preliminary Screening of Antibacterial and Antitumor Activities of Papua New Guinean Native
Medicinal Plants, Int J Pharmacog 31 1: 3-6 (1993)
1671) Heinrich, M.: Parasitological and Microbiological Evaluation of Mixe Indian Medicinal Plants (Mexico) J
Ethnopharmacol 36 1: 81-85 (1992)
1672) Antoun, MD.: Screening of the Flora of Puerto Rico for Potentialantimalarial Bioactives. Int J Pharmacog 31 4:
255-258 (1993)
1673) Gbeassor, M.: In Vitro Antimalarial Activity of Six Medicinal Plants. Phytother Res 4 3: 115-117 (1990)
1674) Tattersfield, F.: The Insecticidal Properties of Certain Species of Annona and an Indian Strain of Mundulea
Sericea (Supli). Ann Appl Biol 27 : 262-273 (1940)
1675) Hasrat JA: Isoquinoline derivatives isolated from the fruit of Annona muricata as 5-HTergic 5-HT1A receptor
agonists in rats: unexploited antidepressive (lead) products. J Pharm Pharmacol. ; 49(11): 1145-1149, 1997.
1676) Unpublished Data, National Cancer Institute. Anon: Nat Cancer Inst Central Files – (1976) from Napralert Files,
University of Illinois, 1995
1677) Zeng L.: Five new monotetrahydrofuran ring acetogenins from the leaves of Annona muricata. J Nat Prod. 1996
Nov; 59(11): 1035-1042.
1678) Padma P.: Effect of the extract of Annona muricata and Petunia nyctaginiflora on Herpes simplex virus. J
Ethnopharmacol. 1998 May;61(1):81-3.
1679) Gleye C.: cis-monotetrahydrofuran acetogenins from the roots of annona muricata1. J Nat Prod. 1998
1680) Mikolajczak K.L.: Control of Pests with Annonaceous Acetogenins (pesticidal use patent on acetogenins) U.S.
Patent No. 4,721,727, issued January 26, 1988.
1681) Mikolajczak K.L.: Control of Pests with Annonaceous Acetogenins, (divisional patent on asimicin) U.S. Patent
No. 4,855,319, issued August 8, 1989.
1682) McLaughlin J.L.: Chemotherapeutically Active Acetogenins, (bullatacin and bullatacinone) U.S. Patent No.
5,229,419, issued July 20, 1993.
1683) McLaughlin J.L.: Bioactive Acetogenins and Derivatives, (Protects several new structures), U.S. Patent No.
5,536,848, issued July 16, 1996 (International Serial No. PCT/US95/07490, international date June 13, 1995).
1684) Hopp D.C.: Use of Selectively Cytotoxic Annonaceous Acetogenins, filed February 4, 1997, P-97006.00 U.S.
1685) Hopp D.C.: Annonaceous Acetogenins Selectively Cytotoxic Against Pancreatic Tumors, filed February 17, 1997,
P-97019.00 U.S.
1686) Oberlies N.H.: Use of Annonaceous Acetogenins to Treat Multidrug Resistant Tumors, disclosed to Purdue
Research Foundation, February 17, 1997, P-97020.00.U.S..
1687) McLaughlin J.L.: Use of Annonaceous Acetogenins against Pesticide-Resistance, disclosed to Purdue Research
Foundation, October 15, 1997, P-97059.00. US.
1688) Kim GS: Two new mono-tetrahydrofuran ring acetogenins, annomuricin E and muricapentocin, from the leaves
of Annona muricata. J Nat Prod. 1998 Apr;61(4):432-6.
1689) Rieser MJ: Five novel mono-tetrahydrofuran ring acetogenins from the seeds of Annona muricata. J Nat Prod.
1996 Feb; 59(2): 100-108.
1690) Rieser, M J.: Muricatacin: a Simple Biologically Active Acetogenin Derivative from the Seeds of Annona
Muricata (Annonaceae). Tetrahedron Lett 32 9: 1137-1140 (1991)
1691) Ferguson PJ: In vivo inhibition of growth of human tumor lines by flavonoids fractions from cranberries extract.
Nutr. Cancer 2006; 56: 86-94
1692) Bruce Halstead, Amygdalin (Laetrile) Therapy, Los Altos, CA: Choice Publications. 1978. In Culbert, „Apricot
Power,” 72.
1693) Moss, The Cancer Industry, pp.: 133.
1694) Kim H.: The plant flavonoid wogonin suppreses death of activated C6 rat glial cells by inhibiting nitric oxide
production, Neurosc. Lett. , 309, pp: 167-1771, 2001
1695) Galletti S.: Glucobrassicin enhancement in woad (Isatis tintoria) leaves by chemical and physical treatments,
Journal of the Science of Food and Agricolture, 86, pp: 1833-1838, 2006
1696) Mastronardi V.: Cancro, stress, lutto e studi immunologici, Cancer, stress, mourning and immunologic studies,
Giornale di Medicina militare, anno 153, fasc. 2-3, giugno 2003
1697) Levy S.M., Persistently low natural killer cell activity in normal adults: immunological Hormonal and mood
correlates, in natural and immunological cell growth regulation, Vol. 8, 1988, pp. 173-186.
1698) Levy S.M., Perceived social support and tumor estrogen /progesteron e receptor status as predictors of natural
killer cell activity in breast cancer patients, Psychosomatic Medicine, vol. 52, 1990, pp. 73-85
1699) Irwin M., Plasma cortisol and natural killer cell activity during bereavement, Biological Psychiatry, Vol. 24,
1988, pp. 173-178
1700) Irwin M., Electroencephalographic Sleep and natural killer activity in depressed patients and control subjects,
Psychosomatic Medicine, vol. 54, pp. 10-21, 1992
1701) Diamond, WJ. et al, eds. An Alternative Medicine Definitive Guide to Cancer. Tiburon, CA: Future Medicine
Pub., 1997
1702) Harris JE. Interaction of dietary facotrs with oral anticoagulants: review and applications, J Am Dietet Assoc.
95: 580-584, 1995
1703) Tinozzi S.: Effect of bromelian on serum and tissue levels of amoxicillin, Drug Exp Clin Res; 4: 39-44, 1978.
1704) Luerti M.: Influence of bromelian on penetration of antibiotics in uterus, salpinx and ovary, Drug Exp Clin Res 1
4: 45-48, 1978
1705) International Immunopharmacology, settembre 2006
1706) Orrell RW.: Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease, Cochrane Database
Syst. Rev. 2004 (4): CD002829
1707) Graf M.: High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a
placebo-controlled double-blind study, J.Neural. Transm., No.:112, pp: 649-660, 2005
1708) Dib M.: Vitamin E and neurodegenearative diseases, Rev. Neurol. (Paris), No. 159, 6-7 Pt 1), pp: 618-621, 2003
1709) Carter GT.: Drug therapy for amyotrophic lateral sclerosis: where are we now ?, Drug, No.6, pp: 147-153, 2003
1710) Di Matteo V.: Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer’s disease,
Parkinson’s disease, and Amyotrophic Lateral Sclerosis, Curr. Drug Targets CNS Neurol. Disord., No. 2, pp: 95-107,
1711) Esposito E.: A review of specific dietary antioxidants and the effects on biochemical mechanisms related to
neurodegenerative processes, Neurobiol. Aging, No.23, pp: 719-735, 2002
1712) Butterfield DA: Vitamin E and neurodegenerative disorders associated with oxidative stress, Nutr. Neurosci,
No.5, pp: 229-239, 2002
1713) Halliwell B: Role of free radicals in the neurodegenerative disease: therapeutic implications for antioxidant
treatment, Drugs Aging, No.18, pp: 685-716, 2001
1714) Beal MF: Coenzyme Q10 administration and its potential for treatment of neurodegenerative disease, Biofactors,
No.9, pp.: 261-266, 1999
1715) J.Neurol. Neurosurg. Psychiatr. On-line 2006, pubblicato il 28/4/2006
1716) Galbusera C.: Increased susceptibility to plasma lipid peroxidation in Alzheimer disease patients, Curr.
Alzheimer Res., No.1, pp: 103-109, 2004
1717) Bernsobs J.: Aetiology of multiple sclerosis, Nature 1963, No.10, pp: 523-530
1718) Neu I.S.: Essential fatty acids in the serum and cerebrospinal fluid of multiple sclerosis patients, In Gonsette RE
EDS, Immunological and clinical aspects of multiple sclerosis, Boston, MA:MTP Press, 1984: ch. 35
1719) Homa S.T.: Levels of linolenate and arachidonate in red blood cells of healthy individuals and patients with
multiple sclerosis, J.Neurol. Neurosurg. Psychiatr., 1980, No. 43, pp: 106-110
1720) Wright HP.: Platelet adhesiveness in mumtiple sclerosis , Lancet, 1965, pp: 1109-1110.
1721) Cullen CF.: Intravascular aggregation and adhesiveness of the blood elements associated with alimentary
lipemia and injection of large molecular substances, Effect on blood-brain barrier, Circulation 1954, No. 9, pp: 335-
1722) Haeren A.F.: A study of the blood cerebrospinal fluid-brain barrier in multiple sclerosis, Neurology, 1964, N. 14,
pp: 345-351
1723) Swank R.: Oxygen availability in brain tissues after lipid meals, Am. J. Physiol. 1960, N. 198, pp: 217-220.
1724) Zapatero MD.: Serum aluminium levels in Alzheimer’s disease and other senile dementias, Biol. Trace Element
Res. 1995, No. 47, pp.: 235-240
1725) Frolich L.: Free radical mechanisms in dementia of the Alzheimer’s type and the potential for antioxidative
treatment. Drug Res., 1995, No. 45, pp.: 443-446
1726) Walton J.: Uptake of trace amounts of alluminium into the brain from drinking water, Neurotoxicology, 1995,
N.16, pp: 187-190
1727) Shin R: Interaction of aluminium with paired helical filament tau is involved in neurofibrially pathology of
Alzheimer’s disease, Gerontol. 1997, 43,(suppl.1), pp: 16-23
1728) Costantinidis J.: The hypothesis of zinc deficiency in the pathogenesis of neurofibrillary tangles, Med. Hypoth.
1991, No. 35, pp: 319-323
1729) Burnet F.M.: A possible role of zinc in the pathology of dementia, Lancet, 1981, No.1, pp: 186-188
1730) Tlly CL: Serum zinc, senile placques, and neurofibrillary tangles. Findings from the Nun Study, Neuroreport
1995, No.6, pp.: 2105-2108.
1731) Costantinidis J.: Treatment of Alzheimer’s disease by zinc compounds, Drug Develop Res., 1992, N.27, pp: 1-14
1732) Molis TM: Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human
breast cancer, J.Pineal.Res., 1995, 18, pp.: 93-103
1733) Reiter RJ.: Melatonin suppression by static and extremely low frequency electromagnetic fields. Relationship to
the reported increased incidence of cancer, Rev. Environ Health 1994, No.10, pp: 171-186
1734) Lissoni P.: A randomized study with subcutaneous low dose interleukin 2 alone vs interleukin 2 plus the pineal
neurohormone melatonin in advanced solid neoplasms other than renal cancer and melatonina, Br. J. Cancer 1994,
No.69, pp: 196-199.
1735) Nolan CR: Aluminum and Lead absorption from dietary sources in women ingesting calcium citrate, Southern
Med. J., 1994, No. 87, pp.: 894-989
1736) Glick J.L.: The role of magnesium deficiency and hypothesis concerning the pathogenesis of Alzheimer’s disease,
Med. Hypoth., 1990, No. 31, pp.: 211-225
1737) F. Di Costanzo : Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a
randomised phase II trial of the Italian oncology group for clinical research (GOIRC), British Journal of Cancer, No.
93, pp. 185-189, 2005 ; ].
1738) Cavener D.: The GCN2 eIF2alpha kinase regulates fatty-acid homeostasis in the liver deprivation of an essential
amino acid, Cell Metabolism, 5, pp.: 103-114, 2007
1739) Maasaki, Blood, vol.93, No.11, June 1, 1999, pp. 3922-3930
1740) Woitsch, Romer : Impact and interaction of lipophilic antioxidants in mutans and transgenic plants, Journal of
Plant Physiology, 162, 2005, pp.: 1197-1209

Dă clic pentru a accesa Nacci_Vitamins_in_GMO_Plants.pdf

1741) Sobrero A.: Efficacy and safety of Bevacizumab in combination with irinotecan and infusional 5-Fluorouracil
treatment for patients with metastatic colorectal cancer, Journal of Clinical Oncology, 2006, ASCO Annual Meeting
Supplement, pp: 3544 ;
1742) Axel Grothey: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic
colorectal cancer: results from a large observational cohort study, Journal of Clinical Oncology, vol. 26, No.33, 2008,
pp.: 5326-5334;
1743) Fairooz Kabbinavar : Addition of Bevacizumab to bolus Fluorouracil and Leucovorin in first-line metastatic
colorectal cancer: results of a randomized phase II trial, Journal of Clinical Oncology, vol. 23, No. 16, 2005, pp: 3697-
1744) Asami D.: Comparison of the total phenolic and ascorbic acid content of freeze-dried and corn grown using
conventional, organic, and sustainable agricultural practices, J. Agricultural Food Chemistry, No 51, pp.: 1237-1241,
1745) Mader P.: Wheat quality in organic and conventional farming: results of a 21 year field experiment, J. Sci. Food
Agriculture No. 87, pp.: 1826-1835, 2007
1746) .
1750) Finamore A.: Intestinal and peripheral immune response to MON810 Maize ingestion in weaning and old mice, J.
Agric. Food Chem, 2008; 56 (23) , pp: 11533-11539
1751) Ramsey P., Larson E.: Medical Therapeutics, Saunders, Harcourt Brace Jovanovich, Inc, Philadelphia,
Pennsylvania, Second Edition, Piccin Nuova Libraria S.p.A. 1995
1752) Ellis P. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III,
randomised controlled trial, Lancet, No. 373, pp. : 1662-1663 e 1681-1692, 2009

Dă clic pentru a accesa Ellis_Lancet,%202009.pdf

1753) “la Teoria dei Traccianti” (tratto da cap. 10 tratto dal libro “La Terapia dei Tumori con Gadolinio 159 in
Risonanza Magnetica Nucleare” Italo Svevo Editore ( ).
1754) Gli Anticorpi Monoclonali nella terapia anti-cancro; dal libro “La Terapia dei Tumori con Gadolinio 159 in
Risonanza Magnetica Nucleare, Italo Svevo Editore
1755) La CronoBioDose nella RadioTerapia Esterna; dal libro “La Terapia dei Tumori con Gadolinio 159 in
Risonanza Magnetica Nucleare, Italo Svevo Editor e
1756) Value Of Drugs For Pre-osteoporosis Exaggerated, Experts Warn, ScienceDaily (Jan. 20, 2008)
1757) Julie T. Lin, MD Joseph M. Lane, MD: Nonpharmacologic Management of Osteoporosis to Minimize Fracture
Risk. Nat Clin Pract Rheumatol 4(1):20-25, 2008.)
1758) Owusu W, Willett WC, Feskanich D, Ascherio A, Spiegelman D, Colditz GA.: Calcium intake and the incidence
of forearm and hip fractures among men, J Nutr 1997; 127:1782-7.
1759) Feskanich D, Willett WC, Stampfer MJ, Colditz GA.: Milk, dietary calcium, and bone fractures in women: a 12-
year prospective study. Am J Public Health 1997; 87:992-7.
1760) Guglielmi G, et al.: Age-related changes assessed by peripheral QCT in healthy Italian women. Eur Radiol
2000;10(4):609-14. , del Puente A, et al, Epidemiology of osteoporosis in women in southern Italy. Aging (Milano)
1998 Feb; 10 (1) :53-8.).
1762) Quesnell WR Minerals.: The essential link to health. Skills Unlimited. 2000. La Mesa, California
1766) Valentine J.Soft Drinks: America’s Other Drinking Problem.
1768) Vanek C, Connor WE: Do n-3 fatty acids prevent osteoporosis? Editorial., Am J Clin Nutr, 2007, vol. 85, pp.
1769) Perugini Billi F.: Mangia grasso e vivi bene. 2006, Ed Junior
1770) „A combination of prebiotic short- and long-chain inulin type fructans enhances calcium absorption and bone
mineralization in young adolescents,” American Journal of Clinical Nutrition 2005; 82(2): 471-476.
1771) Fallon S., Enig M. Dem Bones: Do High Protein Diets Cause Bone Loss?. :
1772) Byrnes S.: Eating Meat Does Not Cause Osteoporosis…etarianism-myths-
1773) Heaney, R.P.,: „Dietary Protein and Phosphorous Do not Affect Calcium Absorption,” The American Journal of
Clinical Nutrition, 72(3), 2000, pages 758-761.
1774) Heaney, R.P.,: „Excess Dietary Protein May not Adversely Affect Bone,” Journal of Nutrition, 128(6), 1998,
pages 1054-1057.
1775) Hannan, M.T., Tucker, K.L., Dawson-Hughes, B., et al.,: „Effect of Dietary Protein on Bone Loss in Elderly Men
and Women: The Framingham Osteoporosis Study,” Journal of Bone Mineral Research, 15(12), 2000, pages 2504-
1776) Bray G.W.: The hypochlorhydria of asthma in childhood, Quart. J. Med. 1931, No. 24, pp: 181-197
1777) Bernard A.: Increased intestinal permeabilità in bronchial asthma, J.Allergy Clin. Immunol. 1996, No. 97, pp:
1778) Akiyama K.: Atopic asthma caused by Candida albicans acid protease. Case reports. Allergy 1994, No. 49, pp:
1779) Freedman B.J.: A diet free from additives in the managrement of allergic disease, Clin. Allergy 1977, No. 7, pp.:
1780) Stevenson D.D.: Sensitivity to ingested metabisulfites in asthmatic subjects, J. Allergy Clin. Immunol. 1981, No.
68, pp.: 26-32
1781) Papaioannou R.: Sulfite sensitiviy – unrecognized threat. Is molybdenum deficiency the cause J. Orthomol.
Psych. 1984, No.,13, pp.: 105-110
1782) Carrey O.I.: Effect of alterations of dietary sodium on the severity of asthma in men, Thorax, 1993, No. 48, pp:
1783) Burney P.G.: A diet rich in sodium may potentiate asthma: epidemiological evidence for a new hypothesis, Chest,
1987, No. 91, pp: 143-148
1784) Terapia medica d’urgenza, Piccin Editore
1785) Bock S.A.: Food-related asthma and basic nutrition, J. Asthma 1983, No. 20, pp: 377-381
1786) Oehling A.: Importance of food allergy in childhood asthma, Allergol. Immunopathol. 1981, IX, pp.: 71-73
1787) Ogle K.A.: Children with allergic rhinits and/or bronchial asthma treated with elimination diet. A five-year
follow-up, Ann Allergy 1980, No. 44, pp: 273-278
1788) Businco L.: Food allergy and asthma, Pediatric Pulmonol. Suppl., 1995, No. 11, pp: 59-60
1789) Bircher A.J: IgE to food allerens are highly prevalent in patients allergic to pollens, with and without symptoms
of food allergy, Clin. Exp. Allergy 1994, No. 24, pp: 367-374
1790) Hodge L.: Assessment of food chemical intolerance in adult asthmatic subjects, Thorax 1996, No. 51, pp: 805-
1791) Hide D.W.: Effect of allergen avoidance in infancy on allergic manifestations at age two years, J. Allergy Clin.
Immunol. 1994, No. 93, pp.: 842-846
1792) Lindahl O.: Vegan diet regimen with reduced medication in the treatment of bronchial asthma, J. Asthma , 1985,
No. 22, pp: 45-55
1793) Hodge L.: Consumption of oily fish and childhood asthma risk, MJA 1996, No. 164, pp.: 137-140
1794) Arm J.P.: The effects of dietary supplementation with fish oil lipids on the airway response to inhaled allergen in
bronchial asthma , Am . Rev. Respiratory Dis. 1989, No. 139, pp.: 1395-1400
1795) Dry J.: Effect of a fish oil diet on asthma. Results of a 1-year double-blind study, Int. Arch. Allergy Apply
Immunol. 1991, No. 95, pp.: 156-157
1796) Broughton K.S.: Reduced asthma symptoms with n-3 fatty acid ingestion are related to 5-series leukotriene
production, Am. J. Clin. Nutr. 1997, No. 65, pp.: 1011-1017.
1797) Seaton A.: Increase in asthma. A more toxic environment or a more susceptible population, Thorax 1994, No. 49,
pp.: 171-174.
1798) Hatch G.E.: Asthma, inhaled oxidants, and dietary antioxidants, Am J. Clin. Nutr. 1995, No. 61, pp.: 625S-630S
1799) Fewtrell C.M.S.: Effect of flavone inhibitors of transport ATPase on histamine secretion from rat mast cells,
Nature, 1977, No. 265, pp: 635-636
1800) Bielory L.: Asthma and vitamin C, Annals Allergy , 1994, No. 73, pp: 89-96
1801) Johnston C.S.: Antihistamine effect of supplemental ascorbic acid and neutrophil chemotaxis, J.Am. Coll. Nutr.
1992, No.11, pp: 172-176
1802) Hope W.C.: In vivo inhibition of the biosynthesis of slow reacting substance of anaphylaxis (SRS-A) and
lipoxygenase activity by quercitin, Biochem. Pharmacol. 1983, No. 32, pp.: 367-371
1803) Middleton E.: Quercitin: an inhibitor of antigen–induced human basophil istamine release, J. Immunol. , 1981,
No. 127, pp: 546-550
1804) Foreman J.C.: Mast cells and the actions of flavonoids, J. Allergy Clin. Immunol. , 1984, No. 73, pp.: 769-774
1805) Hope W.C.: In vitro inhibition of the biosynthesis of slow reacting substance of anaphylaxis (SRSA) and
lipoxygenase activity by quercetin, Biochem. Pharmacol. , 1983, No. 32, pp.: 367-371
1806) Grosch W.: Co-oxidation of carotenes requires one soy-bean lipoxygenase isoenzyme, Biochem. Biophys Acta ,
1979, No. 575, pp.: 439-445
1807) Panganamala R.V.: The effects of vitamin E on arachidonic acid metabolism, Ann. NY Acad. Sci. , 1982, No.
393, pp.: 376-391
1808) Misso N.L.: Reduced platelet glutathione peroxidase activity and serum selenium concentration in atopic
asthmatic patients, Clinical Exp. Allergy, 1996, No. 26, pp: 838-847
1809) Stone J.: Reduced selenium status of patients with asthma, 1989, Biochem. Pharmacol No. 77, pp.: 495-500
1810) Kadrabova J.: Selenium status is decreased in patients with intrinsic asthma, Biological Trace Element Research,
1996, No. 52, pp.: 241-248
1811) Carlo Beroldo, Quark, n.4, “Le nuove armi contro il cancro, pag. 133, 2001
1812) Fraser G.E.: Nut consumption, lipids, and risk of a coronary event, Clin. Cardiol. 1999, 22(7 suppl.) : III, pp.: 11-
1813) Sabate J.: Does nut consumption protect against ischaemic heart disease ? , Eur. J. Clin. Nutr. , 1993, 47, Suppl.
1: S7, pp1-5
1814) Hu FB.: Types of dietary fat and risk of coronary heart disease : a critical review, J. Am. Coll. Nutr. 2001, 20(1),
pp: 5-19
1815) Hu FB.: Plant-based foods and prevention of cardiovascular disease: an overview, Am. J. Clin. Nutr. 2003, 78(3
Suppl.) 544S-551S
1816) Sabate J.: Serum lipid response to the graduated enrichment of a Step 1 diet with almonds: a randomized feeding
trial, Am. J. Clin. Nutr. 2003, 77(6), pp: 1379-1384
1817) Ros E.: A walnut diet improves endothelial function in hypercholesterolemic subjects: a randomized crossover
trial, Circulation, 2004, 109(13) , pp: 1609-1614
1818) Jambazian PR.: Almonds in the diet simultaneously improve plasma alpha-tocopherol concentrations and reduce
plasma lipids, J.Am. Diet. Assoc. 2005, 105(3), pp: 449-454
1819) Lovejoy JC: Effect of diets enriched in almonds on insulin action and serum lipids in adults with normal glucose
tolerance or type 2 diabetes, Am. J. Clin. Nutr. 2002, 76(5), pp: 1000-1006
1820) The Lancet, Vo. 366, Issue 9492, 1 October 2005, pagg. 1165-1174
1821) Effectiveness of inactivated trivalent influenza vaccine in long-term care institutions, Toronto, 2003-2004,
Canada Communicable Disease Report, Vol.30, No.12, 15 june 2004, pp.109-116”
1822) Eelko H.: Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical
conditions, Arch. Int. Med., Vol. 165, No. 3, February 14, 2005
1823) Bensley EH.: Trial of Vitamin E therapy in diabetes mellitus, Can. Med. Assoc. J., 1949, 61, pp.: 260-264
1824) Bonfigli AR.: Vitamin E intake reduces plasminogen activator factor inhibitor type in T2Dm patients, Diabetes
Nutr. Metab. 2001, 14, pp: 71-77
1825) Ceriello A.: Vitamin E reduction of protein glycosylation in diabetes, Diabetes Care 1991, 14, pp: 68-72
1826) Devaraj S.: Alpha-tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels
in type 2 diabetic patients, Diabetes Care 2002, 25, pp.: 524-529
1827) Gokkusu C.: Oxidant and antioxidant systems in NIDDM patients: influence of Vitamin E supplementation,
Endocr. Res. 2001, 27, pp: 377-386
1828) Halliwell B.: Vitamin E and the treatment and prevention of diabetes: a case for a controlled clinical trial,
Singapore Med. J., 2002, 43, pp.: 479-484
1829) Manzella D.: Chronic administration of pharmacologic doses of Vitamin E improves the cardiac automatic
nervous system in patients with type 2 diabetes, Am. J. Clin. Nutr. 2001, 73, pp.: 1052-1057
1830) Neri S.: Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a
single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance,
and healthy controls, Clin. Ther. 2005, 27, pp: 1764-1773
1831) Pinkney JH.: Endothelial dysfunction in Type I diabetes mellitus: relationship with LDL oxidation and the effects
of Vitamin E. Diabet. Med. 1999, 16, pp: 993-999
1832) Pollack H.: The effect of vitamin E administration upon diabetes mellitus, Am J. Med. Sci. 1950, 219, pp.: 675-
1833) Prolisso G.: Pharmacologic doses of Vitamin E improve insulin action in healthy subjects and non-insulindependent
diabetic patients, Am. J. Clin. Nutr. 1993, 57, pp: 650-656
1834) Regensteiner JG.: Oral L-arginine and Vitamins E and Vitamin C improve endothelial function in women with
Type 2 diabetes, Vasc. Med. 2003, 8, 169-175
1835) Sharma A.: Effect of glycemic control and Vitamin E supplementation on total glutathione content in noninsulin-
dependent diabetes mellitus, Ann.Nutr. Metab. 2000, 44, pp: 11-13
1836) Skyrme-Jones RA: Vitamin E supplementation improves endothelial function in Type I diabetes mellitus: a
randomized, placebo-controlled study, J. Am. Coll. Cardiol., 2000, 36, pp: 94-102
1837) Stephens NG.: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart
Antioxidant Study (CHAOS) , Lancet 1996, 347, pp: 781-786
1838) Usitalo L.: Serum alpha-tocopherol concentrations and risk of type 1 diabetes mellitus: a cohort study in siblings
of affected children, J. Pediatr. Endocrinol. Metab. 2005, 18, pp.. 1409-1416
1839) Androne L.: In vivo effect of lipoic acid peroxidation in patients with diabetic neuropathy, In Vivo, 2000; 14,
1840) Dicter N.: Alpha–lipoic acid inhibits glycogen synthesis in rat muscle via its oxidative activity and the uncoupling
of mitochondria, J. Nutr. 2002, 132, pp.: 3001-3006
1841) Evans JL.: Pharmacokinetics, tolerability and fructosamine-lowering effect of a novel, controlled-release
formulation of alpha-lipoic acid, Endocr. Pract. 2002, 8, pp: 29-35
1842) Evans JL: Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2
diabetes, Diabetes Technol. Ther. 2000, 2, pp.: 401-413
1843) Packer L: Molecular aspects of lipoic acid in the prevention of diabetic complications, Nutrition , 2001, 17, pp.:
1844) Ruhe RC.: Use of antioxidant nutrients in the prevention and treatment of type 2 diabetes, J. Am. Coll. Nutr.
2001, 20, pp: 363S-369S
1845) Ruhnau KJ.: Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in
symptomatic diabetic polyneuropathy, Diabetic Med. 1999, 16, pp.: 1040-1043
1846) Ziegler D.. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid,
Diabetologia, 1995, 38, pp: 1425-1433
1847)Raju J.: Trigonella Foenum Graecum (fenugreek) seed powder improves glucose homeostasis in alloxan diabetic
rat tissues by reversing the altered glycolytic, gluconeogenic, and lipogenic enzymes, Mol. Cell. Biochem. 2001, 224,
pp.: 45-51
1848) Hannan JM.: Effect of solubile dietary fibre fraction of Trigonella foenum graecum on glycemic, insulinemic,
lipidemic and platelet aggregation status of type 2 diabetes model rats, J. Ethnopharmacol. , 2003, 88, pp: 73-77
1849) Khosia P.: Effect of Trigonella foenum graecum (fenugreek) on blood glucose in normal and diabetic rats, Indian
J. Physiol. Pharmacol., 1995, 39, pp.: 173-174
1850) Gupta A.: Effect of Trigonella foenum–graecum (fenugreek) seed glycemic control and insulin resistance in type
2 diabetes mellitus: a double blind placebo controlled study, J.Assoc. Physicians India, 2001, 49, pp.: 1057-1061
1851) Anwar MM.: Oxidative stress in streptozotocin-induced diabetic rat effects of garlic oil and melatonin, Comp.
Biochem. Physiol. A. Mol. 2003, 135, pp: 539-547
1852) Babu P.S.: Influence of dietary capsaicin and onion on the metabolic abnormalities associated with
streptozotocin induced diabetes mellitus, Mol. Cell. Biochem., 1997, 175, pp.: 49-57
1853) Campos KE.: Hypoglycemic and antioxidant effects of onion, Allium Cepa: dietary onion addition, antioxidant
activity and hypoglycemic effects on diabetic rats, Int. J. Food Sci. Nutr., 2003, 54, pp.: 241-346
1854) Jain RC.: Hypoglycaeic action of onion and garlic, Lancet, 1973, 2, pp: 1491;
1855) Kawasakishi S.: New inhibitor of platelet aggregation in onion oil, Lancet, 1988, 2, 330;
1856) Kelkar S.M.: Determination of antidiabetic activity in Allium Cepa (onion) tissue cultures, Indian J. Biochem.
Biophys. 2001, 38, pp.: 277-279
1857) Kumari K.: Antidiabetic and hypolipidemic effects of S-methyl cysteine sulfoxide isolated from Allium cepa,
Indian J. Biochem. Biophys., 1995, 32, pp.:49-54
1858) Legnani C.: Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects,
Arzneimittelforsch, 1993, 43, pp.: 119-121;
1859) Louria DB.: Onion extract in treatment of hypertension and hyperlipidemia: a preliminary communication, Curr.
Ther. Res., 1985, 37, pp.: 127-131.
1860) Phelps S: Garlic supplementation and lipoprotein oxidation susceptibility, Lipids, 1993, 28, pp.: 475-477;
1861) Sharma KK.: Antihyperglycemic effect of onoin: effect on fasting blood sugar and induced hyperglycemia in man,
Indian J.Med. Res., 1977, 65, pp.: 422-429;
1862) Silagy C.A.: Garlic as a lipid lower agent a meta-analysis, J. R. Coll. Physicians London, 1994, 28, pp: 39-45;
1863) Silagy CA: A meta-analysis of the effect of garlic on blood pressure, J.Hypertens. 1994, 12, pp.: 463-468;
1864) Tjokroprawiro A.: Metabolic effects of onion and green beans on diabetic patients, Tohoko J. Exp. Med., 1983,
141, pp: 671-676
1865) Matsuda H.: Study on anti-cataract drugs from natural sources. II. Effects of buddleyae flos on in vitro aldose
reductase activity, Biol. Pharm. Bull., 1995, 18(3) pp.: 463-466
1866) Andallu B.: Effect of mulberry (Morus indica) therapy on plasma and erythrocyte membrane lipids in patients
with type 2 diabetes, Clin. Chem. Acta, 2001, 314, pp.: 47-53
1867) Ragoobirsingh D., Phytotherapy Research , 2001, 15, pp.: 391-394
1868) Silver AA.: The effect of the ingestion of burdock root on normal and diabetic individuals a preliminary report,
Ann. Intern. Med., 1931, 5, pp.: 274-284
1869) Chitra P.: Influence of aloe vera on the healing of dermal wounds in diabetic rats, J. Ethnopharmacol., 1998, 59,
pp.: 195-201
1870) Ghannam N.: The antidiabetic activity of aloes: preliminary clinical and experimental observations, Horm. Res.
1986, 24, pp.. 288-294
1871) Agarwall O.P.: Antidiabetic activity of Aloe: preliminary clinical and experimental observation, Horm. Res.
Vol. 24, No.4, pp.: 288-294
1872) Venkatakrishna-bhatt H.: Retardation of retinopathy by Momordica charantia (Bitter Gourd) fruit extract in
alloxan diabetic rats, Indian J. Exp. Boil., 1987, 25, pp.: 571-572
1873) Srivastava Y.: Effect of Momordica Charantia pomous aqueous extract on cataractogenesis in murrin alloxan
diabetics, Pharm. Res. Commun. 1988, 20 (3), pp.: 201-209
1874) Leatherdale BA.: Improvement in glucose tolerance due to Momordica Charantia (karela) , Br. Med. J., 1981,
282, pp: 1823-1824
1875) Anderson RA: Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes,
J. Am. Coll. Nutr., 2001, 20, pp: 212-218
1876) Arquilla ER.: The effect of zinc on insulin metabolism, Endocrinology, 1978, 103, pp: 1440-1449
1877) Emdin SO.: Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell,
Diabetologia, 1980, 19, pp.: 174-182
1878) Gupta R.: Oral zinc therapy in diabetic neuropathy, J. Assoc. Physicians India, 1998, 46, pp: 939-942
1879) Hendricks DG.: Glucose tolerance in zinc-deficent rats, J. Nutr., 1972, 102, pp: 1079-1084
1880) Herington AC.: Effect of zinc on insulin binding to rat adipocytes and hepatic membranes and to human
placental membranes and IM-9 lymphocytes, Horm Metab. Res., 1985, 17, pp: 328-332
1881) Holden JM: Zinc and copper in self-selected diets, J. Am. Diet. Assoc. 1979, 75, pp: 23-28
1882) Kinlaw WB.: Abnormal zinc metabolism in type II diabetes mellitus, Am. J. Med. 1983, 75, pp.: 273-277
1883) Kojima Y.: Blood glucose lowering and toxicological effects of zinc (II) complexes with maltol, threonin, and
picolinic acid, Res. Commun. Mol. Pathol. Pharmacol., 2002, 112, pp: 91-104
1884) Kumar S.: Blood and urinary zinc levels in diabetes mellitus, Nutr. Metab., 1974, 17, pp.: 231-235
1885) Meltzer LE: The urinary excretion pattern of trace metals in diabetes mellitus, Am. J. Med. Sci., 1962, 244, pp.:
1886) Niewoehner CB.: Role of zinc supplementation in type II diabetes mellitus, Am. J. Med. 1986, 81, pp: 63-68.
1887) Roussel AM: Antioxidant effects of zinc supplementation in Tunisia with type 2 diabetes mellitus, J. Am. Coll.
Nutr. 2003, 22, pp.: 316-321
1888) Solomon SD.: Effect of low zinc intake on carbohydrate and fat metabolism in men, Fed. Proc. 1982, 42, pp: 391
1889) Song MK: Synergistic antidiabetic activities of zinc, cyclo (his-pro), and arachidonic acid, Metabolism 2001, 50,
pp: 53-59
1890) Song MK: Anti-hyperglycemic activity of zinc plus cyclo (his-pro genetically diabetic Goto-Kakizaki and aged
rats, Exp. Biol. Med. 2003, 228, pp: 1338-1345
1891) Tarui S.: Studies on zinc metabolism. III. Effect of the diabetic state on zinc metabolism: a clinical aspect,
Endocrinol. Jpn, 1963, 10, pp.: 9-15
1892) Wolman SL: Zinc in total parenteral nutrition: requirements and metabolic effects, Gastroenterology 1979, 76,
pp: 458-467
1893) Yoshikawa Y.: Insulinomimetic bis(maltotalato) zinc(II) complex: blood glucose normalizing effect in KK-A (y)
mice with type 2 diabetes mellitus, Biochem. Biophys. Res. Commun., 2001, 281, pp: 1190-1193.
1894) Asayama K.: Effect of vitamin E deficiency and selenium deficiency on insulin secretory reserve and free radical
scavenging systems in islets: decrease of islet manganosuperoxide dismutase, J. Lab. Clin. Med. , 1986, 107, pp: 459-
1895) Eckhert CD: Association between low serum selenium and diminished visual function in diabetic women, Fed.
Proc. , 1985, 44, pp: 1670
1896) Faure P: Protective effects of antioxidant micronutrients (vitamin E, zinc, and selenium) in type 2 diabetes
mellitus, Clin. Chem. Lab. Med. , 2003, 41, pp: 995-998
1897) Kljai K.: Selenium and serum levels in diabetic patients, Biol. Trace Elem. Res., 2001, 83, pp: 223-229
1898) Mueller AS: The chemical form of selenium affects insulinomimetic properties of the trace element:
investigations in type 2 diabetic dbdb mice, J. Nutr. Biochem. , 2003, 14, pp: 637-647
1899) Skripchenko ND: Effect of selenium enriched diet on lipid peroxidation in patients with diabetes mellitus type 2,
Vopr Pitan, 2003, 72, pp: 14-17
1900) Stapleton SR : Selenium : an insulin-mimetic, Cell. Mol. Life Sci., 2000, 57, pp: 1874-1879
1901) Hassel CA.: Impaired glucose tolerance in copper-deficient rats, J.Nutr. , 1983, 113, pp: 1081-1083
1902) Ito S.: Urinary copper excretion in type 2 diabetic patients with nephropaty, Nephron 2001, 88, pp: 307-312
1903) Klevay LM.: An increase in glycosylated haemoglobin in rats deficient in copper, Nutr. Rep. Int., 1982, 26, pp:
1904) Klevay LM: Diminished glucose tolerance in two men due to a diet low in copper, Am. J. Clin. Nutr., 1983, 37,
pp: 717
1905) Klevay LM: Decreased glucose tolerance in two men during experimental copper depletion, Nutr. Rep. Int. ,
1986, 33, pp: 371-382
1906) Wolf WR: Daily intake of zinc and copper from self selected diets, Fed Broc., 1977, 36, pp: 1175
1907) Hardell L. Eriksson M: A case-control study of non-Hodgkin lynfoma and exposure to pesticides, Cancer, 15
marzo 1999, vol. 85, No. 6
1908) Toepfer EW.: Preparation of chromium-containing material of glucose tolerance factor activity from brewer’s
yeast extracts and by synthesis, J.Agric.Food Chem., 1977, 25, pp.: 162-166
1909) Schroeder HA : Chromium deficiency in rats: a syndrome simulating diabetes mellitus with retarded growth,
J.Nutr., 1996, 88, pp: 439-445
1910) Davidson WF: Changes in carbohydrate metabolism of squirrel monkeys with chromium dietary
supplementation, Proc. Soc.Exp.Biol.Med., 1968, 127, pp: 66-70
1911) Preston AM: Effect of low chromium diet on glucose tolerance in streptozotocin-injected guinea pigs and rats,
Fed. Proc. 1983, 42, 925
1912) Li Y.C.: Effects of chromium and yogurt on liver weights and insulin/glucose ratios in obese mice, Fed Proc.
1984, 43, 472
1913) Appleton DJ.: Dietary chromium tripicolinate supplementation reduces glucose concentrations and improves
glucose tolerance in normal-weight cats, J. Feline Med. Surg. 2002, 4, 13-15
1914) Jeebhoy KN.: Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium
supplementation, in a patient receiving long-term total parenteral nutrition, Am. J. Clin. Nutr., 1977, 30, pp: 531-538
1915) Freud H.: Chromium deficiency during total parenteral nutrition, JAMA 1979, 241, 496-498
1916) Mertz W.: Chromium and its relation to carbohydrate metabolism, Med. Clin. North Am, 1976, 60, pp: 739-744
1917) Schroeder HA: Chromium deficiency as a factor in atherosclerosis, J. Chronic Dis., 1970, 23, pp: 123-142
1918) Anderson RA: Chromium intake, absorption and excrection of subjects consuming self-selected diets, Am. J.
Clin. Nutr., 1985, 41, pp: 1177-1183
1919) Martinez OB.: Dietary chromium and effect of chromium supplementation on glucose tolerance of elderly
Canadian women, Nutr. Res., 1985, 5, pp: 609-620.
1920) Potter JF.: Glucose metabolism in glucose-intolerant older people during chromium supplementation.
Metabolism, 1985, 34, pp.: 199-204.
1921) Levine RA: Effects of oral chromium supplementation on the glucose tolerance of elderly human subjects,
Metabolism, 1968, 17, pp: 114-125.
1922) Glinsmann WH.: Effect of trivalent chromium on glucose tolerance, Metabolism, 1966, 15, pp: 510-512
1923) Kobla HV.: Chromium, exercise, and body composition, Crit. Rev. Food Sci. Nutr. , 2000, 40, pp: 291-308
1924) Anderson RA: Chromium in the prevention and control of diabetes, Diabetes Metab., 2000, 26, pp: 22-27
1925) Jain SK.: Chromium chloride inhibits oxidative stress and TNF-alpha secretion caused by exposure to high
glucose in cultured U937 monocytes, Biochem. Biophys. Res. Commun. 2001, 7, pp: 289
1926) Anderson RA: Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes
mellitus, J.Am. Coll. Nutr., 2001, 20, pp: 212-218
1927) Usitupa U.: Effect of inorganic chromium supplementation on glucose tolerance , insulin response, and serum
lipids in non-insulin dependent diabetics, Am. J. Clin., Nutr., 1983, 38, pp: 404-410.
1928) Sherman L: Failure of trivalent chromium to improve hyperglicemia in diabetes mellitus, Metabolism, 1968, 17,
pp: 439-442
1929) Gutierrez J.: Saccharomyces carlsbergensis: microbiological assay for unidentified factor related to glucose
tolerance, J. Agric. Food Chem., 1974, 22, pp: 100-103
1930) Rabinovitz H.: Effect of Chromium supplemtation on blood glucose and lipid levels in type 2 diabetes mellitus
elderly patients, Int. J. Vitam. Nutr. Res., 2004, 74, pp: 178-182
1931) Cheng HH: Antioxidant effects of chromium supplementation with type 2 diabetes mellitus and euglycemic
subjects, J. Agric. Food Chem., 2004, 52, pp: 1385-1359
1932) Ghosh D.: Role of chromium supplementation in Indians with type 2 diabetes mellitus, J. Nutr. Biochem. , 2002,
13, pp: 690-697
1933) Vladeva SV.: Folia Med. 2005, 47, pp: 59-62
1934) Racek J. : Influence of chromium-enriched yeast on blood glucose and insulin variables, blood lipids, and
markers of oxidative stress in subjects with type 2 diabetes mellitus, Biol. Trace Elem Res, 2006, 109, pp: 215-230
1935) Fuhr JP.: Use of chromium picolinate and biotin in the management of type 2 diabetes mellitus: an economic
analysis, Dis. Manag. 2005, 8, pp: 265-275
1936) Mita Y.: Supplementation with chromium picolinate recovers renal Cr concentration and improves carbohydrate,
Biol. Trace Elem. Res. 2005, 105, pp: 229-248
1937) Cheng HH: Antioxidant effects of chromium supplementation with type 2 diabetes mellitus and euglycemic
subjects, J.Agric. Food Chem., 2004, 52, pp: 1385-1389
1938) Boden G.: Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulindependent
diabetes mellitus, Metabolism, 1996, 9, pp: 1130-1135
1939) Badmaev V.: Vanadium: a review of its potential role in the fight against diabetes, J. Altern. Complement Med.,
1999, 5, pp: 273-291
1940) Shafrir E.: Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionallyinduced
diabetes in the Psammomys obesus gerbil, Diabetes Metab. Res. Rev., 2001, 17, pp: 55-66
1941) Shinde UA.: Effect of chronic treatment with Bis (maltolato) oxovanadium (IV) in rat model of non-insulindependent-
diabetes, Indian J. Exp. Biol., 2001, 39, pp: 864-870
1942) Li H.: Conformational changes in brain calcineurin in diabetic rats with or without treatment with vanadyl
sulphate, IUBMB life, 2001, 51, pp: 373-376
1943) Ding W.: Effect of long-term treatment with vanadate in drinking water on KK mice with genetic non-insulindependent
diabetes mellitus, Biol. Trace Elem. Res., 2001, 80, pp: 159-174
1944) Melchior M.: Insulin-enhancing vanadium (III) complexes, Inorg. Chem., 2001, 27, pp: 4686-4690
1945) Domingo UL.: Relationship between reduxtion in food intake and amelioration of hyperglycemia by oral
vanadate in STZ-induced diabetic rats, Diabetes 1994, 4, pp: 1267
1946) Thompson KH.: Comparison of anti-hyperglycemic effect amongst vanadium, molybdenium, and other metal
maltol complexes, J. Inorg. Biochem. 2004, 98, pp: 683-690
1947) Scarlett JA: Acute effect of ascorbic acid infusion on carbohydrate tolerance, Am. J. Clin. Nutr., 1976, 29, pp:
1948) Garg MC.: Effect of vitamin C supplementation on oxidative stress in experimental diabetes, Indian J. Exp. Biol.,
1997, 35, pp: 264-266
1949) Abdel-Wahab YH: Vitamin C suppplemetation decreases insulin resistance and improves glucose homeostasis in
obese hyperglycaemic mice, Metabolism, 2002, 51, pp: 514-517
1950) Secher K: The bearing of the ascorbic acid content of the blood on the course of the blood sugar curve, Acta
Med. Scand., 1942, 60, pp: 255-265
1951) Erikkson J.: Magnesium and ascorbic acid supplementation in diabetes mellitus, Ann. Nutr. Metab., 1995, 39,
pp: 217-223
1952) Stankove L.: Plasma ascorbate concentrations and blood cell dehydroascorbate transport in patients with
diabetes mellitus, Metabolism, 1984, 33, pp.: 347-353
1953) Sarij KE : Decreased platelet vitamin C in diabetes mellitus: possible role in hyperaggregation, Thromb. Res. ,
1979, 15, pp: 639-650
1954) Cunningham JJ.: Reduced mononuclear leukocytre ascorbic acid content in adults with insulin-dependent
diabetes mellitus consuming adequate dietary Vitamin C, Metabolism, 1991, 40, pp: 146-149
1955) Al-Zuhair H.: Vitamin C attenuation of the development of type I diabetes mellitus by interferon-alpha,
Pharmacol. Res., 1998, 38, pp: 59-64
1956) McAuliffe AV.: Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect
on albumin excretion, 1998, 80, pp: 277-284
1957) Gaede P.: Double-blind, randomized study of the effects of treatment with Vitamin C and E on albuminuria in
diabetic patients, Diabet. Med., 2001, 18, pp: 756-760
1958) Evans M.: Effects of insulin lispro and chronic Vitamin C therapy on postprandial lipaemia, oxidative stress and
endothelial function in patients with type 2 diabetes mellitus, Eur. J. Clin. Invst, 2003, 33, pp: 231-238
1959) Mullan BA.: Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes, Hypertension 2002,
40, pp: 804-809
1960) Lal J.: Effect of oral magnesium supplementation on the lipid profile and blood glucose of patients with type 2
diabetes mellitus, J.Assoc. Physicians India, 2003, 51, pp: 37-42
1961) Ceriello A.: Hypomagnesemia in relation to diabetic retinopathy, Diabetes Care, 1982, 5, pp: 558-559
1962) McNair P.: Hypomagnesemia and heart complications in diabetes mellitus, Chin. Med.Journal, 1987, 100, pp:
1963) Vanroelen WF.: Serum and erythrocyte magnesium levels in Type I and in Type II diabetics, Acta Diabetol. Lat.,
1985, 22, pp: 185-190
1964) Sjogren A.: Magnesium deficiency in IDDM related to level of glycosylated haemoglobin, Diabetes, 1986, 35, pp:
1965) Fort P.: Magnesium status in children with insulin-dependent diabetes mellitus, J. Am. Coll. Nutr., 1986, 5, pp:
1966) Morgan KJ.: Magnesium and calcium dietary intakes of the U.S. population, J.Am.Coll. Nutr., 1985, 4, pp: 195-
1967) Lakshmanan FL.: Magnesium intakes, balances, and blood levels of adults consuming self-selected diets, Am. J.
Clin. Nutr., 1984, 40, pp: 1380-1389
1968) Srivastava US.: Mineral intakes of university students: magnesium content, Nutr. Rep. Int. , 1978, 18, pp: 235-
1969) Paolisso G.: Daily magnesium supplements improve glucose handling in elderly subjects, Am.J.Clin.Nutr., 1992,
55, pp: 1161-1167
1970) de Valk HW.: Magnesium in diabetes mellitus, Neth. J. Med., 1999, 54, pp: 139-146
1971) Tosiello L: Hypomagnesemia and diabetes mellitus: a review of clinical implications, Arch. Intern. Med., 1996,
156, pp: 1143-1148
1972) Djurhuus MS.: Magnesium reduces insulin-stimulated glucose uptake and serum lipid concentrations in type I
diabetes, Metabolism 2001, 50, pp: 1409-1417
1973) Rodriguez-Moran M.: Low serum magnesium levels and foot ulcers in patients with type 2 diabetes, Arch. Med.
Res., 2001, 32, pp: 300-303
1974) Lopez-Ridaura R.: Magnesium intake and risk of type 2 diabetes in men and women, Diabetes Care, 2004, 27, pp:
1975) Song Y.: Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women,
Diabetes Care, 2004, 27, pp: 270-271
1976) Haugen HN : The blood concentration of thiamine in diabetes, Scand. J. Clin. Lab. Invest. , 1964, 16, pp: 260-
1977) Vorhaus MG.: Studies on crystalline Vitamin B1: observations in diabetes, Am. J. Dig Dis., 1935-1936, 2, pp:
1978) Valerio G.: Lipophilic thiamine treatment in long-standing insulin-dependent diabetes mellitus, Acta Diabetol.,
1999, 36, pp.: 73-76
1979) Heyliger CE.: Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats,
Science, 1985, 227, pp: 1747-1477
1980) Muroyama K.: Anti-obesity effects of a mixture of thiamine, arginine, caffeine, and citric acid in non-insulin
dependent diabetic KK mice, J. Nutr. Sci. Vitaminol (Tokyo) 2003, 49, pp.: 56-63
1981) Spergel G.: Effects of hypokalemia on carbohydrate and lipid metabolisms in the rat. Diabetes, 1967, 16, pp:
1982) Norbiato G.: Effects of potassium suplementation on insulin binding and insulin action in human obesity:
protein-modified fast and refeeding, Eur. J. Clin. Invest., 1984, 14, pp: 414-419
1983) Helderman JH: Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium,
Diabetes, 1983, 32, pp: 106-111
1984) Sobey CG : Potassium channel function in vascular disease, Arterioscler. Thromb. Vasc. Biol. 2001, 21, pp: 28-
1985) Crane M.G.: Regression of diabetic neuropathy with vegan diet, Am. J. Clin. Nutr., 1988, 48, pp: 926
1986) Fava D.: Relationsh between dairy product consumption and incidence of IDDM in childhood in Italy, Diabetes
Care 1994, 17, pp: 1488-1490
1987) Levy-Marchal C.: Antibodies against bovine albumin and other diabetes markers in French children, Diabetes
Care , 1995, 18, pp: 1089-1094
1988) Karjalainen J.: A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus, N.Engl. J.
Med., 1992, 327, pp. 302-307
1989) Atkinson MA: Lack of immune responsiveness to bovine serum albumin in insulin-dependent diabetes,
N.Engl.J.Med., 1993, 329, pp: 1853-1858
1990) Pereira MA: Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA
study, JAMA, 2002, Apr., 287, pp: 2081-2089
1991) Hassan N.: The optimum dose of nicotinamide for protection of pancreatic beta-cells against the cytotoxic effect
of streptozotocin in albino rat, J. Ayub. Med. Coll. Abbottabad, 2001, 13, pp: 26-30
1992) Urberg M.: Evidence for synergism between chromium and nicotinic acid in the control of glucose tolerance in
elderly humans, Metabolism, 1987, 36, pp: 896-899
1993) Molnar GD.: The effect of nicotinic acid in diabetes mellitus, Metabolism, 1964, 13, pp: 181-189
1994) Hoffer A.: Nicotinic acid and diabetes mellitus, J. Appl. Nutr., 1990, 42, pp: 33-35
1995) Masiello P.: Nicotinamide and streptozotocin diabetes in the rat. Factors influencing the effectiveness of the
protection, Experientia, 1977, 33, pp: 1246-1247
1996) Fuji E.: Effects of nicotinamide and insulin on glycosylated haemoglobin and blood glucose in thyroidectomized
streptozotocin diabetic rats, Jpn. J. Pharmacol., 1982, 32, pp: 903-907
1997) Banerjee S.: Effect of certain substances on the prevention of diabetogenic action of alloxan, Science, 1947, 106,
pp: 128-130
1998) Tjalve H.: The uptake in the pancreatic islet of nicotinamide, nicotinic acid and tryptophan and their ability to
prevent streptozotocin diabetes in mice, Acta Endocrinol. 1976, 83, pp: 357-364
1999) Vague P: Nicotinamide may extend remission phase in insulin-dependent diabetes, Lancet, 1987, 1, pp: 619-620
2000) Elliott RB.: Prevention or delay of tipe 1 (insulin dependent) diabetes mellitus in children using nicotinamide,
Diabetologia, 1991, 34, pp: 362-365
2001) Osar Z.: Nicotinamide affects oxidative burst activity of neutrophils in patients with poorly controlled type 2
diabetes mellitus, Exp. Diabesity Res., 2004, 5, pp: 155-162
2002) Polo V.: Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with
secondary failure to sulphonylureas, Acta Diabetol. , 1998, 35, pp: 61-64
2003) Spiroux de Vendomois J.: A comparison of the effects of three GM Corn varieties on Mammalian Health,
International Journal of Biological Sciences, 2009, 5, pp: 706-726
2004) Diabetes Care, 2008, 31, 173, 175
2005) Anderson JW.: High-carbohydrate, high fiber diets, for insulin-treated men with diabetes mellitus, Am. J. Clin.
Nutr., 1979, 32, pp: 2312-2321
2006) Anderson JW.: Metabolic effects of high-carbohydrate, high-fiber diets for insulin-dependent diabetic
individuals, Am. J. Clin. Nutr., 1991, 54, pp: 936-943
2007) Manhire A.: Unrefined carbohydrate and dietary fiber in treatment of diabetes mellitus, J. Hum. Nutr., 1981, 35,
pp: 99-101
2008) Harold MR.: Effect of dietary fiber in insulin-dependent diabetics: insulin requirements and serum lipids, J. Am.
Diet. Assoc., 1985, 85, pp: 1455-1460
2009) Simpson HCR : A high carbohydrate leguminous fiber diet improves all aspects of diabetic control, Lancet,
1981, 1, p: 1-5
2010) Jenkins DJA.: Slow release dietary carbohydrate improves second meal tolerance, Adm. J. Clin. Nutr. , 1982, 35,
pp: 1339-1346
2011) Narain JP: Metabolic responses to four week barley supplement, Int. J. Fd. Sci. Nutr., 1992, 43, pp: 41-46
2012) Sharma KK: Antihyperglycemic effect of anion: effect on fasting blood sugar and induced hyperglicemia in man,
Indian Journal Med. Rres., 1977, 65, pp: 422-429
2013) Jain RC.: Hypoglycemic action of anion and garlic, Lancet, 1973, 2, 1491
2014) Silagy C.: Garlic as a lipid lower agent – a meta-analysis, J.R. Coll. Physicians London, 1994, 28, pp: 39-45
2015) Phelps S.: Garlic supplementation and lipoprotein oxidation susceptibility, Lipids 1993, 28, pp: 475-477
2016) Legnani C.: Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects,
Arzneimittelforsch, 1993, 43, pp: 119-121
2017) Silagy CA: A meta-analysis of the effect of garlic on blood pressure, J. Hypertens., 1994, 12, pp: 463-468
2018) Kawakishi S.: New inhibitor of platelet aggregation in onion oil, Lancet, 1988, 2, pp: 330
2019) Louria DB.: Onion extract in treatment of hypertension and hyperlipidemia: a preliminary communication, Curr.
Ther. Res., 1985, 37, pp: 127-131
2020) Hollman PCH: Abdsorption and disposition kinetics of the dietary antioxidant quercetin in man, Free Rad. Biol.
Med., 1996, 21, pp: 703-707
2021) Varma SD.: Inhibition of lens aldose reductase by flavonoids: their possible role in the prevention of diabetic
cataracts, Biochem. Pharmacol., 1976, 25, pp: 2505-2513
2022) Held DD.: Isolation of a non-chromium insulin-enhancing factor from brewer’s yeast, Fed. Proc., 1984, 43, pp:
2023) Funk C.: The presence of a blood-sugar reducing substance in yeast, Proc. Soc. Exp. Biol. Med., 1923, 20, pp:
2024) Ribes G.: Effects of fenugreek seeds on endocrine pancreatic secretions in dogs, Ann. Nutr. Metab., 1984, 28,
pp.: 37-43
2025) Sharma R.D.: Effect of fenugreek seeds on blood glucose ans serum lipids in type I diabetes, Eur. J. Clin. Nutr. ,
1990, 44, pp: 301-306
2026) Mada Z.: Glucose-lowering effect of fenugreek in non-insulin dependent diabetics, Eur. J. Clin. Nutr., 1988, 42,
pp: 51-54
2027) Pocoit F.: Nicotinamide-biological actions and therapeutic potential in diabetes prevention, Diabetologia, 1993,
36, pp: 574-576
2028) Cleary J.P.: Vitamin B3 in the treatment of diabetes mellitus: case reports and review of the literature, J.Nutr.
Med., 1990, 1, pp: 217-225
2029) Pozzilli F.: The potential role of nicotinamide in the secondary prevention of IDDM, Diabetes Metabol. Rev.,
1993, 9, pp: 219-230
2030) Mandrup P.T.: Nicotinamide in the prevention of insulin dependent diabetes mellitus, Diabetes Metabol. Rev.,
1993, 9, pp: 295-309
2031) Andersen HU.: Nicotinamide prevents interleukin-1 effects on accumulated insulin release and nitric oxide
production in rat islets of Langerhans, Diabetes, 1994, 43, pp: 770-777
2031) The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation,
and treatment of high cholesterol in adults, Arch. Intern. Med., 1988, 148, pp: 136-169
2032) The Coronary Drug Project Group. Clofibrate and niacin in coronary heart disease, JAMA, 1975, 231, pp.: 360-
2033) Canner P.L.: Mortality in Coronary Drug Project patients during a nine-year post-treatment period, J. Am. Coll.
Cardiol. , 1986, 8, pp: 1245-1255
2034) Henkin Y.: Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin,
JAMA, 1990, 264, pp.: 241-243
2035) Welsh A.L.: Inositol hexanicotinate for improved nicotinic acid therapy, Int. Record Med., 1961, 174, pp.: 9-15
2036) El-Enein: The role of nicotinic acid and inositol hexaniacinate as anticholesterolemic and anti-lipemic agents,
Nutr. Rep. Intl., 1983, 28, pp.: 899-911
2037) Sunderland G.T.: A double blind randomized placebo controlled trial of hexopal in primary Raynaud’s disease,
Clin. Rheumatol., 1988, 7, pp: 46-49
2038) Davie S.J.: Effect of vitamin C on glycosylation of proteins, Diabetes, 1992, 41, pp: 167-173
2039) Vinson JA.: In vitro and in vivo reduction of erythrocyte sorbitol by ascorbic acid, Diabetes, 1989, 38, pp.: 1036-
2040) Cunningham JJ.: Vitamin C. An aldose reductase inhibitor that normalizes erythrocyte sorbitol in insulindependent
diabetes mellitus, J.Am.Coll.Nutr., 1994, 4, pp: 344-350
2041) Welihinda J.: Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes, J.
Ethnopharmacol., 1986, 17, pp: 277-282
2042) Srivastava Y.: Antidiabetic and adaptogenic properties of Momordica charantia extract. An experimental and
clinical evaluation, Phytotherapy Res., 1993, 7, pp.: 285-289
2043) Welihinda J.: The insulin-releasing activity of the tropical plant Momordica charantia, Acta Biol. Med. Germ.,
1982, 41, pp.:1229-1240
2044) Mooradian AD.: Micronutrient status in diabetes mellitus, Am.J.Clin.Nutr., 1987, 45, pp.: 877-895
2045) Hegazi SM.: Effect of zinc supplementation on serum glucose, insulin, glucagons, glucose-6-phosphatase, and
mineral levels in diabetics, J.Clin. Biochem. Nutr., 1992, 12, pp: 209-215
2046) Engel ED.: Diabetes mellitus. Impaired wound healing from zinc deficiency, J. Am. Pod. Assoc., 1981, 71, pp.:
2047) White J.: Magnesium and diabetes. A review. Ann.Pharmacother., 1993, 27, pp.: 775-780
2048) Khaw KT.: Dietary potassium and blood pressure in a population, Am. J. Clin. Nutr., 1984, 39, 963-968
2049) Wimhurst JM.: Comparison of ability of Mg and Mn to activate the key enzymes of glycolysis, FEBS Letters,
1972, 27, pp.: 321-326
2050) ED.: Manganese and glucose tolerance, Nutr. REV., 1968, 26, PP.: 207-210
2051) Sotaniemi E.: Ginseng therapy in non-insulin-dependent diabetic patients, Diabetes Care, 1995, 18, pp.: 1373-
2052) Allen FM.: Blueberry leaf extract. Physiologic and clinical properties in relation to carbohydrate metabolism,
JAMA, 1927, 89, pp: 1577-1581
2053) Bever B.: Plants with oral hypoglycaemic action, Quart. J. Crude Drug Res., 1979, 17, pp.: 139-196
2054) Caselli L.: Clinical and electroretinographic study on activity of anthocyanosides, Arch. Med. Int., 1985, 37, pp..
2055) Passariello N.: Influence of anthoryanosides on the microcirculation and lipid picture in diabetic and dyslipidic
subjects, Gazz. Med. Ital. , 1979, 138, pp.: 563-566
2056) Coget JM.: Anthocyanosides and microcirculation, J.Mal. Vasc., 1980, 5, pp.: 43-46
2057) Scharrer A.: Anthocyanosides in the treatment of retinopathies, Klin. Monatsbl. Augenheilkd, 1981, 178, pp..
2058) Kaleab Asres: Naturally derived anti-HIV agents, Phytotherapy Research, 19, pp: 557-581, 2005
2059) Gregersen S.: Glycaemic and insulinaemic responses to orange and apple compared with white bread in noninsulin
dependent diabetic subjects, Eur. J. Clin. Nutr., 1992, 46, pp: 301-303
2060) Koivisto V.A.: Fructose and insulin sensitivity in patients with type 2 diabetes, Journal of Internal Medicine,
1993, 233, pp: 145-153
2061) Rodin J.: Effects of pure sugar vs. mixed starch fructose loads on food intake, Appetite, 1991, 17, pp: 213-219
2062) Rodin J.: Comparative effects of fructose, aspartame, glucose and water preloads on calorie and macronutrient
intake, AJCN, 1990, 51, pp: 428-435
2063) Spitzer L.: Effects of fructose and glucose preloads on subsequent food intake, Appetite, 1987, 8, pp.: 135-145
2064) Del Mistro A. in “Aspetti metodologici ed applicativi della citogenetica nelle lesioni linfoproliferative” in:
Savagno L: I Linfomi Non Hodgkin, Piccin Nuova Libraria S.p.A., Padova, 1996, pp.141-148
2065) Offit K: Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin’s lymphoma :
correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment, Genes Chromosom Cancer ,
1991, 3, pp: 189-201
2066) Nowell PC: The clonal evolution of tumor cell populations, Science, 1976, N. 194, pp: 23
2067) Rowley JD: Ph-positive leucemia, includine chronic myelogenous leucemia, Clin. Haematol., 1980, 9, pp: 85-86
2068) Gauwerky CE.: Pre B cell leucemia with a t(8;14) and t(14;18) translocation is preceded by follicular lymphoma,
Oncogene, 1988, No.2, pp: 431-435
2069) Gauwerky CE.: Activation of c-myc in a masked t(8;17) traslocation results in an aggressive B-cell leukaemia,
Proc. Natl. Acad. Sci. USA, 1989, No. 85, p: 8867-8871
2070) Armitage JO.: Correlation of cytogenetic abnormalities with histolologic appearance in NON-Hodgkin’s
lymphomas bearing t(14;18) (q32;q21), J. Natl.Cancer Inst., 1988, No. 80, pp: 576-580
2071) Levine EG.: Sequential karyotypes in NON-Hodgkin’s lymphoma: their nature and significance, Genes
Chromosom Cancer, 1990, No. 1, pp: 270-280
2072) Wolman S.R.: Cytogenetic, flow cytometric and ultrastructural studies of 29 nonfamilial renal cell carcinomas,
Cancer Research, 1988, No. 48, pp.: 2890-2897
2073) Soloman E.: Colorectal cancer genes, Science, 1990, No. 342, pp: 412-414
2074) Bloomfield CD.: Non-randam chromosome abnormalities in lymphoma, Cancer Research, 1983, No. 43, pp:
2075) Berger R.: Cytogenetic studies on ANLL in relapse, Cancer Genet. Cytogenet, 1988, No. 34, pp: 11-19
2076) Offit K.: Cytogrenetic analysis of chimerism and leukaemia relapse in chronic myelogenous leukaemia patients
after T cell depleted bone marrow transplation, Blood, 1990, No. 75, pp: 1346-1355
2077) Chen Z: Application of Fluorescence In Situ Hybridization in haematological disorders, Cancer Genet
Cytogenet, 1992, No. 63, pp: 62-69
2078) Paddighe PJ.: Interphase cytogenetics of haematological cancer: comparison of classified karyotyping and in situ
hybridization using a panel of eleven chromosome-specific DNA probes, Cancer Res. , 1991, No.51, pp: 1959-1967
2079) Anastasi J.: Interphase cytogenetic analysis detects minimal residual disease in a case of acute lymphoblastic
leukaemia and resolves the question of origin of relapse after allogenic bone marrow transplation, Blood, 1991, No.
77, pp: 1087-1091
2080) Sahlin P.: Detection of hidden structural rearrangements by FISH in leomorphic adenomas, Genes Chromosom
Cancer, 1995, No. 12, pp: 81-86
2081) Progressi nella ricerca sul cancro , Le Scienze, 1989

Dă clic pentru a accesa Nacci_GLICOPROTEINA.pdf

2082): Burt R.K.: Polichemioresistenza da glicoproteina P, Minuti, ottobre 1990, pp.: 37-46
2083) Juranka PF.: P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins,
FASEB Journal, No. 3, pp: 2583, 1989
2084) Endicott JA.: The biochemistry of P-glycoprotein-mediated multidrug resistance, Ann. Rev. Biochem., No. 58,
pp. 137, 1989
2085) Kessel D.: Resistance to antineoplastic Drugs, CRC Press, Boca Raton, Fla, 1989
2086) Ozols RF.: Drug Resistance in Cancer Therapy, Kluwer Academic, Norwell, Mass, 1989
2087) Meloni A.: Trisomy 10 in Renal Cell Carcinoma, Cancer Genet. Cytogenet., 1991, No. 51, pp: 137-138
2088) Naasami I: Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human
cancer cells in vitro and in vivo, Cancer Res., 2003, No.63, pp.: 824-830



3 gânduri despre „Scientific Studies DATABASE PAGE 8


  2. Pingback: Scientific Studies DATABASE PAGE 1 | TRATAMENTE CANCER EFICIENTE, NON - toxice

Exprimati-va pararea!

Completează mai jos detaliile tale sau dă clic pe un icon pentru a te autentifica:


Comentezi folosind contul tău Dezautentificare /  Schimbă )

Fotografie Google

Comentezi folosind contul tău Google. Dezautentificare /  Schimbă )

Poză Twitter

Comentezi folosind contul tău Twitter. Dezautentificare /  Schimbă )

Fotografie Facebook

Comentezi folosind contul tău Facebook. Dezautentificare /  Schimbă )

Conectare la %s

Acest site folosește Akismet pentru a reduce spamul. Află cum sunt procesate datele comentariilor tale.